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Substitution reactions of aqua ligands from cis-Pt(II) square-planar complexes by thiourea 
nucleophiles were studied by stopped-flow and UV-vis spectrophotometric techniques at pH 
2 as a function of concentration and temperature. Six mononuclear complexes bearing an 
N,S-bidentate core ligand containing either a pyridyl or quinolyl backbone linked via a flexible 
methylene linker to a thioether were synthesised and fully characterised by NMR (1H, 13C and 
195Pt), IR spectroscopy, mass spectrometry and elemental analysis. Substituents at the para-
position of the phenyl group on the thioether differ in their electronic and steric properties. 
The solutions of the thiourea nucleophiles viz., thiourea (tu), N,N’-dimethylthiourea (dmtu) 
and N,N,N’,N’-tetramethylthiourea (tmtu) were provided in at least 10-fold excess to the 
complex concentration to ensure pseudo-first-order kinetics onto the reactions. Low energy 
chemical structures and related data were calculated by Density Functional Theory (DFT) and 
the data was used to explain trends in the experimental results.  
The rate of substitution of the aqua co-ligands was found to be sensitive to the nature 
of the para-substituents on the phenyl group of the thioether moiety of the N,S-bidentate 
ligands. Both positive and negative σ-inductive substituents on the phenyl ring accelerated 
the rate of substitution compared to the unsubstituted complex albeit by different 
mechanisms. The positive σ-inductive effect of the tert-butyl group enhanced the σ-trans-
labilizing effect of the thioether in the ground-state of the complexes. The negative σ-
inductive effect of the fluoro group activated the π-acceptor property of the thioether which 
pulled electron density away from the metal centre making it more electrophilic. The effect 
of changing the donor group from pyridyl to a quinolyl led to reduced rates of substitution 
due to the poor π-acceptor properties of the latter.  
The pKa results show that deprotonation of the aqua ligands is sensitive to the nature 
of the substituents on the phenyl group; lower pKa values were observed for σ-inductive 
electron-withdrawing groups. 195Pt NMR studies using Pt(pySPhF)Cl2 as an example, showed 
that upon reaction with thiourea nucleophiles, the N,S-bidentate ligand eventually 
underwent ring-opening at the N-end. The reactivity of the complexes is influenced by steric 
sizes of the nucleophiles; sterically bulk nucleophiles retarded the rate of substituting the 
aqua ligands. The low and positive enthalpy as well as the high and negative entropy values 
supported an associative mode of activation associated with substitution reactions in square-
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pySPh   2-(phenylthiomethyl)pyridine 
pySPh(t-But)  2-(4-tert-butylphenylthiomethyl)pyridine  
pySPhF   2-(4-fluorophenylthiomethyl)pyridine  
QnSPh   2-(phenylthiomethyl)quinoline 
QnSPh(t-But)  2-(4-tert-butylphenylthiomethyl)quinoline   
QnSPhF   2-(4-fluorophenylthiomethyl)quinoline   
Complexes 
Pt(pySPh)  Pt{2-(phenylthiomethyl)pyridine}(H2O)2]2+  
Pt(pySPh(t-But))    Pt{2-(4-tert-butylphenylthiomethyl)pyridine}(H2O)2]2+    
Pt(pySPhF)    Pt{2-(4-fluorophenylthiomethyl)pyridine}(H2O)2]2+   
Pt(QnSPh)  Pt{2-(phenylthiomethyl)quinoline}(H2O)2]2+  
Pt(QnSPh(t-But))  Pt{2-(4-tert-butylphenylthiomethyl)quinoline}(H2O)2]2+   
Pt(QnSPhF)   Pt{2-(4-fluorophenylthiomethyl)quinoline}(H2O)2]2+  
Other chemicals 
LiOTf   lithium trifluoromethanesulfonate, CF3SO3Li 
HOTf   trifluoromethanesulfonic acid, CF3SO3H 
AgOTf    silver trifluoromethanesulfonate, CF3SO3Ag 
HCl   hydrochloric acid  
tu   thiourea   
dmtu   N,N-dimethylthiourea 
tmtu   N,N,N’,N’-tetramethylthiourea  
iv 
 
EtOH   ethanol 
 
Other abbreviations 
A   Absorbance 
A   Associative mechanism 
Å   Angstrom (10-10 m) 
oC   Celsius 
CDC3-d  deuterated chloroform 
DMF-d7  deuterated dimethylformamide 
DFT   Density Functional Theory 
D   dissociative 
DNA   deoxyribonucleic acid 
HOMO   Highest Occupied Molecular Orbital  
I   Ionic strength 
I   Interchange 
Ia   Associatively activated interchange 
Id   Dissociatively activated interchange 
IR   Infrared 
LFER   Linear Free Energy Relationship 
LUMO   Lowest Unoccupied Molecular Orbital 
kobs   averaged observed rate constants 
k1, k-1, k2, k-2  rate constants 
K   Kelvin 
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ΔE   Energy gap between the HOMO and LUMO 
M   Molarity (mol dm-3) or metal 
NBO   Natural Bond Orbital 
NER   nucleotide excision repair 
nm   nanometer   
NMR   Nuclear Magnetic Resonance 
Nu   nucleophile 
s, d, t   (NMR) singlet, double, triplet 
ΔH≠   activation enthalpy 
ΔS≠   activation entropy 
ppm   parts per million 
py   pyridine   
R   gas constant (8.3145 JK-1 mol-1) 
T   temperature 
T.S.   transition state(s) 
UV   ultraviolet 
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Chapter 1 
Metal-based compounds as anticancer therapeutics 
1.0 Introduction  
1.1  Cancer Treatment by Metal-based Drugs 
Cancer is an abnormal growth of tissue resulting from a continuous proliferation of 
mutative cells that have the ability to invade and metastasise to other tissues.1 Major causes 
of cancers in human are prolonged exposure to carcinogenic chemicals, ultra-violet (UV-B) 
radiation, prolonged dietary intakes of food contaminated with carcinogenic additives, 
smoking and in some cases hereditary defects.  
Cancerous cells can grow into malignant tumours from connective and supportive 
tissue, such as bone, cartilage, nerve, blood vessels, muscle, and fat.2 These tumours are 
called sarcomas. It can also originate from cells in the epithelial tissues e.g., skin and the lining 
of the body cavities and organs, and glandular tissues.2 These are called carcinomas. When 
cells in the blood and lymph fluids become cancerous, the results are leukaemias or 
lymphomas.2  
Cancer tumours are mitigated from proliferation mainly through surgical removal, 
radiology and chemotherapy.2 Nowadays, a combination of the therapies can be used to treat 
aggressive cancers. In most cases, chemotherapy is used as one of the methods in the 
combination therapies. The chemical drugs used in chemotherapy include: alkylating agents, 
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1.2 Platinum(II) Complexes as Anti-tumour Agents 
1.2.1 Cisplatin Chemistry 
For a long time, metal complexes have been known to treat cancer. Platinum(II) metal-
based drugs were the first to be used to treat cancer. However, metal complexes of other 
metal ions such as Ru(II) and Ru(III); Os(II); Ir(I); Pt(IV); Au(I) and Au(III) can potentially treat 
cancer. The major underlying mechanism that kill cancer cells by metal-based antitumour 
drugs is DNA-complex formation via ligand exchange substitution reactions.5 Due to the 
efficacy of cisplatin as a chemotherapeutic drug, numerous square-planar Pt(II) complexes 
have been prepared and used as model complexes for understanding the mechanisms and 
rates of substitution of labile ligands from the complexes.6 
Cisplatin, cis-diamminedichloroplatinum(II) Figure 1.1 (a), was the first metallo-drug 
to be used for combating aggressive cancer, usually in a combination with other therapeutic 
methods.5  It was a revelation that this seemingly simple inorganic compound could in fact 
inhibit cell division, let alone suppressing tumour growth given that it had been known for 
more than a century.7 The anticancer properties of cisplatin were discovered by chance by 
Rosenberg et al.8, 9 In an experiment designed to study the effect of an electric field on the 
growth of bacteria, cisplatin and its Pt(IV) analogue, cis-[Pt(NH3)2Cl4], were unexpectedly 
formed in electrochemical cells from a chemical reaction involving the Pt electrode and NH3 
electrolyte buffer. These two compounds caused E. coli to grow into filaments, prompting 
their investigation as possible inhibitors of DNA replication.10  
Cisplatin was clinically approved by America’s Food and Drug Administration (FDA) in 
1978 and has since been routinely used as a cytostatic drug against epithelial malignancies of 
the lung, ovarian, bladder, testicular, breast, head and neck, oesophageal, gastric and 
pancreatic.11-13 Although cisplatin is an effective anticancer drug, it is quite toxic, and this is 
caused by side reactions with non-targeted species such as sulphur-containing biomolecules, 
proteins, amino acids and enzymes. Side effects which include: neuphrotoxicity, 
neurotoxicity, ototoxicity, myelosuppression, and emesis have been reported in patients 
undergoing cisplatin chemotherapy.12 In addition, cisplatin is only sensitive to a limited range 
of tumours. In some cancer cells, it is intrinsically inactive. It can develop resistance in some 
cells after an initial response.14 This meant that new metallo-drugs were required to address 
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the following challenges of cisplatin: (i) acute toxicity, (ii) cisplatin resistance, (iii) poor water 
solubility, (iv) increase the spectrum of anticancer activity, and (v) increase tumour 
selectivity.12 Figure 1.1 shows the structure of cisplatin and other related complexes which 









Figure 1.1: Structures of cisplatin and its active analogues: (a) cisplatin, (b) carboplatin, (c) 
oxaliplatin, (d) nedaplatin, (e) heptaplatin, and (f) lobaplatin. 
The guiding rules to improving cisplatin’s chemotherapeutic potency were 
pronounced as a structure-activity relationships (SARs) checklist.3,15-17 The empirical 
structure-activity rules predicted the following structural features are crucial in the 
development of platinum-based anticancer drugs for effective activity: 
 A cis configuration which on substitution forms a 1,2 DNA-metallocycle adduct. 
 The complex must be neutral. Neutrality enhances efficient uptake of the drug due 
to ease of absorption.18 
 The general formula should be cis-[Pt(Am)2X2], in which Am = a non-leaving 
monodentate or chelating am(m)ine ligand and X = a monodentate anionic or ring-
forming ligand (e.g. chloro, carboxylate, hydroxo etc.). 
 The presence of at least one N-H group, important for hydrogen bonding 
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Extensive research, guided by a strict adherence to the SAR rules was undertaken by 
many biochemists globally.20 The impetus was to synthesise as well as conduct cytotoxicity 
tests on some of the potential anticancer compounds which would ameliorate cisplatin 
therapeutic shortcomings. It only yielded lead compounds, which were structurally similar to 
cisplatin and could only inhibit rapid cell growth by the same mechanism.21-23 Later on, trans-
square planar Pt(II) compounds (Figure 1.7) were also discovered to possess cytostatic activity 
comparable to cisplatin both in vitro and in vivo (vide infra).24  
1.2.2 Mechanism of Action and Resistance  
Most of what is known on the chemotherapeutic effect and development of resistance 
is based on the data of cisplatin.25 Because cisplatin is toxic and has poor solubility, it is 
administered intravenously at an average dose of 100-200 mg d-1 for up to 5 consecutive days 
for effective treatment.11,26 The drug is predominantly excreted in the kidney and liver 
organs.27 It is believed that cellular uptake of cisplatin and related metallo-drugs into the cells 
occurs by passive diffusion and in some cells by an active transport mechanism(a copper influx 
transporter through constitutive triple response 1 (CTR1) receptor, in mammalian cells).28,29  
Prior to cellular absorption, the drug remains in its neutral form, cis-[Pt(NH3)2Cl2], due 
to the high concentration of chloride ions in the plasma, which suppress hydrolysis.12 Inside 
the cell the concentration of the chloride ions is low (4 mM) and this facilitates a stepwise 
reversible hydrolysis to produce the charged mono- and diaqua species, cis-Pt(NH3)2(Cl)(H2O)+ 
and cis-Pt(NH3)2(H2O)22+, respectively.30 These active species of cisplatin are highly reactive 
towards DNA, are frequently deactivated by ubiquitous and nucleophilic compounds in the 
cytosol of the cell.31 These reactive species cause the acute toxicity of cisplatin and in some 
cases development of drug resistance.24  
Nucleophilic substitution reactions of active cisplatin species with DNA, in which the 
labile water ligands are displaced, lead to the covalent binding of the cis-Pt(NH3)22+ unit to the 
purine heterogeneous bases.28 It has been suggested that only 1% of the drug reaches its 
critical target DNA due to the ever-present detoxifying agents, particularly sulphur-containing 
species, that it can possibly interact with.32 Figure 1.2 depicts the equilibria of cisplatin and 
its active species in the cytosol.   










Figure 1.2: Biochemical equilibrium reactions of cisplatin and related compounds.13,33    
The major bifunctional DNA adducts formed by cisplatin comprise: 
 ca. 65% 1,2-intrastrand cross-links between adjacent bases, with cis-[Pt(NH3)22+] (cis-
GG) as the major type;  
 25% cis-[Pt(NH3)2{d(ApG)}] (cis-AG); 
  ca. 5-10% 1,3-intrastrand cross-links between non-adjacent guanines, 1,3-d(GpNpG) 
(cis-GNG); and  
 1-3% interstrand adducts, and mono-functional binding to guanine.34  
The binding of the cis-Pt(NH3)22+ unit of cisplatin induces a major groove bending of 
30-35%, and a 13% local unwinding of the DNA double helix. Solution studies aimed at 
understanding the in vivo pharmacokinetics of cisplatin using nuclear magnetic resonance 
spectroscopy (NMR) (15N, 195Pt)35,36 and x-ray crystallographic37,38 data, showed that the N7 
atom of the purine bases is the preferred site for platinum binding.  
Figure 1.3 shows the possible binding products of cisplatin to DNA purine bases. Due to its cis 
configuration, it can form:12,39  
 an interstrand adduct cross-linking two different strands of one DNA molecule,  
 an intrastrand adduct cross-linking two neighbouring nucleobases of a single DNA 
strand,  

















cis-Pt(NH3)2(H2O)(OH)2+ cis-Pt(NH3)2(OH)22+ cis-Pt(NH3)2(H2O)22+ 
cis-Pt(NH3)2(Cl)(H2O)+ cis-Pt(NH3)(Cl)(OH)
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Figure 1.3: Structure of the cisplatin DNA adduct formed mainly through the N7 atom of 
guanosine. This causes axial instability with an axial twist of about 13%.19   
The same alteration on the structure of the double helix of DNA is imparted by carboplatin 
and oxaliplatin, two analogues with carboxylate leaving groups. The pre-binding interactions 











Figure 1.4 Absorption and pre-binding interactions of cisplatin and its analogues with 
DNA.25,40 (i) Drug uptake; (ii) Activation by chloride metathesis; (iii) DNA adducts formation and (iv) DNA-helix 






cisplatin binds at N7
C-G DNA base pair
[Cl-] = ~100 mM (blood)
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The covalent binding of cisplatin to the double-helical structure of DNA leads to the 
twisting and bending of helix and triggers obstruction of cellular pathways such as replication 
and transcription in fast growing cells.18 Consequently, programmed cell death, or apoptosis, 
is executed. A group of proteins called the high mobility group box (HMGB1) are immobilised 
to the Pt-DNA damaged lesions and activate apoptosis leading to cell death.37,41 These 
proteins can be systematically bypassed by another counteracting arsenal: the nucleotide 
excision repair (NER) machinery.42 The nucleotide excision repair facilitates the restoration of 
platinum damaged DNA by the removal of such lesions. The easy recognition as well as 
removal by the NER machinery of these lesions accounts for one of the mechanisms of 
acquired or intrinsic resistance of platinum-based anticancer drugs. The possible platinum-













Figure 1.5: Different structural cross-links formed by platinum complexes on DNA 
nucleobases.43 
8 | P a g e  
 
The activity of cisplatin and related compounds can be reduced in vivo by platinum 
loving biomolecules. Since Pt(II) is a soft and easily polarizable ion, it has a great affinity to 
bind to other soft donors. Among these are nitrogen and sulphur-containing proteins and 
amino acids. This binding to biological substrates leads to the development of resistance of 
tumours to treatment. Acquired resistance of cisplatin as well as other active platinum 
complexes can also be a result of the following:39,44,45 
 Inefficient absorption of the drug leading to reduced levels of uptake and/or increased 
efflux. 
 Reactions with cellular sulphur-containing platinophiles, e.g. Glutathione (GSH) and 
Metallothionein (MT). 
 Efficient DNA repair and/or increased damage tolerance, and  
 Failure of cell-death pathways (apoptosis) due to repair of platinum-modified DNA 
lesions. 
1.2.3 Active cisplatin analogues 
Cisplatin chemotherapeutic index is unsurpassed and thus widely employed as a 
standalone or in combination with other non-metal anticancer drugs.33 Despite impressive 
treatment rates of up to 45 to 95 % for testicular cancer, its clinical use is impeded by severe 
and unpleasant side-effects (cumulative nephrotoxicity being dose-limiting) which 
significantly lowers its pharmacological efficacy.46,47 These drawbacks are promoting 
scientists to engage in platinum drug-development research. The fundamental goal of this 
study was to design (whilst adhering to the SAR rules) and synthesise potential drug 
candidates which would address cisplatin short-comings such as its selective cell-killing ability. 
Emphasis was for the future drugs to show minimum or no side effects for the benefit of 
patients.  
Carboplatin (cis-diammine-[1,1-cyclobutanedicarboxylato]platinum(II) (CDBCA or 
JM8) (Figure 1.1 (b)), was developed in the UK and introduced into the clinics in 1989.26,48 It 
retains the similar structural attributes as cisplatin with two inert (ammine groups) as well as 
the bidentate labile (cyclobutane-1,1-dicarboxylato unit) ligand in a square-planar geometry 
associated with compounds designed from a ‘classical’ SARs viewpoint. The six-membered 
cyclobutane-1,1-dicarboxylato sub-unit introduces enhanced kinetic stability against 
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hydrolysis and good aqueous solubility.18,39 This ensures slow associatively-activated ligand 
substitution reactions of the drug in vivo.31 As a result, carboplatin is less toxic (diminished 
kidney toxicity and neurotoxicity) when compared to cisplatin despite having both drugs 
exhibit a similar spectrum of activity to tumours. Lower toxicity of carboplatin allows for a 
higher average dose of 400 mg/m2 when compared to the 100 mg/m2 for cisplatin.11,23,31  
Just like cisplatin, carboplatin is also administered intravenously; oral administration 
has been shown to cause gastrointestinal toxicity and poor absorption in patients.5 
Myelosuppression, particularly thrombocytopenia, is dose-limiting for this drug.26,31,47 
However, the use of combination of carboplatin with other active drugs, notably paclitaxel 
and gemcitabine in vitro,49 results in better cytotoxicity and reduced toxicity.13 Combination 
therapy is effective on ovarian, head and neck and bladder cancers as well as on non-small 
cell lung cancer.49 
Another ‘second generation’ drug resembling carboplatin, cis-diammine-gylcolato-
O,O’-platinum(II) (nedaplatin or 254-S (Figure 1.1 (d)), (granted permission in 1995 only in 
Japan) showed encouraging results at Phase II trials for treating head and neck, testicular, 
lung, oesophageal, bladder, ovarian, and cervical cancers.22,48 The cis ammine non-leaving 
groups in nedaplatin are retained as in cisplatin and carboplatin. Due to the thermodynamic 
“chelate effect” the complex has additional stability when compared to its non-chelated 
analogues.50 The ring-forming glycolate, improves the water solubility (10 mg/mL) of the 
complex when compared to the mono-dentate chloride ligands of cisplatin (2.5 mg/mL).25 
Nedaplatin shows reduced nephrotoxicity, neurotoxicity, and gastrointestinal toxicity when 
compared to cisplatin.49 However, further tests have since been abandoned due to severe 
myelosuppression being dose-limiting as well as for not showing any significantly better 
potency toward cisplatin-sensitive and resistant tumours.31  
Although carboplatin and nedaplatin are less toxic than cisplatin, they are only 
sensitive in the same regime of cells as cisplatin. Kidani and co-workers synthesised trans-L-
diaminocyclohexane)oxalatoplatinum(II) (oxaliplatin or L-OHP (Figure 1.1 (c)), a complex 
which was later discovered to have enhanced efficacy and lower resistance and toxicity when 
compared to cisplatin.51,52 This drug is not cross-resistant with either cisplatin nor carboplatin 
in sensitive cells. It is mainly used for the treatment of secondary metastatic colorectal 
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cancer.13 Cisplatin and carboplatin are inactive against this cancer. It also does not exhibit 
neurotoxicity; myelosuppression nor ototoxicity.  
By introducing the bulky 1,2-diaminocyclohexane (DACH) carrier ligand, this complex 
showed a lack of cross-cellular resistance in cisplatin-resistant cell lines.51 The difference in 
activity of this drug is linked to the formation of the {cis-Pt(DACH)}4 adducts, which are 
different to those formed by cisplatin, carboplatin and nedaplatin. It is also used as a 
combination drug. For instance, a combination of oxaliplatin and 5-fluorouracil (5FU)/folic 
acid (FA), gemcitabine, cisplatin, carboplatin, topoisomerase I inhibitors, and taxanes 
enhances the treatment rates compared to when the drug is used as a single agent.4,49 
Oxaliplatin, however, has limited approval for clinical use in China, Europe and, for colorectal 
cancer, in USA.24    
Heptaplatin (Figure 1.1 (e)) developed under the name SKI 2053R) was approved by 
the Korean Food and Drug Administration in 1999 for the treatment of gastric cancer.25 The 
two R stereo centres in the seven-membered chelating carrier ligand are presumed vital for 
the anti-tumour activity of this drug. The leaving dianionic ring-forming group, malonate, can 
be hypothesised to introduce slow ligand aquation due to enhanced stability as well as 
conferring good saline solubility similar to carboplatin (vide supra). This is significant since the 
drug has a lower toxicity profile when compared to cisplatin.  
Lobaplatin (1,2-diaminocyclobutanelactatoplatinum(II) (D-19466) (Figure 1.1 (f)), has 
clinical approval only in China, received in 2010.20 It is clinically utilized for the treatment of 
chronic myelogenous leukemia (CML), small cell lung cancer (SCLC), and metastatic breast 
cancer.49 Patients undergoing lobaplatin treatment experience gastrointestinal side-effects 
with hematologic toxicity being dose-limiting.20  
The investigations that have been made to date, prove that a careful study on the 
effect of changing the structure for both the non-leaving and leaving groups around the 
square-planar geometry, remains a promising approach into unlocking new drugs of improved 
potency.41,53 A recent study by Liu et al.54 on oxaliplatin derivatives has demonstrated that 
altering the structure of carboplatin by introducing a dichloroacetate group in the 1,1-
dicarboxylate moiety produces derivatives that induce marked activity on human (A549) and 
ovarian (SK-OV-3, SK-OV-3/DDP) cancer cell lines. 
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Recently, Shahabadi et al.55 reported the synthesis of a cis-Pt(II) complex which 
adheres to the benchmark ‘classical’ SAR rules (Figure 1.6). The structure has been altered 
from the cis-ammines of carboplatin to bear a 4,7-diphenyl-1,10-phenathroline bidentate 
chelate.55 Such alterations in structure are anticipated to have reduced toxicity of the 
compound as was found for carboplatin.  The complex was used for DNA studies using calf 
thymus DNA.55 The mode of DNA binding was found to be the formation of adducts though 
DNA-intercalation.55 The binding of the complex causes a kink in the double-helical structure 







Figure 1.6: Structure of DNA-intercalating [PtCl2(DIP)], DIP = 4,7-diphenyl-1,10-
phenathroline.55 
 
1.3 Non-classical platinum complexes:  A unique mechanism of activation to 
cisplatin 
1.3.1 trans-Pt complexes 
A group of trans square-planar Pt(II) complexes emerged that disobeyed the initially-
proven structure-activity relationships blueprint for active metallo-drugs.56,57 It had been 
established initially that the geometric isomer of cisplatin, trans-
diamminedichloroplatinum(II), trans-DDP (Figure 1.7 (g)), had no cancer killing properties.57 
This was attributed to its kinetic instability caused by rapid hydrolysis in vivo.39 Additionally, 
trans-DDP was incapable of forming the important 1,2-intrastrand DNA crosslinks known for 
the cytotoxic effect of cisplatin.39 The kinetically preferred 1,3-intrastrand crosslinks formed 
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by trans-DDP on DNA bases were easily recognised and repaired by the nucleotide excision 








Figure 1.7: Structures of inactive transplatin (g) together with active trans-Pt(II) complexes 
with various heterocyclic N-donor ligands.56 
Altering the structure of transplatin by introducing sterically hindered or planar 
heterocyclic nitrogen spectator ligands afforded therapeutic drugs with a different spectrum 
of activity from cisplatin. The active trans-Pt(II) complexes generally have the formula trans-
[PtCl2(NH3)(L)] and trans-[PtCl2(L)(L’)] comprising: 
i. L = N-donor aromatic heterocycle and L’ = ammine, sulphoxide or a second aromatic 
N-donor ligand;56 
ii. L = iminoethers and ketimines and L’ = ammine or iminoether; and 
iii. L = aliphatic amines and L’ = a secondary aliphatic amine. 
The mode of activity of these groups of trans-Pt(II) compounds is different from that of their 
cis counterparts: the former characterised by the formation of mono-functional adducts and 
interstrand cross-links with DNA.  
 1.3.2 Multinuclear Platinum complexes 
One of the promising approaches of circumventing platinum acquired or natural 
resistance in tumours was to develop polynuclear (i.e. bi-, tri, or tetranuclear) platinum 
complexes.45,59 Failure by many cisplatin analogues to overcome resistance is primarily due 
to the formation of similar Pt-DNA adducts as the prototype drug. The many possibilities in 
L and L' =
(g) trans-[Pt(Cl)2(NH3)(L)] and trans-[Pt(Cl)2(L)2]
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which multinuclear Pt compounds can bind to DNA meant that unique adducts could be 
formed with DNA purine bases. The unique adducts would induce distinct anticancer activity 
in cells that are insensitive to cisplatin.  
Because these compounds possess two or more platinum metals tethered by a flexible 
or rigid linker, they are able to bind covalently with DNA at more than one side forming long 
range intra- or interstrand cross-links which are immune to repair by proteins.25 Multinuclear 
complexes induce different conformational changes on the helix of DNA. Thus, cytotoxicity 
profiles were found to be different from those of cisplatin whilst also being active against 
cisplatin-resistant tumours.25  
The lead compound in this class of complexes is a tri-nuclear compound BBR3464 
(Figure 1.8).45 The structure consists of two trans-[PtCl(NH3)2] units joined by a tetra-amine 
[trans-Pt(NH3)2{H2N(CH2)6NH2}2]2+ unit. BBR3464 has a high formal charge of +4 which confers 
the compound with enhanced molecular binding to DNA when compared to neutral cisplatin 
and related drugs. Since it possesses two platinum binding sites, BBR3464 can form long-
range intra- and interstrand cross-links unique and different to cisplatin and related 







Figure 1.8: Structure of trans-{bis[trans-diamminechloroplatinum(II)(µ-1,6-hexadiamine)]} 
diammineplatinum(II).45 
1.3.3 Platinum(IV) pro-drugs 
A great deal of research has focused on Pt(II) complexes at the expense of Pt(IV) 
despite a Pt(IV) compound being identified as one of the two compounds that had led to the 
inhibition of bacterial DNA replication in early experiments by Rosenberg.60 The ligand 
BBR3464
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substitution reactions of Pt(IV) compounds are slower when compared to their Pt(II) 
counterparts due to their octahedral structure. Thus, they have a greater pharmacological 
chance to survive inactivation. They are orally administered due to a higher formal charge.61,62 
Most importantly Pt(IV) drugs can be used in sophisticated ‘synchronous’ targeting and 
delivery systems.25,63,64 Activation of Pt(IV) drugs occurs via an irreversible redox-reduction 
step in vivo, resulting in loss of the two axial ligands, to yield their active cis-Pt(II) complexes 
which react with the target DNA.61,65 The biochemical intra- and/or extracellular components 
are known to aid in this process. Glutathione and ascorbic acid are intracellular reducing 
agents that have been reported to facilitate the two-electron reduction process of Pt(IV) 
compounds through reaction steps compared to other related thiols.65,66 For this reason, 
active Pt(IV) compounds are pro-drugs and the structures of some active complexes are 










Figure 1.9: Structures of Pt(IV) complexes which have undergone clinical trials. 
The kinetics of the reduction of several Pt(IV) complexes containing various carrier 
groups have been studied with reductants such as GHS66, ascorbate52, 5’-GMP.67,68 The axial 
ligand bonds confer varying kinetic stabilities which affect both the rate of substitution and 
reduction. The steric hindrance and electronic factors in the axial and carrier ligands were 
observed to greatly influence the reduction potentials of these Pt(IV) complexes.39 This in turn 
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 Figure 1.10: Hydrogen peroxide-assisted oxidation of cisplatin to its octahedral Pt(IV) 
derivative, which is subsequently reduced by a biological reductant.63 
Ormaplatin (also known as tetraplatin) is a Pt(IV) pro-drug for oxaliplatin comprising 
of a DACH ligand as a trans-R,R- and  trans-S,S racemic mixture. Ormaplatin has marked 
cytotoxic effects against cisplatin-resistant cell lines as well as showing diminished 
nephrotoxicity when compared to cisplatin.49 However, ormaplatin failed Phase I of clinical 
trials due to its acute brain toxicity encountered by patients. The cyclohexane-1,2-diamine 
motif in this drug is proposed to confer this neurotoxic effect similar to its Pt(II) congener 
oxaliplatin.32  Iproplatin (cis,trans,cis-dichlorodihydroxobis(isopropylamine)platinum(IV), 
JM9) is another drug that went to clinical trials as a potential anticancer active compound.25 
It is cytotoxic to cancers of the lung, ovary, breast, head and neck, as well as showing no cross-
resistance with cisplatin and carboplatin. However, it does not readily undergo reduction by 
bio-related reductants.25 This is proposed to aid in a prolonged bio-distribution of the drug in 
the biological system. Nevertheless, it has not met the crucial requirements to permit its use 
as an anti-proliferative cancer agent.25   
Satraplatin, (bis(acetato)ammine-dichloro(cyclohexyamine)platinum(IV), JM216) is an 
orally administered Pt(IV) lipophilic cytotoxic, active in hormone-refractory prostate cancer.49 
It comprises of a cisplatin-like fragment (cis ammine and aminocyclohexane non-leaving 
ligands) and two axial acetate ligands. The drug undergoes an in vivo reduction elimination 
reaction with a loss of the axial acetate ligands. This biotransformation produces several 
products, the most prominent being JM118 (cis-amminedichloro-
cyclohexyamineplatinum(II).26 The drug interacts with DNA bases by most likely forming the 
adducts having the {Pt(NH3)(NH2C6H11} fragments. Combination therapy of satraplatin 
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together with an anti-inflammatory agent, prednisone, for the treatment of hormone-
refractory prostate cancer looks promising with survival rates of 14.9 months in patients 
compared to 11.9 months for prednisone alone.26,69  
LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) is a 
novel Pt(IV) drug that has recently entered Phase I clinical trials. It bears a 1-adamantylamine 
non-leaving group which differs from the cyclohexylamine ligand contained in its derivative 
satraplatin. LA-12 shows superior cytotoxic effects than cisplatin and satraplatin, as well as 
reduced acute toxicity in vivo.20   
1.4 Non-platinum anticancer active complexes: ruthenium complexes as 
anticancer agents 
The slow ligand exchange kinetics of ruthenium, particularly Ru(II) and Ru(III) ions, are 
comparable to that of Pt(II), making this transition metal ion a favourable candidate for 
anticancer and anti-metastatic investigations.69 Ru(III) is transported as a complex by serum 
proteins called transferrins.44 This is because ruthenium has the ability to imitate iron species, 
a property which suits it well for medicinal purposes such as tumour targeting.70 However, 
there is not much research that has been conducted on ruthenium complexes as potential 
anticancer agents. This presents a need for Ru-focused research as anticancer agents. The 
scope can include the development of homonuclear (Ru-Ru) and heteronuclear (Ru-Pt, Ru-
Pd) complexes. A change of the metal ion to Ru may give complexes with better and low 
toxological profile, good aqueous solubility for oral administration, improved spectrum of 
anticancer activity and more vitally compounds showing minimum or no resistance to 
tumours. The structures of the two most promising Ru(III) compounds that have entered 
human clinical trials are shown in Figure 1.11. 
The first ruthenium compound to enter clinical trials for cancer treatment was the 
low-spin d5 octahedral ruthenium(III) complex, NAMI-A, imidazolium trans-[tetra-
chloro(dimethlysulfoxide)(imidazole)ruthenate(III)].71 The activity of NAMI-A is dissimilar to 
that of cisplatin where covalent bifunctional adducts with DNA are formed. NAMI-A is 
transported by a vesicle transferrin receptor-mediated endocytosis mechanism to the site of 
cancerous cells where it gets localised unhindered as a Ru(III) species. It induces its activity by 
suppressing tumours.69 At the site of action and under conditions of low pH,  the inert Ru(III) 
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complexes undergo an activation-by-reduction reaction to their active Ru(II) congeners.70 
Therefore, in this manner they act as pro-drugs. The metal-metal bond formation of the Ru-
transferrin complex is reversible.44 NAMI-A is active against secondary metastatic tumours. A 
formation of severe blisters on the hands and feet of patients undergoing NAMI-A therapy 










Figure 1.11: Anticancer and anti-metastatic Ru(III) agents NAMI-A71 and KP101970 which act 
by unique mechanisms to Pt(II) compounds. 
Indazolium Ru(III) complex trans-[tetrachloro-bis(1H-indazole)ruthenate(III)] (KP1019 
or FFC14A) is an anticancer agent with comparable rates of hydrolysis as cisplatin.44 Unique 
to NAMI-A, KP1019 does have cytotoxic effects against primary tumours such as colorectal 
cancer, for which clinical trials are still undergoing.69 A similar mechanism of transport to that 
of NAMI-A is proposed for this cytotoxic in which two ligands of the KP1019 complex bind to 
transferrin. The exact mechanism for the cytotoxicity it is not fully known. When delivery of 
KP1019 to the cancerous cells occurs, the drug can either bind to biomolecules such as DNA, 
preferentially to guanine and adenine residues,69 forming Ru-DNA strands which cause a kink 
in the double-helical structure. Alternatively, the drug may interact with histidine protein 
residues,69 although this latter mechanism has no substantial backing. Between these two 
ruthenium-based antineoplastic drugs, only KP1019 has been proposed to enter Phase II of 
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1.5 Mechanistic studies of cis-Pt(II) and Pd(II) complexes with bidentate non-
leaving ligands 
The realisation that antitumour activity could still be maintained when mono-dentate 
ammine (NH3) groups of cisplatin are substituted by bidentate ligands as found in the 
structures of carboplatin, oxaliplatin and other complexes raised the hope that a future 
cisplatin analogue can be possible through careful choice or adjusting of the peripheral groups 
on existing bidentate ligands.29 An example of such design attempts is the DNA intercalator 
and covalent binder PtCl2(DIP), presented in Figure 1.6 in Section 1.2.3 of this Chapter. 
Kineticists are curious to understand the reactivity and mechanism of such candidate 
complexes. 
Summa et al.72 synthesised a series of cis-Pt(II) complexes with en 
(ethylenediammine), dach (cis-1,2-diaminocyclohexane), amp (2-aminomethylpyridine) and 
bipy (N,N’-bipyridine) N,N-bidentate chelates (Figure 1.12) and studied their substitution 
reactions with bio-relevant nucleophiles viz., (thiourea (tu), L-methionine (L-Met) and 
guanosine-5’-monophosphate (5’-GMP). The rate of aqua substitution from the complexes 
was studied under pseudo-first order conditions. The rate increased with increasing number 
of pyridines due to back donation of electrons from the metal orbitals into the π*-acceptor 









Figure 1.12: Structures of the cis-Pt(II) complexes with N,N-bidentate chelates studied by 
Summa et al.72 
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In the case of dach, the rate was influenced by the positive inductive donation toward the Pt 
metal centre as well as steric bulk effects, both of which decreased the rate. The ratio for the 
magnitude of retardation from en to bipy was observed to be: tu (1:149); L-Met (1:31); and 
5’-GMP(1:6).   
In another study, Summa et al.73 reported the aqua substitution from Pt(dach) 
derivatives differing in the bidentate groups O-O (CBDCA; O,O-cyclobutane-1,1-
dicarboxylate); N-O (gly, glysine), and N-S (L-Met, methionine) (Figure 1.13 below) using 
thiourea (tu), L-methionine (L-Met), glutathione (GSH) and guanosine-5’-monophosphate (5’-
GMP) as nucleophiles. Substitution of bidentates proceeded consecutively via a direct 
nucleophilic attack of one end (ring-opening) of the coordinated O-O (CBDCA; O,O-
cyclobutane-1,1-dicarboxylate ); N-O (gly, glysine),and N-S (L-Met, methionine) followed by 







Figure 1.13 Structures of the Pt(dach) analogues studied by Summa et al.73 
The reactivity of the complexes increased in the following order: Pt(dach)(CBDCA) < 
Pt(dach)(L-Met) < Pt(dach)(gly). The trend in the reactivity of the nucleophiles was: thiourea 
> GSH > L-Met > 5’-GMP. The soft S-donor biomolecules have a high affinity for platinum 
which may exacerbate the in vivo toxicity of Pt(II) drugs in addition to deactivating them 
before reaching the nucleus of the cell. Thus, the in vitro kinetic data as well as the proposed 
mechanisms of substitution affords a better understanding of the possible modes of 
interactions of such complexes with platinophiles prior to DNA binding. 
Recently, Ray et al.74 compared the reactivity of Pt(dach)(oxalate) and 
Pt(bipy)(oxalate) towards thiourea, 2-thiouracil, diethyldithiocarbamate, DL-peniciallamine 
    Pt(CBDCA)   Pt(gly) Pt(L-Met)
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and thiosermicarbazide. The Pt(dach)(oxalate) complex was used to model the in vivo 
reactivity of oxaliplatin. They observed the same order of reactivity reported by Summa et 
al.73 Pt(bipy)(oxalate) was found to be more reactive when compared to Pt(dach)(oxalate) 
towards all the nucleophiles. The bipy ligand of Pt(bipy)(oxalate) disperses electron density 
from the metal via the π-acceptor effect. This makes the Pt(II) metal centre more electrophilic 
and better at stabilising the transition state during the formation of a new bond with the 
incoming nucleophile. The rate of substitution is thereby increased.   
Bogojeski et al.75 examined the chloride ligand substitution reactions of four cis-Pt(II) 
complexes bearing N,N-carrier groups. Two of the complexes that were studied, [Pt(dach)Cl2] 
and [Pt(en)Cl2], were similar to those studied by Summa et al.76 However, Summa’s complexes 
were aqua derivatives which by comparison, were more reactive towards N-donor 
nucleophiles namely 5’-GMP, L-histidine and 1,2,4-triazole. Since the aqua ligand is weaker 
when compared to the chloride ligand and it is easily substituted.77 Similarly, the [Pt(dach)Cl2] 
complex is more labile than [Pt(dach)(CBDCA)] or [Pt(dach)(gly)] towards substitution.73 Put 
together, the rate of substitution from the cis-Pt(II) complexes with N,N-bidentate non-
leaving ligand could be controlled either by varying the inert spectator ligands or the labile 
leaving groups and this can be a gateway to optimise their potential cytotoxicity. 
Kinetic data of Pd(II) complexes is relevant to the search of antitumour metallo-drugs 
even though their reactivity are 104-105 times more than those of Pt(II) complexes which are 
considered reference cytostatic complexes due to their moderate and comparable rate of 
ligand exchange to that of replication in cancerous cells. Bogojeski et al.78 investigated the 
rate of chloride substitution in a set of cis-Pd(II) complexes. Imidazolin-2-imine spectator 






dimethyl-imidazol-2-imine, DACH(ImiPr)2) of varying steric and electronic properties were 
coordinated to the Pd(II) metal centre (Figure 1.14). The complex [Pd(en)Cl2] was used as a 
model reference to the reactivity of cisplatin. The reactivity trend for the step-wise 
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substitution of the chloride ligands by all bio-relevant nucleophiles thiourea (tu), L-methionine 
(L-met), L-histidine (L-his) and glysine (gly) decreased in the order: [Pd(en)Cl2] > 
[Pd(EAImiPr)Cl2] > [Pd(DMEAImiPr)Cl2] > [Pd(DPENImiPr)Cl2] > [Pd(BLiPr)Cl2] > 
[Pd(DACH(ImiPr)2)Cl2].  
The rate constants, k1 and k2 for the first and second substitution steps decreased by 
factors of 4238: 762: 41: 31: 1 and 215: 12: 6: 4: 3: 1 for [Pd(en)Cl2]: [Pd(EAImiPr)Cl2]: 
[Pd(DMEAImiPr)Cl2]: [Pd(DPENImiPr)Cl2]: [Pd(BLiPr)Cl2]: [Pd(DACH(ImiPr)2)Cl2], respectively, 
when thiourea (tu) was the entering nucleophile.78 The reactivity trend was attributed to both 
steric bulkiness and σ-donation properties of the substituents on the imidazolin-2-imine non-
leaving ligands.78 Donation of electron density onto the Pd(II) centre leads to a decrease in 
electrophilicity of Pd and slowing of the approach of the entering ligand, leading to lower 
rates of substitution. Through careful design of the steric hindrance/bulk of non-leaving and 
leaving groups the highly reactive and anti-tumour inactive Pd complexes can be kinetically 
moderated into less reactive species which may be anti-tumour active and have good 







Figure 1.14: Structures of Pd(II)-imidazolin-2-imine complexes studied by Bogojeski et al.78  
Hochreuther et al.79-81 investigated the σ-donor and π-acceptor effects on the rate of 
substitution from two diaqua cis-Pt(II) complexes namely, Pt(mtp) (mtp = 2-
methylthiomethylpyridine) and Pt(amp) shown in (Figure 1.15). The complexes bear a 
thioether (-SCH3) and pyridine ring or amine (-NH2) in their bidentate ligands. The thioether 
and primary amine units have different effects on the rate of substitution of the leaving 
groups. The first aqua ligand to be substituted is the one trans to the S-thioether due to the 
[Pd(en)Cl2] R' = H      [Pd(BL
iPr)Cl2]
R' = DACH   [Pd(DACH(ImiPr)2)Cl2]
R' = H  ; R = H     [Pd(EAImiPr)Cl2]
R' = H  ; R = CH3 [Pd(DMEAImiPr)Cl2] 
R' = Ph; R = H      [Pd(DPENImiPr)Cl2]
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strong trans labilizing effect of sulphur in the Pt(mtp) complex. However, in Pt(amp), the aqua 
ligand trans to pyridine is substituted first as was also noted by Samanta et al.82 on the same 
complex. The pyridine ring accepts electron density from the metal centre rendering it more 
electrophilic and increasing the rate of aqua ligand substitution. Between the two complexes, 
Pt(mtp) is more reactive than Pt(amp). Similar results were reported for the dinuclear Pt 





Figure 1.15: Structures of mononuclear Pt(II) complexes studied by Hochreuther et al.79-81  
1.6 Aims of the Study 
For more than 40 years since its discovery and clinical use, cisplatin has proven to be 
the only superior platinum-based drug.29 Several structurally related ‘classical’ derivatives as 
well as structurally unrelated ‘non-classical’ compounds were subsequently produced but 
with less efficacy when compared to cisplatin. The need to find novel platinum complexes 
with better anti-mutative properties but diminished natural or acquired resistance to cancer 
proliferation still exists. Rational design of platinum complexes with carefully chosen carrier 
ligands to facilitate their stability may be one of the many approaches in the search of new 
lead Pt-compounds for clinical trials. In general, chelation of a non-leaving group stabilises 
the square-planar Pt(II) geometry, and where the ligand is planar, the complex may 
intercalate between the base pairs of DNA in addition to covalent binding to it, both of which 
induces helical instability and downstream apoptotic-related cellular pathways. Imperative to 
this search of lead compounds is the kinetics and thermodynamics data. Such data is 
fundamental in understanding mechanisms of drug toxicity in general and specifically the 
mode of alleviating sulphur deactivation through chemo-protection and reducing the intrinsic 
reactivity of platinum(II) complexes.62,77 Square-planar platinum complexes can be 
systematically modified through electronic push-and-pull factors as well as steric effects.  
Pt(mtp) Pt(amp)
2+ 2+
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In the current study, six mononuclear cis-Pt(II) complexes with mixed N,S-bidentates 
comprising of either a 2-(phenylthiomethyl)pyridine or 2-(phenylthiomethyl)quinoline core 
chelates were synthesised and characterised. The thioether was incorporated into the non-
leaving group to stabilise the complexes against aqueous hydrolysis (Figure 1.16 below). The 
difference in the structures of the N,S-bidentate enables one to infer on the effect on the rate 
of substitution of changing the N-donor (pyridyl/quinolyl), and also the role of the 
substituents on the phenyl ring of the thioether S-donor end of the bidentate chelates. Their 
substitution kinetics was done using bio-relevant thiourea nucleophiles under pseudo-first-















Figure 1.16: Structures of cis-Pt(II) complexes with N,S-bidentate ligands.   
As already pointed out, there are few reports on the reactivity of cis-Pt(N,S)(H2O)2.81 
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on the rates of aqua substitution from a structurally related set of cis-Pt(N,N)(H2O)2 where 
N,N is a flexible (pyrazolylymethyl)pyridine or (pyrazolylmethyl)quinoline bidentate ligand. An 
interesting anomalous trend was that the analogues complex with a quinoline in the N,N-
bidentate was less reactive when compared to its pyridine counterpart. This was attributed 
to the accumulation of electron density on the metal centre due to the relative poor π-
acceptor ability of quinoline despite its conjugated benzopyridine rings. This anomalous 
observation was first reported in the work of Ongoma and Jaganyi.85 Kinunda and Jaganyi 86 
and Wekesa and Jaganyi 87 also confirmed a slow rate of substitution of the leaving group for 
tridentate Pt(II) complexes, where the quinoline formed part of the chelate in a cis position. 
Also noted was that one of the pyridine coordinated-complex studied by Khusi et al.83 had 
been shown by Segapelo et al.53 to have remarkable cytotoxicity against a model of human 
HeLa cell lines.  
The nucleophiles viz., thiourea (tu), N,N’-dimethylthiourea (dmtu) and N,N,N’,N’-
tetramethylthiourea (tmtu) were carefully chosen because of their biological relevance. 
These S-containing nucleophiles have an interesting biphilic character in that they can either 
act as σ-donors (thioether) or π-acceptors (thiolates), a property which is also known for some 
biomolecular species.  Therefore, it is vital to understand the reactivity of these model cis-
Pt(II) complexes with such nucleophiles to elucidate their possible mechanism of action with 
the hope of advancing the medicinal use of metal-based drugs.     
For convenience of reporting, the six complexes were grouped into sub-groups i.e. 
those that have pyridine and quinoline at the donor end of the N,S-bidentate. Through a 
comparative analysis of the second order rate constants, k1 and k2, in each sub-category of 
the complexes, the effect of the substituent on the phenyl ring of the thioether on the 
reactivity of the Pt complexes was assessed. A comparison of the rates of substitution for 
paired analogues of the pyridine/quinoline in each set was used to confirm the effect of 
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Chapter 2 
Theoretical considerations of the substitution reactions in square-planar 
complexes 
2.0 Introduction 
Extensive research has been carried out on the substitution of Pt(II) square-planar complexes 
since the discovery of the antitumour properties of cisplatin by Rosenberg and co-workers.1 
The mechanism by which cisplatin imparts its cytotoxicity involves, in part, nucleophilic 
substitution reactions with DNA nucleobases.2 Data on the substitution kinetics of Pt(II) 
complexes cement the understanding of the interactions of the complexes in terms of 
maximising efficacy and minimising toxicity of potential new anticancer compounds and the 
development of resistance from cytoplasmic nucleophiles.3 
A ligand substitution reaction entails replacement of a labile ligand in the coordination 
shell by another usually with stereochemical retention.4 In an act of a simple substitution, 
there is no change in the oxidation state of the reaction centre. However, since bond-making 
and bond-breaking processes are involved, there is a temporary change in the coordination 
number in moving reactants to the transition state.  
Substitution at the metal centre of coordination complex is similar to one at the 
carbon atom for organic reactions. In inorganic reactions, substitution reactions are classified 
per the way bonds are formed or broken. An electron pair in a chemical bond can be broken 
by having both electrons being shared between the reaction centre and the process is 
referred to as a homolysis reaction.5 If an electron pair is added to the new bond with the 
reaction centre the process is called electrolytic.5 If the leaving group departs with its pair of 
electrons, the bond between the electrophile and the nucleophile is said to have dissociated 
heterolytically. The aforementioned reactions can be described according to Equations 2.1 - 
2.3, in which M and X represent the metal centre and the leaving group, respectively.6  
M : X    →     M* +   X* Homolysis            (2.1) 
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M : X    →     M+ + : X- Nucleophilic heterolysis          (2.2) 
M : X    →     M: - +   X+ Electrophilic heterolysis          (2.3) 
Electrophilic and nucleophilic heterolysis processes correspond to the organic-type 
Lewis acid-base reactions. An electrophilic process presents the metal centre (M) as a Lewis 
base whilst a nucleophilic process presents it as a Lewis acid. In the latter case, the oxidation 
state of the reaction centre is insensitive to the change in number of the coordinated ligands 
and has no effect upon the number of bonding electrons.4, 5 However, the electrophilic 
process is sensitive to the bonding of the previously non-bonding electrons, which correspond 
to a two-electron oxidation. Departure of the ligand as a Lewis acid completes the 
electrophilic substitution, whilst the attachment of a Lewis base (+L :) from the medium leads 
to a stabilization of the higher oxidation state. The electrophilic bonding and non-bonding 
processes are summarized in Figure 2.1 below.    
Two-electron reductive

















32 | P a g e  
 
2.1 Substitution reaction mechanisms 
The concepts of stoichiometric and intimate mechanisms, were coined by Langford 
and Gray to describe the modes of substitution of inorganic reactions particularly those of 
transition metals (Figure 2.2).7 The stoichiometric mechanism is classified according to three 
categories depending on the nature of the intermediate species:4,5,8 
I. An associative (A) process – the reaction coordinate has an identifiable intermediate 
of higher coordination number formed by an attack of the entering ligand onto the 
coordination sphere. The formation of the new bond is the rate-determining step, and 
hence the rate of the reaction is sensitive to the entering ligand. The first transition 
state (T.S.1) has a maximum of higher energy when compared to that of the second 
(T.S.2). 
II. A dissociative (D) process – is characterized by an intermediate of lower coordination 
number in which a bond on the reactant is broken first. The rate of reaction is 
dependent upon the strength of the bond between the metal and the leaving group 
making it the rate-determining step. The second transition state (T.S.2) has a 
maximum of higher energy when compared to that of the first (T.S.1). 
III. An interchange (I) process – has an act of bond-breaking and bond-making occurring at 
the same time or within a pre-formed aggregate. 
The stoichiometric interchange mechanism can be further classified per its intimate 
character, which is an indication of its mode of activation. 
I. Associative Interchange (Ia) – the rate-determining step and hence the transition 
state is the formation of the bond between the metal (M) and the oncoming ligand 
(Y). 
II. Dissociative Interchange (Id) – the rate-determining step and transition state is the 
breaking of the bond between the metal (M) and the leaving ligand (X). 
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Figure 2.2 Energy profile of the substitution mechanisms moving from D or Id to A or Ia. 
2.2 Substitution Reactions of Square-planar Complexes 
The mechanism of ligand exchange in square-planar, particularly of Pt complexes has 
been studied extensively. This is due to the ease with which reactions can be monitored 
because of their time-scale.9-11 Square-planar complexes are formed from coordination of 
four ligand sites around a d8 metal ion such as Pt(II), Pd(II), Au(III), Ni(II), Rh(I) and Ir(I) to form 
16-electron species which are coordinatively unsaturated. They can easily undergo oxidative 
addition to attain an 18-electron octahedral coordination geometry.12 This can be viewed as 
the mechanism that is prevalent if their substitution is associative. However, when the 
mechanism involves the loss of electrons from a 16-electron square-planar to form a 14-
electron three-coordinate (T-shaped) transition state, substitution is described as being 
dissociative.13 These cases are rare and require that the non-leaving ligand is sterically bulk 
so that the approach of the oncoming ligands is well shielded.14  
Alkyl and aryl groups with positive σ-inductive effects coordinated directly onto the 
metal ion aid the accumulation of electron density onto the metal centre, making it 
electronegative. This results in the repulsion of charge from the oncoming ligands. Romeo 
and co-workers15 studied the thioether ligand substitution by nucleophiles in complexes of 
the type cis-[PtR2S2] (R =Me or Ph; S = thioethers or Me2SO). The mode of substitution was 
dissociatively activated.  
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2.2.1 Mechanism of Substitution 
The mechanism of substitution in square-planar complexes usually involves a direct 






Represented by reaction 2.4 is a bimolecular substitution of the leaving group (X) 
containing a two-term rate law. The first term is first-order with respect to the complex 
(PtL2AX) while the second is first-order with respect to both the metal complex (PtL2AX) and 
the entering nucleophile (Y)  
= −
[ ]
=  [ ] + [ ][ ] = ( + [ ])[ ]     (2.5) 
If the concentration of the entering ligand, [Y], is at least 10-fold greater than the 
concentration of the complex, [PtL2AX], then Equation 2.5 simplifies to Equation 2.6, where 
the observed pseudo-first-order rate constant, kobs, is related to individual rate constants by 
Equation 2.7: 
=  [ ]               (2.6) 
=  +  [ ]                         (2.7) 
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[Nu]/ M  
Figure 2.3 Plot of kobs vs [Nu] for the first aqua substitution in the complex cis-[Pt{2-(4-tert-
butylphenylthiomethyl)pyridine}(H2O)2]2+ in 0.1 M LiOTf/HOTf at 25 oC (Chapter 4, Figure 
4.7).  
Under such conditions a plot of kobs vs [Y] yields a linear regression for which the y-
intercept equals to k1 while the slope gives k2, the second-order rate constant for the direct 
substitution of the leaving group (X).7,16 The reaction in Figure 2.3 has plots passing through 
the origin indicating the absence of the k1 term. The value of k1 is independent of the nature 
and concentration of the entering ligand while k2 is sensitive to the nature of the entering 
nucleophile.16,17 
For coordinating solvents, such as water and methanol a rate constant k1 represents 
the rate of solvent participation in the substitution process.18,19 Solvent participation in the 
substitution process is presented in the first pathway in Figure 2.4. For this mechanistic 
pathway, the leaving group (X) is first substituted slowly by the solvent (S) followed by a fast 
substitution of S by the entering nucleophile (Y).18,19  






































Figure 2.4 Substitution in square-planar d8 complexes showing (i) the slow formation of a five-
coordinate solvent-complex intermediate ML2ASX prior to a rapid substitution by entering 
ligand Y and (ii) a direct substitution of the leaving group X by Y.   
In a square-planar geometry the low energy pz orbital of Pt(II) complexes can readily 
accept a lone pair of electrons from an oncoming ligand in the transition state. This leads to 
the formation of an energetically favoured 18-electron five-coordinate transition state during 
the substitution process. Thus in the majority of cases the substitution is characteristically 
limiting associative.4 Evidence of a rapid formation of a long-lived, stable distorted square 
pyramidal five-coordinate intermediate has been isolated and characterized by X-ray 
crystallography for the complex [Pt(bpy)2{PPh(PhSO3)2}].5.5H2O  where bpy = 2,2’-bipyridine 
and PPh(PhSO3)22- = bis(p-sulfonatophenyl)-phenylphosphine.20 Retention of the starting 
geometrical configuration of the cis and trans species during substitution provides further 
proof of an associative mode of substitution in square-planar complexes as shown in Figure 
2.5.       






























Figure 2.5 Retention of the starting geometrical cis and trans configurations during associative 
nucleophilic substitution in square-planar complexes. 
2.2.2 Geometries of the intermediates 
The dominant associatively activated substitution pathway in square-planar complexes has a 
five-coordinate transition state(s) and an intermediate of higher coordination number 
between the two transition states.5,21 As illustrated in Figure 2.5, the substitution process 
occurs with a complete retention of the cis or trans configurations as shown by complexes 1 
and 9 in Figure 2.6. During substitution, the cis ligands occupy the axial positions while the 
entering ligand is positioned on the equatorial site and the process takes place with retention 
of the trigonal bipyramid symmetry for both the transition states and the intermediate 
species.     
















Figure 2.6 Schematic energy profile and possible coordination changes during associative 
substitution in square-planar complexes of ligand X by Y. Energy maxima at 2, 4, 6, and 8 
represent the transition states and intermediates have energies 3, 5, and 7.17 
2.3 Factors controlling the reactivity of square-planar complexes 
The substitution behaviour of the leaving group (X) by the oncoming ligand (Y) in square-
planar complexes is affected by various factors described in the following sections: 
2.3.1 The trans-effect 
The most important role of a non-leaving ligand on the rate of substitution in Pt square-planar 
complexes has been its trans-effect.5,7,8,17,22,23 The leaving group trans to the non-leaving 
ligand can be labilised depending on the strength of its trans-effect. This effect can be through 
σ-inductive or π-acceptor properties of the ligand. This was demonstrated in the classical 
experiment of Werner24 for the synthesis of cisplatin and transplatin via a careful choice of 
the reactants and order of substituting the ligands. The complex order covering the strong σ-
donor/π-acceptor ligand to the least trans-labiliser follows the order:    
CO, CN-, C2H4 > PR3, H- > CH3-, SC(NH2)2 > C6H5-, NO2-, I-, SCN- > Br-, Cl- > py, NH3, OH-, H2O 
The trans-effect is mostly utilized in the synthesis of desired Pt(II) complexes of 
differing cis and trans geometries. A prime example demonstrating the trans-directing ability 
of non-leaving ligands is presented in Schemes 2.1 and 2.2 for the synthesis of the isomeric 
cis- and trans-Pt(NH3)2Cl2 complexes.14    
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+ NH3+ NH3
- Cl- - Cl-
Charges omitted  
Scheme 2.1 Preparation of cisplatin from PtCl42- as a starting reactant. 
The first ammonia (NH3) ligand can enter at any of the coordination sites of the PtCl42- 
complex. The chloro group trans to ammonia in PtNH3Cl3- is inert to substitution by the second 
NH3 ligand due to its greater trans labilizing effect when compared to NH3.14 Therefore, the 
second NH3 group enters the cis position resulting in the formation of cis-Pt(NH3)2Cl2.   
- NH3- NH3
+ Cl- + Cl-
Charges omitted  
Scheme 2.2 Preparation of transplatin from Pt(NH3)42+ as a starting reactant. 
The trans isomer is synthesised from Pt(NH3)42+, in which the already coordinated 
chloride ion in Pt(NH3)3Cl+ substitutes the NH3 group trans to itself for the formation of trans-
Pt(NH3)2Cl2. The trans-effect originates from two theories: the σ-bonding and π-bonding 
theories which are considered in the next section. Both effects contribute to the overall 
influence of a trans-directing ligand on the properties of the trans metal-leaving group bond 
in square-planar complexes.    
2.3.1.1 The σ-trans-Effect 
The σ-trans-effect which can be partially explained by the Grinberg’s polarization theory25 
which presumes the electrostatic dipolar interactions between the Lσ-Pt-X axis, (Lσ = σ-donor 
ligand, X = leaving group) as the drivers for labilising X.26 The dipoles on the Lσ-Pt bond induce 
a dipole on the Pt-X bond trans to it, which is off opposite polarity. This weakens the Pt-X 
bond characterised by a longer bond length.4,14 This is also called the trans-influence of Lσ.7,27 
It affects the thermodynamics of the complex via destabilising the energies of the bond trans 
to the affector ligand which also renders it labile. A true σ-trans-effect will be observed if Lσ 
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has a greater share of the empty 6pσ orbital of the metal in the ground-state when compared 
to the transition state. This would lead to a lesser change in the energy difference between 
the ground and transition states.26 The overlap of the valence orbitals of the σ-trans-directing 
ligands with that of the metal ion 6pσ orbitals determines the strength of the σ-trans-effect 
of that particular ligand. Figure 2.7 illustrates the charge distribution between the trans-
directing ligand (L) and the trans-leaving group (X) on labilizing this bond due to electrostatic 
repulsion of its negative charge and the induced dipole of the Pt(II) metal ion.     
 
Figure 2.7 Charge distribution in induced dipoles by σ-fashion in the L-Pt-X coordinate. (i) The 
σ-bond strengths of L and X are identical (ii) The σ-bond strength of L is much greater than that of X. 
The order of the σ-trans-effect decreases in the following order:       
H- > PR3 > SCN- > I- > CH3-, CO, CN- > Br- > Cl- > NH3 > OH- 
The ligands CO and CN- lie lower in the σ-trans-effect series when compared to the overall 
trans-effect which reflects their influence as π-acceptors which has little effect on this series. 
Effects of π-acceptor ligands on the rate of substitution are considered below.  
2.3.1.2 The π-trans-effect 
The π-trans-effect for square-planar complexes accounts for the change in reaction rate 
induced by a π-acceptor ligand (Lπ) which utilizing empty orbitals of π-symmetry, 
accommodates electron density from the filled metal dxz orbital making it 
electroposititve.14,22,26,28,29 The ground-state of the complex is not affected by π-acceptor 
property of Lπ.18,19,30 Therefore, when a group with a high π-trans-effect is coordinated trans 
to the leaving group (X) two things will happen during a substitution process: 
I. The oncoming ligand (Y) will be nucleophilically coordinated on the metal ion at the 
site of the leaving group (X), due to its lower electron density. This would lead to its 
subsequent substitution via a five-coordinate activated complex. 
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II. The five-coordinate 18-electron trigonal bipyramidal transition state, where Lπ, X and 
the oncoming ligand (Y) are coordinated to the metal, is stabilised by the back 
donation of electron density into the empty π* orbitals of the π-acceptor ligand 
Lπ.26,28,31 This increases the electrophilicity of the metal ion leading to high rates of 
substituting the leaving group X from the complex.  
Likewise, the overlap of the valence orbitals of the π-trans-directing ligand with the 6pπ 
orbitals (Figure 2.8) of the metal ion account for the observed high trans-effect of some 
ligands as follows:   
H2C=CH2, CO > CN- > NO2- > SCN- > I- > Br- > Cl- > NH3 > OH- 
Because the π-trans-effect involves a five-coordinate transition state, it is applicable only in 
associatively activated mechanisms (A or Ia) such as in substitution reactions in square-planar 
complexes.   
 
Figure 2.8 Schematic representation of the π-bonding mechanism for the trans-effect.26 (i) π-
trans-director L forms only a σ bond,  no π-bonding involved ; (ii) L forms both a σ bond for the donation of 
electron density from L onto filled d-orbitals of the metal ion and π-bonds for back-donation of this electron 
density from the metal onto the empty π*orbitals of L.14  
2.3.1.3 The σ and π-trans-Effects 
The σ- and π-trans-effects for square-planar complexes discussed in the preceding sections 
2.3.1.1 and 2.3.1.2, respectively, can be alternatively explained using Molecular Orbital (MO) 
theory. Figure 2.9 depicts the MO diagram of PtCl42- which shall be used to sum up the 
phenomena of the trans effect.  
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Figure 2.9 Schematic representation of the Molecular Orbital diagram of PtCl42-. 
The σ- and π-bonding orbitals positioned on the four chloride ligands are the first and 
second most stable, respectively.14 Derived from the 5d atomic orbitals of Pt(II) are the σ- and 
π-antibonding MO orbitals with the symmetries πxz*, πyz*, σz2* and πxy* which follow in terms 
of stability. The highest in energy is the non-bonding σ pz valence orbital containing 
antibonding orbitals with symmetries σs*, σx*, and σy*.4, 14 
The four σ-bonding atomic orbitals which can be used for square-planar complex 
formation are dx2-y2, s, px, and py.14 The p orbitals have the trans directing properties useful 
for overlap in the L-Pt-X x-axis of trans-PtA2LX. Both the trans ligand (L) and the leaving group 
(X) share the same σx orbital in the overall MO arrangements. The strong σ-donor trans-ligand 
(Lσ) receives the greater share of this σx orbital when compared to X. Thus, the Pt-X bond is 
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lengthened in the ground-state, leading to it being weakened which enhances the 
substitution of X by the entering nucleophile (Y) (Figure 2.7). Langford and Gray elaborated 
further on the influence of the reaction rate based on the stabilization of the trigonal 
bipyramidal intermediate.7 The ground-state has a singular p orbital, px, for bonding of the 
trans ligands L-Pt-X on the x-axis of the square-planar complex. Availability of additional 
orbitals during associative substitution in the transition state for σ bonding when compared 
to the ground-state square-planar complex, means that the addition of the oncoming ligand 
(Y) from above the xy plane leads to X moving down out of the plane, resulting in a trigonal 
plane containing Pt, L, X, and Y (Figure 2.10). Two p orbitals, px and pz, are contained in this 
newly formed intermediate for bonding of three ligands (66.6 % statistical electron charge 
distribution) when compared to one orbital shared between two ligands in the ground state 
(50 %). Consequently, the high trans-effect of a good σ-donor ligand such as H- and CH3- 
referred to as the σ-trans-effect is due to this additional strength of Pt-Lσ p bond character in 
its molecular orbital with this metal centre.       
 
Figure 2.10 The σ-trans-effect due to the stabilization of the trigonal bipyramidal interdiate. 
(i) The ground-state has only the px orbital available for σ-bonding of ligands A and X (ii) σ-bonding of ligands A, 
X and Y in the trigonal plane are accommodated on the px and pz orbitals. 
The MO theory places only three molecular orbitals namely πxz*, πyz*, and πxy*, to 
have suitable π-bonding symmetry to π-metal centred dπ orbitals in square-planar 
complexes.14 These can participate in the back donation of electron density from the metal 
ion, thereby stabilising the formation of the trigonal bipyramidal transition state.14 Effectively, 
the strong π-acceptor ligand A (Figure 2.10) delocalizes electronic charge to the ligands X and 
Y and lowers the activation energy in the transition state leading to its stabilization.14     
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2.3.2 The cis-effect 
The influence of the cis-positioned ligand (L) (Figure 2.11) on the reaction rate in square-
planar complexes is generally weak when compared to the ligand positioned trans to the 
leaving group (X = Cl-). An exception, however, is when the cis ligand is sterically bulky which 
leads to a slower associative rate of substitution of the leaving group (X).12,32 Steric hindrance 
of the cis ligand affects the stability of the five-coordinate intermediate formed during the 
attack of the oncoming ligand (Y = py). The trans ligand (L = phenyl, o-tolyl and mesityl) in the 
trigonal bipyramidal intermediate occupies the equatorial position in the trigonal plane and 
is away from the oncoming ligand and leaving group by an angle of 120o.12 Conversely, when 
these ligands are positioned cis, they occupy axial sites in the activated complex and interact 
more effectively with the oncoming and leaving groups which are only 90o away via electron-
electron repulsion.12 Such modification of square-planar complexes through steric effects is 
vital when designing novel Pt(II) complexes of improved chemotherapeutic activity.33-35  
A decrease in the rate of substitution of the leaving ligand(s) in a square-planar 
complex is usually accompanied by an increased inertness of the drug toward deactivation.36 
This is observed in carboplatin ( as discussed in Chapter 1, section 1.2.3 Figure 1.1(b)) which 
has a chelating and sterically bulk cyclobutane-1,2-diammine spectator ligand, properties 
which account for less toxicity of the drug due to inertness.37,38 The use of sterically bulk 
ligands with carbon donor ligands has been reported to cause a mechanistic changeover from 
associative to dissociative in square-planar Pt(II) complexes.39,40 For a dissociative 
mechanism, steric hindrance increases the rate of substitution due to the relief of steric strain 
in the ground-state which facilitates a rapid approach of the oncoming ligand.15,41,42   






P = PEt3            Y = py
L = phenyl; o-tolyl; mesityl  
Figure 2.11 Steric effects of a mesityl ligand in a square-planar complex showing the trigonal 
intermediate for the cis and trans isomers.16  
For an associative mechanism of substitution where there is an increase in the 
coordination number of the trigonal bipyramidal intermediate due to an oncoming ligand, 
increase in steric bulk of the ligands in the cis position shields the approach of the oncoming 
ligand (Y = py). This steric crowding of the equatorial position of the leaving group destabilizes 
the trigonal bipyramidal transition state and retards the rate of substitution. These 
observations are supported experimentally for the substitution reactions of the chloride 
ligand by pyridine (py) in the square-planar complexes cis- and trans-Pt(Et3)2LCl where L = 
phenyl, o-tolyl and mesityl. Increase in steric size of the aryl ligands from phenyl to mesityl 
positioned perpendicular to the square plane blocks the attack by an oncoming py 
nucleophile. The steric hindrance to attack is higher for the mesityl ligand which has two ortho 
methyl substituents shielding the approach on both sides of the square plane. The cis-steric 
ratios on the reactivity was reported to be 80 000: 200: 1. In sharp contrast, the ratio of only 
35: 5: 1 was reported when the trans-Pt(Et3)2LCl replaced its cis isomer for phenyl: o-tolyl: 
mesityl, respectively, when py is the oncoming ligand.16 Table 2.1 indicates that even though 
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both the cis and trans forms of Pt(Et3)2LCl are affected by increase in the steric size of L, the 
cis steric effect is more pronounced when compared to the trans-steric-effect.  
Table 2.1 Steric effects on the rates of substitution of cis- and trans-Pt(PEt3)2LCl by pyridine 
at various temperatures.16  
  kobs (s-1) 
 Ligand cis (0 oC) trans (25 oC) 
 
L = phenyl 
 
 
8.0 x 10-2 
 
1.2 x 10-4 
 
 




2.0 x 10-4 
 
 
1.7 x 10-5 
 
 









3.4 x 10-6 
 
For unsubstituted terpy Pt(II) complexes where steric crowding or hindrance is absent, 
replacement of a pyridine with a strong σ-donor deprotonated phenyl ring in the trans 
position retards the rate of substitution by a factor of 454 when thiourea is used as a 
nucleophile compared to when the strong σ-donor is positioned cis to the chloro leaving 
group.43 These results on the cis-effect of the Pt-C bond to retard the rate of substitution 
when thioureas and azoles are oncoming nucleophiles, were corroborated by Jaganyi 
et al.44,45 when the cis-positioned Pt-N pyridine bond of terpy was replaced by the Pt-C phenyl 
bond. The reactivity of the complexes for these reactions are purely electronic in nature. 
Electron density from Pt-C bond accumulates on the metal centre making it less electrophilic. 
This repels the approach of the oncoming nucleophiles and destabilizes the transition state.   
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Even though it is generalised that the σ-trans-effect is greater than the σ-cis-effect, a 
study conducted by Hofmann et al.46 indicated that the π-cis-effect is greater than the π-trans-
effect. The π-acceptor pyridine positioned cis in [Pt(N-(pyridyl-2-methyl)-1,2-
diaminoethane)OH2]2+ (aap) reacts slightly faster (k1 = 110 M-1 s-1) compared to when its 
positioned trans in [Pt(2,6-bis-aminoethylpyridine)OH2]2+ (apa) (k1 = 101 M-1 s-1) when 
thiourea is considered as an oncoming nucleophile.  The slower reactivity of apa was 
attributed to the ground-state accumulation of electron density on Pt(II) making it less 
electrophilic and thus retarding the rate of substitution. Despite this, the cis-effect is generally 
smaller when compared to the trans-effect.46 
2.3.3 The substituting nucleophile (Y) 
The rate of substitution for an associatively activated mechanism is sensitive to the nature 
and concentration of the oncoming ligand (Y). Nucleophility, which measures the strength of 
the nucleophile on substitution reactions in square-planar complexes, is affected by various 
factors such as:16 
i. Basicity: highly basic nucleophiles have a lone pair that can be used to form a bond at 
the metal centre leading to high rates of substituting the leaving group by 
nucleophile.47 
ii. Polarizability: This is explained by Pearson’s Hard Soft Acid Base (HSAB) theory which 
states that a more polarizable ligand should be a better electron donor and therefore 
a better nucleophile.  
The nucleophilicity of some ligands towards substitution decreases in the following order: 
PR3 > tu > I- , SCN- , N3- > NO2- > Br- > py > NH3, Cl- > H2O > OH- 
2.3.4 The leaving ligand (X) 
The effect of the leaving group on the reaction rate depends on the strength of the Pt-X bonds 
in the complex. For example, the Pt-OH2 bond is more labile than Pt-Cl. This in turn depends 
on the nucleophilicity of the leaving ligand. The chloride ligand is a better nucleophile towards 
substitution when compared to water. Also, the bulkiness of the leaving ligand affects the 
reaction rate. Sterically bulk ligands are weakly bonded and thus easier to substitute. Catallini 
et al.48 found that for the reactions of the type [Pt(bipy)(RSR’)]+ by halide ligands depended 
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on the substitution of the leaving thioether groups (RSR’) for which the bond breaking 
transition state was the maxima with the highest energy. The high energy maxima for bond 
breaking indicated that this was the rate determining step for the reaction.14     
To investigate the effect of the leaving group (X) on the rate of substitution in square-
planar complexes, both the cis and trans groups must be kept constant. To provide 
information on the leaving group effects, substitution reactions of various leaving groups by 
pyridine as the oncoming nucleophile in the inert mononuclear complex [Pt(dien)X]+ have 
been systematically studied (Equation 2.8).4,12  
                         [Pt(dien)X]+  + py → [Pt(dien)py]2+ + X                                           (2.8) 
The rate of substitution of the leaving groups by pyridine decreased in the following order: 
NO3- > H2O > Cl- > Br- > I- > N3- > SCN- > NO2- > CN- 
In this order of reactivity, the harder ligands NO3- and Cl- are substituted more rapidly while 
the soft ligands NO2- and CN- with π-bonding properties are substituted slowly. This is 
supported by the σ- and π-trans-effect theories, which suggest that good trans-labilizing 
groups form strong bonds to the metal centre. The reactivity factor between the most 
reactive H2O and the least reactive CN- is greater by six orders magnitude. This is indicative of 
the sensitivity of rate of substitution on the energy of bond breaking in the transition state 
albeit the reaction follows an associative mode of substitution. 
2.3.5 The role of the solvent 
Substitution reactions in square-planar complexes are accompanied by a two-term rate law 
as indicated above in Equation 2.3. The k1 rate constant (independent of the nature and 
concentration of the entering ligand (Y)) in the first-term is attributed to the solvolysis 
pathway in which the solvent participates in the overall substitution reaction (Figure 2.3). The 
values of k1 are also not affected by changes in charge of the complex. However, they are 
sensitive to steric hindrance as they are inversely related.22  
The data in Table 2.3 shows that the magnitude of the solvento rate constants, k1, 
correlate positively with the coordinating ability of the solvent. For example, in a chloride 
substitution reaction in DMSO, molecules competed favourably for coordinating to Pt(II) on 
the basis of the softness of S donor atom.12 For these reactions there are larger values of k1 
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when compared to k2 values. On the other hand, for weakly coordinating solvents e.g. 
acetone, the reactions proceed by a direct attack of the oncoming Cl- nucleophile and are thus 
sensitive to concentration of Cl-.  
                     trans-Pt(py)2Cl2 + 36Cl- → trans-Pt(py)2Cl(36Cl) + Cl-                                             (2.9)   
Table 2.3 Solvent effects on chloride substitution reactions.49 
Coordinating ability Solvent k/10-5 s-1 
 DMSO 380 
Strong H2O 3.5 
 EtOH 1.4 
 n-PrOH 0.4 
Coordinating ability Solvent k/M-1 s-1 
 CCl4 104 
 C6H6 102 
Weak i-BuOH 10-1 
 Acetone 10-2 
 DMF 10-3 
 
Because the effects of the solvents are purely based on their coordinating properties 
and not on dielectric constants, it is particularly interesting to note that nitromethane 
(CH3NO2), generally not a good coordinating solvent, provides an effective path for chloride 
substitution. This is attributed to its π-bonding ability which allows d-orbital electrons on the 
platinum to delocalize into a vacant p-orbital on the nitrogen.22  
Weak coordinating solvents have the propensity to occupy axial positions in the 
ground-state of square-planar complexes. This axial solvation diminishes during associative 
substitution wherein the intermediate of high coordination number is formed. Complexes 
containing strong σ-donor and π-acceptor properties have comparable discriminating 
capacities when interacting with various solvents. This is an indication that the metal-solvento 
interactions have no significance on the substitution kinetics. Thus, Linear Free Energy 
Relationships (LFER) are observed and there is no nucleophilicity order on changing the 
solvent. 
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Chapter 3 
Measurement of kinetic reactions. 
3.1 Introduction. 
Chemical kineticists study the rates of chemical reactions (how fast or slow these reactions 
occur) to determine their mechanism.1-3 For kinetics measurements, the molecularity of a 
chemical reaction which is defined as the number of molecules undergoing covalency 
changes, is important when assigning the mechanism of a chemical reaction. In this respect, 
a chemical process is broken down into elementary reactions characterized into a sequence 
of one or more single-step processes.4 Chemical reactions in square-planar complexes are 
intrinsically bimolecular and can be represented by Equations 3.1 and 3.2 below. In Equation 
3.2, A represents the metal complex, ML3X, whilst B represents the entering ligand, Y.  
(3.1)ML3X Y ML3Y X
k1
k-1  




The forward elementary reaction is second-order, whilst the reverse reaction is first-
order. Thus, the kinetics of the reaction is characterised by mixed-order behaviour. To 
minimize the complexity of the reaction, the forward substitution step is studied under 
pseudo-first-order reaction conditions. Experimentally, this is met by providing at least a 10-
fold excess of B (nucleophile) over that of A (metal complex), such that [B]0 >> [A]0. The 
derivation of the rate law representing a bimolecular reaction of this nature is dealt with 
below in Section 3.3.4 of this chapter.         
The molecularity of a reaction allows for the assessment of the composition of the 
transition state which represents an energy barrier for a reaction to occur.4,5 Entailed in the 
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barrier is the activation energy of the reaction which can give an indication of the rate of 
reaction. A low barrier indicates the ease with which the reactants can overcome the barrier 
to form the products due to having a high thermal energy. Thus, the rate of reaction will be 
fast. A high barrier means the rate of reaction will be slow due to insufficient energy leading 
to fewer reactants capable of overcoming the barrier. The energy barrier to reaction provides 
a source for temperature dependence studies of chemical reactions (Section 3.4.1).    
Several variables influence the rate of a chemical reaction such as: concentration of the 
reactants, temperature and pressure, photophysical properties, ionic strength, pH and 
solvent participation:6 
 The reactants in a chemical reaction have a directly proportional relationship to the 
concentrations of the species involved i.e. the rate of reaction is accelerated when the 
concentration is increased. A catalyst may also influence the rate of a reaction. 
 Physical conditions such as temperature and pressure should be maintained constant 
throughout kinetic measurements. Temperature dependence studies allow, from the 
Gibbs free energy of activation , the determination of the enthalpy and entropy of 
activation parameters, Δ and Δ , respectively. The energy of activation, , can 
also be determined from the temperature dependence studies. Pressure dependence 
studies give the volume of activation, Δ . These parameters are paramount in 
assigning the mechanism of the reactions. 
 Photosensitive chemical reactions may be affected by sunlight or lights in the room, 
changing the rate of a reaction.  
 Ionic strength of the solution should be maintained constant to ensure uniform 
concentration of ions and charge in the solution throughout the course of a chemical 
reaction.  
 pKa determination of the complex solution used for kinetic measurements is also 
crucial and should be accounted for. The pKa values below those of the investigated 
complex solution ensure that it remains aquated.7,8 Above their pKa, deprotonation 
occurs which affects the rate of reaction in these different pH forms of the solution. 
 Solvent participation in a chemical reaction that also influence the rate of reaction. 
Solvent molecules can act as a reactant or form a solvent cage which alters the kinetics 
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of a reaction. Thus, the preceding variables need to be controlled and their effect on 
the reaction quantified when investigating the kinetics of a chemical reaction. 
3.2 The rate law. 
3.2.1 Measurement of the rate constants. 
The rate of a chemical reaction gives an indication of the amount of consumption of reactants 
and the conversion of these into products. For a chemical reaction given below: 
aA + bB → cC + dD                   (3.3) 
the capital letters indicate the chemical compounds while the small letters represent their 
stoichiometry. The rate of a reaction is presented in a manner which is independent of  the 
amount of sample used and for which the units are given as molarity per second (M s-1).1,5 
Rate = − [ ] =  [ ]               (3.4) 
The negative sign indicates that the reactants are being consumed as the reaction proceeds 
and hence the concentration is reduced. 
The rate law is referred to as the study of the dependence of the reaction rates and rates 
constants on the concentrations of the various reactants in a reaction.6 Considering the 
concentration of all the components, the rate can be expressed as: 
Rate = −  . [ ] =  −  . [ ] =   . [ ] =   . [ ]               (3.5) 
Therefore, the rate law is generally represented as: 
Rate = -k ∏ [ ]∝ [ ]                   (3.6) 
where Ai represents the reactants, k the rate constant, Xj any other species (i.e. catalyst) that 
may influence the rate while α and β indicate the order of the reactions. 
The order of the reaction is defined as: 
Order of reaction = ∑                 (3.7) 
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3.3 Integrated Rate Expressions.  
For an arbitrary chemical reaction given by Equation 3.5, the left-hand side of the rate law 
expression will involve the first derivative of concentration with respect to time. It follows 
that to process data acquired experimentally, an integration is necessary to obtain an 
expression which links the reactant concentration and time. 
3.3.1 First-Order Reactions. 
First-order reactions are simple to interpret as they involve less complicated expressions. 
Most reactions follow first-order kinetics or are simplified to approximate first-order.9 A first-




The rate for the above reaction is given as: 
Rate = [ ] = − [ ]                  (3.9) 
which rearranges to give: 
− [ ]
[ ]
=                 (3.10) 
Integrating from t = 0 to t = t, [At] gives 
∫ [ ][ ]
[ ]
[ ] = - ∫                (3.11) 
[ ]
[ ]
=  −                (3.12) 
ln[ ] =  − + ln[ ]                (3.13) 
where [A] = [A]o at time t = 0 and [A] = [A]t at time t = t. 
From Equation 3.13 a linear equation in the form ( = + ) with = [ ] , =  and  
= [ ]  can be deduced. Thus, a plot of [ ]  versus  yields a linear regression for which 
the rate constant, k, can be determined from the slope.1,9 Equation 3.13 can be expressed as: 
[ ]
[ ]
=                 (3.14) 
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and simplified to: 
[ ] =  [ ]                (3.15) 
Furthermore, Equation 3.15 shows that a plot of [ ]  versus  varies exponentially. 
3.3.2 Reversible First-Order Reactions 
Chemical reactions composed of reversible or opposing reactions do not go to completion but 
form an equilibrium between the reactant and product species under certain reaction 






The rate law for the reaction represented by Equation 3.16 is 
Rate =− [ ] =  − [ ] = − [ ] −  [ ]             (3.17) 
At t = 0, B = 0, and [A]t = [A]0, at any time 
[ ] =  [ ] − [ ]                 (3.18) 
Substituting Equation 3.18 into Equation 3.17 gives: 
− [ ] =  [ ]  −  ([ ] − [ ] )             (3.19) 
At equilibrium, no overall reaction occurs. Thus, 
− [ ] = 0                (3.20) 
Applying Equation 3.20 to Equation 3.17 gives 
[ ] =  [ ] =  ([ ] −  [ ] )            (3.21) 
Which can be simplified to: 
[ ] =    [ ]                (3.22) 
Substitution of Equation 3.20 into Equation 3.17 gives 
− [ ] = ( +  )[A] − ( +  )[ ]             (3.23) 
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Separating the variables and integrating eventually leads to 
∫ [ ]([ ]   [ ] ) =  −( +
[ ]
[ ] ) ∫              (3.24) 
solving the limits produces  
ln [ ] [ ]
[ ] [ ]
= ( +  )               (3.25) 
Rearrangement of Equation 3.25 gives 
ln [ ] −  [ ] =  −( +  ) + ln ([ ] − [ ] )           (3.26) 
A plot of ln ([ ] − [ ] ) versus  gives a linear regression with a slope of −( + ). To 
determine each individual rate constant, k1 or k-1, it is important to evaluate the 
thermodynamic equilibrium constant, Keq. 
The equilibrium constant is a ratio of the concentration of the remaining reactant and the 
formed product which can be correlated to the distinctive rate constant as follows: 
= [ ]
[ ]
=               (3.27) 
Two equations with two unknowns can be difficult to treat and may lead to inaccurate 
measurement of [ ] . Furthermore, the observed rate constant, kobs, is equal to the sum of 
the rate constant for the forward and reverse reactions, i.e. 
= +              (3.28) 
3.3.3 Second-Order Reactions 
Second-order reactions generally represent those that use up an equivalent amount of two 





The rate law can be given as: 
Rate = [ ][ ]              (3.30) 
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Rate = [ ] = − [ ] = − [ ] = [ ] [ ]            (3.31) 
If at t = 0, the initial concentration of A and B are [A]0 and [B]0, and at a particular time t, the 
concentration of A is reduced to [A]0 – , and concentration of B would be reduced to 
[B]0 − , where  is the amount of reactants that has reacted to form the product C. 
Therefore, the rate equation can be written as:6 
− [ ] = ([ ] − )([ ] − )              (3.32) 
Since [ ] = [ ] − , hence = − [ ] = − [ ] and thus the rate law shown in Equation 
3.32 can be written as: 
= ([ ] − )([ ] − )             (3.33) 
Separation of the variables gives: 
([ ] )([ ] )
=               (3.34) 
Integrating Equation 3.34 between the limits = 0 to =  and = 0 to =  produces an 
expression: 
∫ ([ ] )([ ] ) =  ∫              (3.35) 
Giving the following expression (provided [A]0 ≠ [B]0): 
[ ] [ ]
[ ] ([ ] )
[ ] ([ ] )
=              (3.36) 
This expression can be simplified to give: 
[ ] [ ]
[ ] [ ]
[ ] [ ]
=              (3.37) 
By using Equation 3.37, the second-order rate constant can only be determined when the 
values of [ ] ,   [ ] , [ ]  and  [ ]  are known. This means kinetic measurements become 
complex and tedious.2,12,13 To simplify the process, second-order reactions are usually studied 
under pseudo-first-order conditions. As previously highlighted, the concentration of one of 
the reagents (typically the nucleophile) is provided in excess.  When [ ] ≫  [ ] , the 
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concentration of  remains unchanged during the reaction. Supposing that the reaction order 
with respect to  is one, then the rate law in Equation 3.31 can be written as:      
−
[ ]
= [ ] [ ]  
= ( [ ] )[ ]  
= [ ]              (3.38) 
where kobs is the observed rate constant with unit of s-1 and is equal to k2[B]0. 
A plot of [ ]  versus time gives a linear regression with the observed rate constant, , 
as the slope. To determine the second-order rate constant, , a series of  values must 
be obtained by varying the concentration of  in excess. This generates several [ ]  values. 
= [ ]              (3.39) 
A plot of  vs  produces the second-order rate constant, k2, with units M-1 s-1. 
3.3.4 Reversible Second-Order Reactions  
Usually, ligand substitution reactions in square-planar complexes do not go to completion, 






By applying pseudo-first-order conditions, the rate law can be expressed as: 
− [ ] = − [ ] = − [ ] = [ ] [ ] − [ ]                3.41) 
[ ] = [ ] − [ ]  
and      [ ] = [ ] − [ ]              (3.42) 
At equilibrium 
[ ] = [ ] − [ ]  
And 
 [ ] = [ ] − [ ]              (3.43) 
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At equilibrium, the rate of the forward reaction is equivalent to the rate of the reserve, as 
indicated by Equation 3.44. 
− [ ] = [ ] [ ] − [ ] = 0             (3.44) 
Hence, 
[ ] [ ] = [ ]              (3.45) 
By substituting for [ ] in Equation 3.45, using the value from Equation 3.41 and rearranging 
gives: 
[ ] = [ ] [ ] + [ ]             (3.46) 
Substitution of [ ]  from Equation 3.42 with the term [ ] − [ ] , and substituting into 
Equation 3.41 gives the rate as: 
−
[ ]
= [ ] [ ] − ([ ] − [ ] ) 
      = [ ] [ ] − [ ] = [ ] )            (3.47) 
Combining Equations 3.46 and 3.47 gives: 
    − [ ] = [ ] [ ] − [ ] [ ] − [ ] + [ ]                      (3.48) 
Applying pseudo-first-order conditions where [ ] ≫ [ ]  Equation 3.48 becomes: 
−
[ ]
= [ ] [ ] − [ ] [ ] − [ ] + [ ]  
   = ( [ ] + )([ ] − [ ] )              (3.49) 
Separating the variables and integrating Equation 3.49 gives: 
∫ [ ]([ ]   [ ] ) =  −( [ ] +
[ ]
[ ] ) ∫   
       ln [ ] [ ]
[ ] [ ]
= −( [ ] + )   
                                = −   
where                           = [ ] +               (3.50) 
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A plot of vs [ ]  gives a linear regression with  as the slope and  as the intercept. 
Pseudo-first-order conditions of this kind are mostly used in kinetic studies of square-planar 
Pt(II) complexes. 
The equilibrium constant, K, can be determined by calculating the ratio:14 
=                (3.51) 
Furthermore, this rate law applies to cases in which the reaction proceeds in two parallel 
pathways where the first is independent of [ ]  and the second is a solvolysis pathway.9 
3.4 Measurement of activation parameters. 
3.4.1 Measurement of enthalpy of activation ( ) and entropy of activation( ). 
The rate of reaction in square-planar complexes have a directly proportional relationship to 
temperature.14,15 Fundamental to assigning the mechanism of a reaction is the rate law.16 
However, determining the thermal activation parameters allows for the interpretation of the 
rate constants when the temperature is systematically varied. The experimental data 
obtained for the various terms that contribute to the rate law is analysed using the Arrhenius 
equation or by the Transition-State Theory (TST).9 For the former, the pre-exponential factor, 
, and activation energy, , are determined. The enthalpy and entropy of activation 
parameters, Δ and Δ , are determined from the latter, respectively.  
The Arrhenius equation expresses the rate constant as a function of temperature:  
                   = ( )             (3.52) 
where:  is the rate constant for the reaction 
  is the Arrhenius pre-exponential factor (M-1 s-1), 
 is the Arrhenius activation energy (J mol-1), 
  is the gas constant (equal to 8.315 J K-1 mol-1) and 
  is the absolute temperature in K. 
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Taking the logarithms of Equation 3.52 gives Equation 3.53 in which  varies linearly with 
. The temperature-independent parameters,  and , can be determined confidently over 
the temperature range 10-50 oC from the intercept and slope, respectively. 
             = − ( )              (3.53) 
The Arrhenius equation finds less use nowadays except in complex systems where there is 
uncertainty about where the measured rate constant is a composite of specific rate 
constants.1,2 
The transition state or activated complex theory developed by H. Eyring, M. Evans and M. 
Polanyi in 1935 concedes that many reactions take place via a pre-equilibrium mechanism.1,17 
This theory works best in processing thermal activation parameters for ligand substitution 
reactions in square-planar Pt(II) complexes. For a bimolecular reaction such as this one: 





The reaction rate can be represented as:  
[ ] = { − − − } *= ≠[ ][ ]            (3.55) 
where:  is the Boltzmann’s constant (1.38 x 10-23 J K-1), 
  is the temperature in Kelvin (K), 
 ℎ is the Planck’s constant (6.626 x 10-34 J s-1), 
 ≠ is the equilibrium constant. 
The experimental second-order rate constant, , is expressed as: 
            = ≠              (3.56) 
The Gibbs free energy of activation, , is expressed as: 
             ≠= − ≠              (3.57) 
                               = ≠− ≠ 
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where: ≠ is the enthalpy of activation (J mol-1) and 
 ≠ is the entropy of activation (J K-1 mol-1). 
Substituting Equation 3.57 into Equation 3.56 affords the following expression: 
= ( ) = ( ) ( )            (3.58) 
Applying the natural logarithm on Equation 3.58 affords: 
ln = ln ( ) − +              (3.59) 
Equation 3.59 can be simplified and expressed in a linear form as:  
ln = − . + +             (3.60) 
where 
              = 23.8               (3.61) 
Thus, from a plot, referred to as the Eyring Plot, of ln ( ) vs , the enthalpy of 
activation, , is determined from the slope and the entropy of activation, , is 
extrapolated at T = 0 from the y-intercept of the graph.1,16,18  
The thermal activation parameters are useful aids in assigning the mechanism of 
ligand substitution reactions in square-planar Pt(II) complexes. Low and positive enthalpy of 
activation values indicate the ease with which a new bond is formed due to the electrophilicity 
of the metal centre. High and negative entropy of activation values indicate a transition state 
that is highly ordered and more compact than either the reactant or product species.1,19 Thus, 
the mechanism of substitution is said to undergo via an associative pathway.  
3.4.2 Measurement of Volume of Activation, . 
A more powerful and reliable parameter for identifying reaction mechanisms is the volume 
of activation, . It is determined from kinetic experiments in which the observed rate 
constants, , are measured as the applied pressure is systematically varied.20 Pressure-
dependence of the rate constant is given by the equation: 
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   = −               (3.62) 
where,  is volume of activation and is equivalent to the difference in the partial molar 
volumes between the transition state and the reactants.10 
Taking integrals of both sides of Equation 3.62 gives:  
       = −( )               (3.63) 
As a result, the plot of  versus applied pressure produces a linear regression with a 
slope equal to  − , from which the activation volume, , can be directly evaluated. An 
increase in the applied pressure is accompanied by an acceleration of the rate constant for 
an associatively activated mechanism.20 Negative volume of activation values imply a 
mechanism that occurs via a compacted transition state involving a greater degree of bond 
making. Conversely, positive volume of activation values corresponds to a dissociatively 
activated pathway in which bond breaking occurs in the transition state. 
3.5 Instrumental techniques used for ligand substitution in Pt(II) complexes. 
In the study of the rate of chemical reactions, it is important to have an accurate recording of 
the concentration of either reactants or products as a function of time. Most the reactions 
are monitored in aqueous solutions. The use of a suitable experimental method to monitor 
ligand substitution reactions in square-planar Pt(II) complexes is determined by the time scale 
of the reaction. For slow reactions, conventional spectroscopic techniques such as nuclear 
magnetic resonance (NMR), UV-visible, and infrared spectroscopy are used for data 
acquisition. For very fast reactions (which take 60 seconds to 10-14 seconds) for completion, 
automated methods are required for data acquisition such as flow-through and pulse 
methods.1 The spectroscopic techniques to be considered and described in detail are UV-
visible spectroscopy (suitable for slow kinetic reactions) and stopped-flow (suitable for fast 
reactions).  
3.5.1 UV-visible spectrophotometer 
UV-visible spectrophotometry is a slow but sensitive technique capable of detecting sample 
concentrations in the range of 10-4 to 10-6 M. It is used in the characterisation of electronic 
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transitions in a compound in which π-electrons are transferred from its highest occupied 
molecular orbital (HOMO) to the lowest unoccupied molecular orbital (LUMO) upon 
absorption of light in the ultraviolet (UV) and visible regions. Figure 3.1 illustrates the skeleton 
diagram of a UV-visible spectrophotometer. 
 
Figure 3.1 Schematic diagram of a double beam UV-visible spectrophotometer.21 
The spectrophotometer measures the amount of light transmitted, , after irradiating a beam 
of light through a sample column. Transmittance is described as:    
=                (3.64) 
where:  is the intensity of the transmitted light (sample intensity) and 
  is the intensity of the incidence light (reference intensity). 
The absorbance, , is calculated from the logarithms of the intensities as follows:  
= log = −              (3.65) 
The optical transmittance,  , is related to the concentration of the species under study by 
the Beer’s law: 
=               (3.66) 
where:  is the absorbance, 
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  is the molar absorptivity or extinction coefficient ( ), 
  is the concentration (  ) of the sample and 
  is the path length ( ). 
For a first-order reaction, represented by Equation 3.6, at any time , the absorbance is   
= [ ] + [ ]              (3.67) 
where:  is the absorption at any time and 
 ,  is the molar absorptivity of X and Y, respectively. 
Once the reaction has reached completion, the absorbance becomes  
      = [ ] + [ ]             (3.68) 
For kinetic measurements, the following expression is obtained from the absorbance: 
       [ ]
[ ]
= ln =              (3.69) 
For experimental determination of rate constants, absorbance-time resolved data is 
acquired at a pre-determined wavelength at which a significant change in absorbance occurs 
with time. Therefore, the observed rate constant for the reaction (taken over a duplet runs) 
is obtained by a least squares fit of an absorbance-time plot at a specified wavelength. A 
concentration dependence study at different concentrations of the reactants allows for the 
determination of the rate constant for the reaction at a specified temperature.    
3.5.2 Flow Methods 
Flow techniques are designed to achieve rapid and efficient mixing of two solutions (metal 
complex and nucleophiles), ensuring that the ensuing reaction is promptly monitored as it 
commences a few milli-seconds after mixing has occurred.11 In these techniques, reagent 
solutions are mixed together by flowing them through a mixer from which the reaction 
solution emerges to be analysed.3  
As depicted in Figure 3.2, the reaction analyser consists of drive syringes filled with 
their respective (metal complex and nucleophile) solutions, thermostated to the required 
temperature through a water bath compartment. The reaction starts as the solutions are 
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charged out of their syringes by a compressed gas-driven piston (800 kPa) on the plunges, 
through the mixing chamber, and along the observation tube to the collector syringe. When 
the plunger of the latter reaches its stop, this both arrests the flow of the mixing solutions 
and triggers the recorder.3 The amount of light, of the wavelength setting of the 
monochromator, transmitted through the mixed solution undergoes changes as the reaction 
proceeds in the now static mixed solution. A photomultiplier unit converts this transmitted 
light into an electric current, a grid resistor generates a voltage proportional to the light 
intensity and, using an analogue-to-digital (A/D) converter, this signal is fed to the computer, 
which samples at pre-determined intervals over an appropriate time interval.3 
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Chapter 4 
Substitution of aqua ligands from cis-Pt(II) complexes bearing 
2-(phenylthiomethyl)pyridine spectator ligands. 
4.0 Abstract 
Three mononuclear cis-Pt(II) complexes comprising pyridine moieties namely, [Pt{2-
(phenylthiomethyl)pyridine}(H2O)2]2+ Pt(pySPh), [Pt{2-(4-tert-
butylphenylthiomethyl)pyridine}(H2O)2]2+ Pt(pySPh(t-But))  and [Pt{2-(4-
fluorophenylthiomethyl)pyridine}(H2O)2]2+ Pt(pySPhF), were synthesized. Acid-base titrations, 
as well as temperature and concentration dependent kinetics measurements of the reactions 
with three sulphur-donor nucleophiles were studied at pH 2. The reactions were monitored 
under pseudo-first-order conditions using stopped-flow and UV-visible spectrophotometric 
techniques in a 0.1 M LiOTf/HOTf aqueous medium.  
The mechanism of substitution of the aqua ligands from the complexes is limiting 
associative, characterised by the dependence on the concentration of the incoming ligand, 
low enthalpy of activation (ΔH≠) and negative entropy of activation (ΔS≠) values. The 
sequential substitution of the first and second aqua ligands is described by the rate law: 
kobs(1/2) = k(1/2)[Nu]. The rate constant, k1, relates to the substitution trans to the sulphur donor 
atom, which occurs first due to the strong σ-trans influence of sulphur while k2 is the rate 
constant for the subsequent substitution of the aqua ligand trans to the pyridine moiety. The 
rate of substitution of the first aqua leaving ligand decreases in the order: Pt(pySPh(t-But)) > 
Pt(pySPhF) > Pt(pySPh) while that of the second ligand decreases in the order: Pt(pySPh(t-But)) > 
Pt(pySPh) > Pt(pySPhF). The order of reactivity of the nucleophiles: tu > dmtu > tmtu is in 
accordance with their steric bulk. The reactivity of the complexes is sensitive to the nature of 
the substituents on the para-position of the phenyl ring of the thioether. The positive σ-
inductive electron-donating tert-butyl increases the rate of substitution by enhancing the 
trans-directing ability of the thioether. The negative σ-inductive electron-withdrawing fluoro 
substituent activates the thioether to have π-acceptor properties which also increases slightly 
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the rate of substitution. Interestingly, the complex with an unsubstituted phenyl Pt(pySPh) 
retards the rate of substitution due to weak σ-donor capacity. Arrayed 195Pt spectra of aged 
solutions of complexes with the thiourea nucleophiles suggest a rapid nucleophile 
concentration-independent ring-opening of the N,S-bidentate ligand from the Pt complexes. 
A peak is observed at -3884 ppm at the end of the reaction and this is due to a Pt species 
coordinated to four S atoms (PtS4). Density functional theory 
(B3LYP(CPCM)/LANL2DZp//B3LYP/-LAN2DZp) calculations were computed to help explain the 
experimental data.  
4.1 Introduction 
The cis geometry of cisplatin is key to cytotoxic activity of current Pt-based drugs.1,2 
The labile ligands are substituted to form covalent linked platinato-purine/pyrimidine cycles 
with DNA.3,4 Similar reactions also occur with other nucleophilic species in cells, most of which 
bring toxicity or development of resistance.5-7 A careful choice of the non-leaving and leaving 
groups is therefore important in regulating the pharmaco-kinetic properties of Pt-drugs. The 
good examples credited for lower toxicity and propensity to avoid cisplatin resistance are 
carboplatin and oxaliplatin.8,9 Recently, a cisplatin-derived Pt(II) complex with an ammine and 
1-methy-7-azaindole ligand was shown to have remarkable activity against cisplatin-sensitive 
A2780 but not against cisplatin-resistant A2780cisR cell lines.10 Bidentate 2-
(aminomethy)pyridine and 2-(pyrazolylmethyl)pyridine ligands coordinated in a cis geometry 
to platinum have been shown to have encouraging signs of anticancer activity on human HeLa 
cancer cell lines.11,12   
The activity at low and less toxic concentration levels, selectivity to target cancerous 
cells, enhanced lipophilicity of the drug and stability in aqueous biological system, remain the 
drivers in the design of new Pt drugs of improved potency.13,14 A cis-Pd(II) complex containing 
1,4-bis(2-hydroxyethyl)piperazine was designed to ensure some favourable non-bonding 
interactions such as hydrogen bonding of its hydroxylethyl with DNA nucleic bases.15 In 
another study, the ammine ligands of cisplatin were replaced with a chelating 4,7-diphenyl-
1,10-phenanthroline ligand to form a cis-Pt(II) complex which can intercalate into DNA in 
addition to forming covalent cross-links.16 Other notable non-leaving ligands whose cis-Pt(II) 
complexes have shown good potential as anticancer agents are 3-hydroxymethylpyridine,17  
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1,2-diaminophenylalkane,18 and 2-aminobenzothiazole.19 The potential antitumour activity 
displayed by these complexes demonstrates that a careful design on the structure for both 
the non-leaving and leaving ligands around the square-planar cis geometry has genesis in the 
substitutional reactivity.  
Often square-planar Pt(II) complexes are used as model complexes for understanding 
the mechanisms of substitution due to their moderate rates of ligand exchange kinetics.20,21 
The mechanistic studies of cis-Pt(II) and cis-Pd(II) complexes with N,N- and N,S-bidentate or 
monodentate non-leaving and/or leaving ligands have been reported in literature.22-30 They 
all share a similar geometry to cisplatin. As a result, it can be hypothesised that they can form 
1,2-intrastrand adducts with potential to induce cytotoxicity to cancer cells as does cisplatin.31 
In keeping with the idea of altering the non-leaving ligands yet keeping the cytostatic 
geometry of cisplatin, three mononuclear cis-Pt(II) complexes with a 
2-(phenylthiomethyl)pyridine (N,S-chelate) non-leaving ligands were synthesized (Figure 4.1). 
The rate of substitution of the aqua ligands, from the complexes, by thiourea nucleophiles 
was measured under pseudo-first order conditions. The nature of the entering nucleophiles 
is important in that they model the possible interactions between the complexes with 
biological species such as sulphur-containing proteins and peptides which are known to have 




Figure 4.1 Formulae of cis-Pt(II) complexes investigated. 
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4.2 Experimental  
4.2.1 Procedures and Chemicals 
The ligands and the Pt complexes were synthesised from 2-(chloromethyl)pyridine 
hydrochloride (98%), thiophenol (97%), 4-tert-butylthiophenol (97%), 4-fluorothiophenol 
(98%), potassium tetrachloroplatinate (K2PtCl4, 99%), silver trifluoromethanesulfonate 
(CF3SO3Ag, 99%, Aldrich), lithium trifluoromethanesulfonate (CF3SO3Li, 99+%, Aldrich) and 
hydrochloric acid (HCl, 32%, Saarchem). All chemicals and reagents were used without further 
purification and stored according to material data sheet specifications. The nucleophiles viz., 
thiourea (tu, 99%), N,N-dimethylthiourea (dmtu, 99%), and N,N,N’,N’-tetramethylthiourea 
(tmtu, 99%) were likewise purchased from Aldrich and used without further purification. 
Ultrapure water (MODULAB purification system) was used for all aqueous reactions. All other 
chemicals and solvents were of reagent grade and used as received. 
4.2.2 Synthesis of the ligands 
The ligands, namely 2-(phenylthiomethyl)pyridine pySPh, 2-(4-tert-
butylphenylthiomethyl)pyridine pySPh(t-But), and 2-(4-fluorophenylthiomethyl)pyridine pySPhF 
were prepared via a nucleophilic S-alkylation reaction of either thiophenol, 4-tert-
butylthiophenol, or 4-fluorothiophenol with 2-(chloromethyl)pyridine hydrochloride in dry 
ethanol (Scheme 4.1) as reported by Malachowski et al.33,34 The three ligands were 
synthesised to yield (57-89 %) yellow or brown oils of adequate purity for subsequent 
coordination on platinum. The purity of the ligands was confirmed by 1H and 13C NMR, TOF-
MS-ESI+ and elemental analysis (CHNS) techniques. The IR spectra of the ligands gave the 
following characteristic frequencies cm-1: 3100-3000 (broad, medium, Csp3-H stretch); 1583 
(sharp and strong, Csp2=N stretch, pyridyl rings). 
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.HCl
R = H         ; pySPh 
R = t-But    ; pySPh(t-But)




Scheme 4.1 Synthesis of the (phenylthiomethyl)pyridine ligands 
2-(phenylthiomethyl)pyridine (pySPh) 
A mass (1.598 g, 9.74 mmol) of 2-(chloromethyl)pyridine hydrochloride was dissolved 
in 3 mL ultrapure water. A solution of 5 M NaOH was added drop-wise until a pink emulsion 
appeared. A solution of thiophenol (1.073 g, 9.74 mmol) in 20 mL ethanol (EtOH, 95%) was 
slowly added to the reaction flask. The mixture was stirred under reflux for 24 hours. The 
solution was allowed to cool to room temperature and extracted four times with 10 mL 
chloroform (CHCl3). The crude extract was concentrated and further purified in a short-
column of aluminium oxide (Al2O3) using a mixture of CH2Cl2 and CHCl3. The combined organic 
phase was back-washed with 2 x 10 mL deionised water and dried with 2-3 g of anhydrous 
MgSO4.  Filtration and removal of the solvent in vacuo gave a bright yellow oil of pySPh.  
The yield of 1.528 g (78 %) for pySPh was obtained. Proton-1 NMR (400 MHz: CDCl3): δH (ppm) 
referenced to TMS; 4.30 (s, 2H, -CH2-), 7.16 (t, 1H, Ph), 7.27 (t, 2H, Ph), 7.37 (d, 2H, Ph), 7.33 
(t, 1H, py), 7.52-7.54 (d, 1H, py), 7.60-7.64 (t, 1H, py), 8.56 (d, 1H, py). Carbon-13 NMR (100 
MHz: CDCl3): δC (ppm); 40.5; 122.1; 123.0; 126.4; 127.6; 128.9; 129.1; 129.7; 136.7; 149.3. 
Infrared (KBr, 4000-650 cm-1) ̅: 3055 (C=C-H Asymmetric stretch), 1583 (C=N, pyridyl). Time-
of-flight MS-ESI+ m/z: 223.0930, 100 (M+Na)+. Anal. Calc. for C12H11NS:  C: 71.60, H: 5.51, N: 
6.96, S: 15.93 %. Found: C: 71.21, H: 5.58, N: 6.24, S: 16.09 %. 
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The ligands pySPh(t-But) and pySPhF were synthesised using a similar procedure as for pySPh, with 
2-(4-tert-butylthiophenol) and 2-(4-fluorothiophenol) replacing the thiophenol, respectively. 
The synthesised oils were stored in Schlenk tubes until their coordination to platinum.  
2-(4-tert-butylthiophenol)pyridine (pySPh(t-But)) 
The yield of 1.457 g (57 %, light-brown) for pySPh(t-But) was obtained. Proton-1 NMR (400 MHz: 
CDCl3): δH (ppm) referenced to TMS; 1.30 (s, 9H, -C(CH3)3), 4.27 (s, 2H, -CH2-), 7.17-7.18 (t,1H, 
py), 7.28 (d, 4H, Ph), 7.36 (d, 1H, py), 7.62-7.65 (t, 1H, py), 8.55 (d, 1H, py). Infrared (KBr, 4000-
650 cm-1) ̅: 3059 (C=C-H Asymmetric stretch), 1598 (C=N, pyridyl). Time-of-flight MS-ESI+ 
m/z: 258.1181, 100 (M+1). Anal. Calc. for C16H19NS:  C: 74.66, H: 7.44, N: 5.44, S: 12.46 %. 
Found: C: 74.47, H: 7.50, N: 5.58, S: 12.28 %. 
2-(4-fluorothiophenol)pyridine (pySPhF) 
The yield of 1.698 g (74 %, light-orange) for pySPhF was obtained. Proton-1 NMR (400 MHz: 
CDCl3):  δH (ppm) referenced to TMS; 4.19 (s, 2H, -CH2-), 6.91-7.00 (d, 2H, Ph), 7.12-7.15 (t, 1H, 
py), 7.23 (d, 1H, py), 7.32(d, 2H, Ph), 7.57-7.60 (t, 1H, py), 8.51-8.52 (d, 1H, py). Carbon-13 
NMR (100 MHz: CDCl3): δC (ppm); 41.8; 115.8; 116.1; 122.1; 123.1; 133.1; 136.6; 149.3; 157.6. 
Infrared (KBr, 4000-650 cm-1) ̅: 3066 (C=C-H Asymmetric stretch), 1588 (C=N, pyridyl). Time-
of-flight MS-ESI+ m/z: 220.0488, 100 (M+1). Anal. Calc. for C12H10FNS:  C: 65.73, H: 4.60, N: 
6.39, S: 14.62 %. Found: C: 65.29, H: 4.31, N: 6.35, S: 14.43 %. 
4.2.3 Synthesis of Pt(II) complexes 
[Pt{2-(phenylthiomethyl)pyridine}Cl2], Pt(pySPh)Cl2, [Pt{2-((4-tert-
butylthiophenol)pyridine}Cl2], Pt(pySPh(t-But))Cl2, and [Pt{2-((4-fluorothiophenol)pyridine}Cl2], 
Pt(pySPhF)Cl2, were synthesised from their respective ligands according to a literature method 
with minor modifications.35 K2PtCl4 (0.47 g, 1.1 mol) was dissolved in ultrapure water (25 mL) 
and stirred for 10-15 minutes and filtered thereafter. A CHCl3 solution of the N,S chelate ligand 
(0.23 g, 1.1 mmol) was added drop-wise into the reaction flask. The reaction mixture was left 
to stir under reflux for 24 h (in a light-free environment). A bright yellow solid precipitate 
which formed was collected via a Millipore micro filter paper after cooling the reaction 
mixture to room temperature. The precipitate was washed with water, ethanol and diethyl 
ether. It was dried under vacuum to give a fine yellow powder. The complexes Pt(pySPh)Cl2, 
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Pt(pySPh(t-But))Cl2 and Pt(pySPhF)Cl2 were characterised by NMR (1H, 13C, and 195Pt), CHN 
elemental analyser, TOF MS-ESI+ and IR spectroscopy. 
Single crystals suitable for X-ray diffraction analysis of Pt(pySPhF)Cl2 were obtained by 
vapour diffusion of ether into the nitromethane solution of its powder. 
The yield of 0.4058 g (77 %, yellow) for Pt(pySPh)Cl2 was obtained. Proton-1 NMR (400 MHz: 
DMF-d7): δH (ppm) referenced to TMS; 4.30 (d, 2H, -CH2-, AB-spin system), 7.16 (t, 1H, Ph), 
7.27 (t, 2H, Ph), 7.37 (d, 2H, Ph), 7.33 (t,1H, py), 7.52-7.54 (d, 1H, py), 7.60-7.64 (t, 1H, py), 
8.56 (d,1H, py). Platinum-195 NMR (400 MHz: DMF-d7): δPt (ppm); -2778. Infrared (KBr, 4000-
650 cm-1) ̅: 3055 (C=C-H Asymmetric stretch), 1583 (C=N, pyridyl). Anal. Calc. for 
C12H11Cl2NPtS:  C: 30.84, H: 2.37, N: 3.00, S: 6.68 %. Found: C: 30.60, H: 2.24, N: 2.91, S: 6.49 
%. 
The yield of 0.3257 g (57 %, light-brown) for Pt(pySPh(t-But))Cl2. Proton-1 NMR (400 MHz: 
CDCl3): δH (ppm) referenced to TMS; 1.30 (s, 9H, -C(CH3)3), 4.27 (d, 2H, -CH2-, AB-spin system), 
7.17-7.18 (t,1H, py), 7.28 (d, 4H, Ph), 7.36 (d, 1H, py), 7.62-7.65 (t, 1H, py), 8.55 (d, 1H, py). 
Platinum-195 NMR (400 MHz: DMF-d7): δPt (ppm); -2786. Infrared (KBr, 4000-650 cm-1) ̅: 
3059 (C=C-H Asymmetric stretch), 1598 (C=N, pyridyl). Anal. Calc. for C16H19Cl2NPtS:  C: 36.72, 
H: 3.66, N: 2.68, S: 6.13 %. Found: C: 36.85, H: 3.53, N: 2.53, S: 7.06 %. 
The yield of 0.698 g (74 %, off-orange) for Pt(pySPhF)Cl2. Proton-1 NMR (400 MHz: CDCl3): δH 
(ppm) referenced to TMS; 4.19 (s, 2H, -CH2-, AB-spin system), 6.91-7.00 (d, 2H, Ph), 7.12-7.15 
(t,1H, py), 7.23 (d, 1H, py), 7.32(d, 2H, Ph), 7.57-7.60 (t, 1H, py), 8.51-8.52 (d, 1H, py). 
Platinum-195 NMR (400 MHz: DMF-d7): δPt (ppm); -2796. Infrared (KBr, 4000-650 cm-1) ̅: 
3066 (C=C-H Asymmetric stretch), 1588 (C=N, pyridyl). Anal. Calc. for C12H10Cl2FNPtS: C: 29.70, 
H: 2.08, N: 2.89, S: 6.60 %. Found: C: 30.14, H: 2.05, N: 2.52, S: 6.20 %. 
4.3 Preparation of the diaqua Pt(II) complexes 
Solutions of diaqua Pt(II) complexes of Pt(pySPh)Cl2, Pt(pySPh(t-But)Cl2, and Pt(pySPhF)Cl2 
were prepared following a method described in literature.36 A known amount of Pt(II) dichloro 
complex and adding a stoichiometric excess (with respect to chloride) of CF3SO3Ag (1.98 molar 
ratio) were dissolved in 0.01 M trifluoromethanesulfonic (triflic) acid. The mixture was 
vigorously stirred at 50 oC for 24 hours in the dark. The white precipitate of silver chloride 
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(AgCl) was filtered off through 0.45 µm nylon membrane using a Millipore filtration apparatus. 
The clear and colourless filtrate was acidified with 0.01 M (CF3SO3H) (triflic) acid in a 
volumetric flask to make the required concentration of the complex in solution. An acidic 
medium (pH = 2) was necessary to ensure that only diaqua complexes and not the mixture of 
the aqua/hydroxo species, were present in solution once the chloride metathesis reaction 
was complete. The adjustment of I = 0.10 M with CF3SO3Li was undertaken to ensure a 
constant ionic strength throughout the kinetic measurements. 
4.4 Instrumentation and physical measurements 
A Bruker NMR spectrometer (Bruker Avance DRX 400 or DRX 500) and a FLASH 2000 
CHN analyser were used for the characterization and chemical analysis of the synthesized 
ligands and complexes, respectively. Low-resolution electron-spray ionization (ESI+) mass 
spectra of the ligands and complexes were recorded on a time-of-flight (TOF) micromass 
spectrometer. A Perkin Elmer Spectrum One FTIR spectrometer was used to obtain Infrared 
(IR) spectra of the ligands and complexes diluted with KBr. Rapid kinetic measurements were 
followed using an Applied Photophysics SX 18MV stopped-flow spectrophotometer coupled 
to an online data acquisition system. The temperature of the reaction was controlled to within 
± 0.1 oC for all measurements. A Cary 100 BIO UV-visible spectrophotometer equipped with a 
Varian Peltier temperature controller with an accuracy of ± 0.05 oC was used for the 
determination of the pKa values of the diaqua complexes. The pH measurements were 
determined on a Jenway 4330 pH meter equipped with a 4.5 µm glass electrode. The micro-
electrode was calibrated at 25 oC using standard buffer solutions (Merck) at pH 4.0, 7.0, and 
10.0. pKa titration curves and time-resolved kinetic traces were graphically analysed using 
Origin 7.5®software package.37  
 4.4.1 pKa determination for the coordinated aqua ligand of the complexes 
Acid-base titrations were undertaken to determine the pKa values of the diaqua 
complexes. The complexes were titrated with NaOH and the pH (in the range 2-9) and the 
absorption spectrum of the solution was recorded. Initially, the base was added in small 
portions of crushed pellets and subsequently as its dilute solutions. After each addition of 
NaOH, ca 0.5 mL of solution was sampled for the pH measurement. The portion was discarded 
to avoid chloride contamination of the solution from leached ions coming from the electrode. 
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The spectral data was analysed with Origin7.5® for which a plot of the pKa values were 
generated from the sigmoidal curve fitting using Boltmann distribution parameters. 
4.4.2 Kinetics studies 
The substitution of the coordinated aqua ligands from all complexes by thiourea 
nucleophiles was studied as a function of concentration and temperature. The concentration 
of the nucleophiles was at least 10-fold greater than the Pt(II) complexes to simplify the 
reaction kinetics to first order. The ionic strength was maintained at 0.1 M with a mixture of 
a 0.09 M lithium trifluoromethanesulfonate (LiOTf) and 0.01 M HOTf. The low basicity of the 
triflate ion precludes its coordination to the Pt(II) metal centre. A pH of 2 ensured that the 
substitution reactions being monitored were that of the coordinated aqua ligands. The 
reactions were monitored on a stopped-flow analyser equipped with a pressure-driven cross-
plugging technique to ensure efficient mixing of the complex and nucleophile solutions. Prior 
to kinetics measurements on the stopped-flow, a preliminary reaction for the change in 
absorbance of the mixture of the Pt(II) metal complex with nucleophile as a function of time 
was undertaken on the UV-visible spectrophotometer. This was done to determine suitable 
wavelengths at which kinetic traces could be followed. All the reported rate constants were 
averages of six to eight independent kinetic runs. The temperature of the medium was varied 
within the range of 15-35 oC to determine the activation parameters ΔH≠ and ΔS≠ from the 
Eyring equation.  
4.4.3 Computer simulation studies 
The geometry optimized molecular structures of the complexes Pt(pySPh), 
Pt(pySPh(t-But)) and Pt(pySPhF) were computed at the DFT level of theory following the 
(B3LYP(CPCM)/LANL2DZp//B3LYP/-LAN2DZp) method38-40 powered by the Gaussian 09 
software suite.41 The geometry optimized structures were conducted in the gaseous phase 
and the calculated structural parameters are presented in the results section. A charge of +2 
was maintained for the cationic diaqua complexes.  
4.4.4 X-ray crystallography 
Single crystal diffraction data of Pt(pySPhF)Cl2 was collected on a Bruker Apex II Duo 
equipped with an Oxford Instrument Cryojet operating at 100 K and an Incoatec microsource 
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operating at 30 W power. A Mo Kα (λ = 0.71073 Å) beam irradiated at a crystal-to-detector 
distance of 50 mm was used to collect the diffraction data. The Bruker instrument was 
calibrated to have the following optimum conditions: omega and phi scans with exposures 
taken at 30 W X-ray power and 0.50° frame widths using APEX2.42 Data reduction was 
performed by the SAINT42 suite of programmes using outlier rejection, scan speed scaling, 
and standard Lorentz and polarisation correction factors. The structure was solved by direct 
methods using SHELXS-9743 and refined using SHELXL-97.43 The Pt(pySPhF)Cl2 crystallized in 
the monoclinic space group, P21/c and contained one molecule with Z = 4. The crystal 
structure and a summary of the crystal data and structure refinement details are shown in 
the results section. 
4.5 Results 
4.5.1 pKa determination of diaqua Pt(II) complexes 
Previous studies have shown that high or low thermodynamic pKa values are an 
indication of the electrophilicity of the metal ion.44,45 The neutralisation of the coordinated 
aqua ligands from the three complexes by NaOH was accompanied by spectral changes in the 
absorption spectrum of the complex Pt(pySPhF) as shown in Figure 4.2. The plot of the 
absorbance at 300 nm versus pH was fitted to two sigmoidal (Boltmann) functions. An inset 
is given as an example in Figure 4.2.  
The hardness and π-acidity of the pyridyl nitrogen as compared to the soft and 
polarisable sulphur of the thioether will contribute differently in the observed pKa values.46  
A  better π-acceptor stabilizes the electro-rich hydroxo species which forms from the 
coordinated aqua ligands upon neutralization with NaOH. Since pyridine is a strong electron 
π-acceptor, the first deprotonation should be on the aqua ligand trans to this moiety.25 The 
pKa1 values for the formation of the aqua/hydroxo complex are: Pt(pySPh) (3.58), 
Pt(pySPh(t-But)) (3.87), and Pt(pySPhF) (3.06). The higher pKa1 values for the complex indicate a 
reduction in charge from +2 (diaqua) to +1 (aqua/hydroxo).  
The second aqua ligand is much weaker than the first due to the strong trans-influence 
of the thioether and thus deprotonates at higher pKa2 values47 of Pt(pySPh) (5.36), 
Pt(pySPh(t-But)) (5.60), and Pt(pySPhF) (5.05). The observed higher pKa2 values are in accordance 
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with the reduction of the overall charge of the complexes from +1 (aqua/hydroxo) to 0 
(hydroxo/hydroxo) following the deprotonation of the second aqua ligand.48  
 





Scheme 4.2 Sequential deprotonation of the diaqua Pt(II) complexes. 
 
Figure 4.2 UV-visible spectra for the titration of 0.2 mM Pt(pySPhF) with NaOH in the pH range 
2-9 at T = 298 K. Inset: Absorbance versus pH data at 300 nm. 
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Table 4.1 Summary of pKa values obtained for the sequential deprotonation of the aqua 
ligands from the cis-Pt(II) complexes. 
 Pt(pySPh) Pt(pySPh(t-But)) Pt(pySPhF) 
pKa1 3.58 ± 0.02 3.87 ± 0.04 3.06 ± 0.02 
pKa2 5.36 ± 0.07 5.60 ± 0.06 5.05 ± 0.04 
 
4.5.2 NMR studies 
The substitution reaction of the dichloro complex Pt(pySPhF)Cl2 by the nucleophile 
thiourea (tu) was confirmed by NMR spectroscopy to detect the possible intermediates and 
final products formed during the substitution process. This data is applicable to the 
mechanism of substitution reactions for diaqua complexes which were used in this kinetic 
study. The substitution reaction of Pt(pySPhF)Cl2 and tu was first confirmed using 1H NMR 
spectroscopy (SI Figure 4.1). The solution of Pt(pySPhF)Cl2 dissolved in DMF-d7 was reacted 
with two equivalents of tu at 303 K.  
 To further confirm the proposed sequential substitution of the leaving chloro ligands, 
the reaction of Pt(pySPhF)Cl2 and two equivalents of tu was followed using the 195Pt NMR 
spectroscopic technique. 195Pt NMR is a useful tool that can be used to identify and follow the 
evolution of species formed during a substitution reaction. Figure 4.3 shows the spectra of 
the 195Pt NMR peaks for the reaction of Pt(pySPhF)Cl2 and tu. The peak labelled as a at -2796 
ppm represents the unreacted Pt(pySPhF)Cl2 complex. During the substitution process, new 
peaks appear at -3414 (b) and -3584 ppm (c), respectively. These peaks are indicative of the 
formation of two new species in solution. These peaks are likely to be due to the intermediate 
products Pt(κ1-SN)tuCl and Pt(κ1-SN)S3 for the substitution of the first and second chloro 
ligands by tu, respectively.  
In addition, the 195Pt NMR data show the ultimate final product with a peak at -3884 
ppm (d). It is known from literature that the δ(195Pt) values within the range -3800 to -4000 
ppm corresponds to [PtS4] usually formed by a complete decoordination of the chelate ligand 
by tu ligands.49 Thus, the peak at -3884 ppm is for a species for which the N,S chelate is 
activated to undergo rapid ring-opening at the pyridyl end as soon as the chloride ligand trans 
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to it is substituted by tu to form the PtS4, Pt(κ1-SPhFpy)(tu)3. The same labilising does not affect 
the thioether end of the ligand due to inertness of the thioether towards substitution.50 Thus, 
a pendant κ1-SN monodentate ligand remains coordinated to the metal centre of 
Pt(pySPhF)Cl2 during the reaction. This is consistent with what was observed by Bellici et al.51 
for the slow ring opening of the S,S 1,2-bis(phenysulfanyl) chelate. 
 














Figure 4.3 195Pt NMR spectra recorded for the reaction of Pt(pySPhF)Cl2 and 2 equiv. of tu, indicating the unreacted cis-Pt(II) complex (a, δ 
= -2796.4 ppm) before the reaction and the final ring-opened product (d, δ = -3884.7 ppm) corresponding to [Pt(κ1-SPhFN) (tu)3]2+. Intermediate 
products (b and c at δ = -3414.5 and -3584.9 ppm) correspond to [Pt(pySPhF)(tu)Cl]+ and [Pt(pySPhF)(tu)2]2+, respectively.
[Pt(pySPhF)Cl2]   + 2 tu Products
ppm 
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4.5.3 DFT-calculated optimised structures 
The DFT-optimised structures of the cis-Pt(II) complexes as well as the calculated 
energy and molecular geometry optimised parameters are shown in Figure 4.4 and Table 4.2, 
respectively. The ground-state geometry of all the complexes adopts a distorted square-
planar arrangement of the coordinated ligands around the Pt atom. For example, Pt(pySPh) 
the computed Pt-S; Pt-Npy; Pt-OH2 (1) and Pt-OH2 (2) (distances are 2.41; 2.02; 2.12; 2.11 Å and 
S-Pt OH2(1) bond angles are closer to linearity in the range 177.2-177.2° and Npy-Pt OH2(2) in 
the range 177.1-178.0°, respectively. The deviation from linearity is probably because of the 
flexible methylene spacer. What is important to note is that going from Pt(pySPh) to 
Pt(pySPh(t-but)) strikingly, the introduction of the positive σ-inductive electron-donating tert-
butyl moiety in Pt(pySPh(t-but)) induces a slight shortening of the S-Pt bond by 0.01 Å when 
compared to Pt(pySPh).  
 The mappings of the frontier molecular orbitals in the ground-state indicate that the 
HOMOs are concentrated directly above and below the Pt(II) ion. The LUMO is concentrated 
on the pyridyl and thioether moieties of the ligands. This points to an electron-rich metal 
centre in which electron density can be back-donated toward the ligand framework. The 
HOMO mappings show significant electron density is also situated on the thioether as well as 
the phenyl ring for all three complexes which can further contribute to an electron-rich metal 
centre. The HOMOs are also found on the tert-butyl and fluoride substituents of the phenyl 
ring for the complexes Pt(pySPh(t-But)) and Pt(pySPhF), respectively.  There is entirely no 
contribution from the pyridine ring and the leaving group ligands.  
Importantly, the LUMOs for all the complexes are more delocalised onto the metal 
centre, the thioether and to a lesser extent on the pyridine ring. The phenomenon that the 
LUMO orbitals are situated to a greater extent on the thioether compared to the π-acceptor 
pyridine can be explained by the combined σ-donor and π-acceptor nature of the sulphur 
atom. The sulphur atom has readily accessible empty 3d π*-orbitals which can readily receive 
electron density from the HOMO orbitals which have significant metal d-orbital character.52-54 
Pitteri et al.55 showed for an N-S-N tridentate complex that sulphur is not only capable of 
substituting the trans leaving ligand due to its strong σ-trans-influence but can also accept 
electron density from the metal centre to stabilize the 18-electron five-coordinate transition 
state. Looking at the LUMO maps it seems the pyridine is a weaker π-acceptor of electron 
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density for the complexes studied. It utilises the π*-orbitals for back-bonding which may not 
be as efficient as the dπ* M.O.s of sulphur. This is because the dπ-dπ* interactions along Pt-S 
bond are more favourable on energy grounds compared to the dπ-pπ* along the Pt-N in 
pulling away electron charge from the metal ion.  
The electrophilicity index (ω) which is a measure of the propensity or capacity of a 
complex to accept electrons56 points to a more electrophic Pt(II) metal centre as increasing in 
the following order: Pt(pySPh(t-But)) (6.48) < Pt(pySPh) (6.68) < Pt(pySPhF) (6.84). The observed 
higher index value of Pt(pySPhF) is due to the π-acceptor properties of the thioether induced 
by the negative σ-inductive electron-withdrawing fluoro substituent, making the Pt(II) metal 
centre more reactive. The lower index value of Pt(pySPh(t-But)) can be accounted to the positive 
σ-inductive electron-donating tert-butyl substituent which enhances the strong σ-trans-
influence of the thioether. This leads to a less electrophilic Pt(II) metal centre due to 
accumulation of electron density.  For the complex Pt(pySPh) has a tendency of accumulating 
electron density onto the metal centre due to a weak σ-donor character of the phenyl ring. 
Hence, a slightly higher index value is observed for Pt(pySPh) compare to Pt(pySPh(t-But)). 
The NBO charges which represent the individual atomic charge57 for the complexes 
give an indication that the electrophilicity of metal atom increases in the following order:  
Pt(pySPh(t-But)) (0.676) < Pt(pySPh) (0.686) < Pt(pySPhF) (0.692). The NBO charges at the Pt(II) 
centre are sensitive to changes in the electron-donating and electron-withdrawing properties 
of the para-positioned substituents. This is in accordance with the change in the observed 
trend in electrophilicity indices which measures the degree of electron deficiency in the entire 
complex56,57 showing a clear trend of decreasing as the positive σ-inductive electron-donation 
increases. The lower NBO charge of Pt(pySPhF) compared to Pt(pySPh(t-But)) emanates from the 
accumulation of electron density at the metal centre. The dipole moment values are also a 
good indicator of the distribution of electrons within the ligand framework of the complexes. 
An increase in the calculated dipole moment of Pt(pySPh(t-But)) (14.9 D) compared to Pt(pySPhF) 
(13.2 D) and Pt(pySPh) (9.03 D) indicate that the electrons can be donated back onto the ligand 
backbone and further away from the metal centre.58,59    
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Figure 4.4 Computer-simulated HOMO and LUMO frontier molecular orbitals of Pt(II) complexes.
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Table 4.2 Computer simulated data by DFT for cis-Pt(II) complexes 
Property Pt(pySPh) Pt(pySPh(t-But)) Pt(pySPhF) 
MO Energy (eV)    
LUMO -3.18 -3.09 -3.23 
HOMO -7.26 -7.09 7.30 
∆EL-H 4.08 4.00 4.07 
NBO Charges    
Pt 0.686 0.676 0.692 
Chemical hardness (eV) 2.04 2.00 2.03 
Chemical potential (eV) -5.22 -5.09 -5.27 
Electrophilicity index (ω) 6.68 6.48 6.84 
Bond lengths (Å)    
d Pt-Npy 2.02 2.02 2.02 
d Pt-S 2.41 2.40 2.41 
d Pt-OH2 (1) 2.12 2.12 2.12 
d Pt-OH2 (2) 2.11 2.10 2.11 
Bond angle (o)    
<S-Pt-OH2 (1) 177.2 177.2 176.6 
< Npy-Pt-OH2 (2) 177.1 178.0 177.9 
Dipole moment (D) 9.03 14.9 13.2 
       H
R = t-Butyl
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4.5.4 Kinetic measurements 
The summary of the proposed reaction pathway for the substitution reaction of aqua 
ligands by thiourea nucleophiles (tu, dmtu and tmtu) is shown in Scheme 4.5. A typical UV-
vis spectrum in Figure 4.5 shows a preliminary reaction of 0.1 mM Pt(pySPh) with 7 mM dmtu 
for the determination of the wavelengths chosen to monitor the two substitution steps. The 
first fast substitution step was followed at the wavelength 310 nm and the second slow 
substitution step at wavelength 290 nm. 
 
Nu = tu; dmtu;tmtu









Scheme 4.5 Representation of the sequential aqua ligand substitution of the complexes 
including a ring-opening step by entering nucleophiles (Nu = tu, dmtu and tmtu). 
The initial two steps, k1 and k2, represent the consecutive substitution of the two aqua 
ligands. Immediately after the first and second substitution of the aqua co-ligands, there is a 
rapid step corresponding to the ring-opening of the bidentate chelate ligand from the 
nitrogen end. The stepwise substitution of the two leaving is hypothesised from the 
unsymmetrical structure of the bidentate ligands coordinated to the Pt(II) complexes. The 
ligands have a thioether known to have a strong trans-labilization effect as well as a π-
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withdrawing pyridine ring. Both substitution steps were monitored by the stopped-flow 
technique.  











Wavelength (nm)  
Figure 4.5 UV-visible spectra recorded for the reaction of 0.1 mM Pt(pySPh) with 7 mM dmtu 
at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
The kinetic traces fitted well to a single exponential function used to generate the 
pseudo-first order rate constants, kobs(1) and kobs(2), at specific nucleophile concentration and 
temperature, for the first and second substitution steps, respectively. Average kobs(1/2) values 
were calculated from data obtained on 6-8 independent kinetic runs from the stopped-flow 
analyser.When the observed pseudo-first order rate constants, kobs(1/2), were plotted against 
concentration of the nucleophiles, the second-order rate constants, k1 and k2, which are a 
measure of the nucleophilic attack on the complex by the nucleophile, were calculated from 
the slopes of the plots. An exemplary time-resolved kinetic trace for the first substitution step 
in the two-step reaction between Pt(pySPh) and 20-fold excess of tu is shown in Figure 4.6.  
 
91 | P a g e  
 














Time/ s  
Figure 4.6 A typical time-resolved kinetic trace for a reaction of 0.1 mM Pt(pySPh) with 2 mM 
tu followed on the stopped-flow at wavelength 321 nm. pH 2 (I = 0.1 M LiOTf/HOTf) and 25 
oC. 
The values of the rate constants (k1 and k2) are summarised in Table 4.3. The 
substitution of the coordinated aqua ligands by the thiourea nucleophiles followed a 
mechanism described by equations (4.1 and 4.2).60, 61 
kobs(1) = k1[Nu] + k-1 ≈ k1[Nu]    (4.1) 
kobs(2) = k2[Nu] + k-2 ≈ k2[Nu]    (4.2) 
A representative plot of the linear regression passing through the origin is shown in Figure 
4.7, indicating that the direct nucleophilic pathway for the substitution of the nucleophiles is 
dominant. The same trend is observed for all the other complexes investigated in this study.  
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[Nu]/ M  
Figure 4.7 Plots of kobs1 vs [Nu] for the first substitution step of the reaction of 0.165 mM 
Pt(pySPh(t-But)) at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
 
Table 4.3 Summary of the rate constants for the consecutive substitution steps of the Pt(II) 
complexes by tu, dmtu and tmtu (I= 0.1 M LiOTf/HOTf). 
 Nu k1/M-1 s-1 k2/10-1 M-2 s-1 
Pt(pySPh) tu 303.7 ± 0.3 11.2 ± 0.8 
 dmtu 349.7 ± 6.0 4.7 ± 0.2 
 tmtu 43.3 ± 0.60 3.4 ± 0.8 
Pt(pySPh(t-But)) tu 4325.4 ± 15.7 242.6 ± 11.6 
 dmtu 635.5 ± 11.1 172.0 ± 0.5 
 tmtu 126.7 ± 2.0 65.9 ± 6.5 
Pt(pySPhF) tu 462.8 ± 1.2 3.97 ± 0.13 
 dmtu 386.5 ± 5.5 3.76 ± 0.19 
 tmtu 61.2 ± 0.5 0.439 ± 0.015 
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4.5.5 Activation parameters 
The temperature dependence of the second-order rate constants, k1 and k2, was 
studied over the temperature range of 15-35 oC at the intervals of 5 oC. A typical Eyring plot 
is shown for the reaction of Pt(pySPh(t-But)) and thiourea nucleophiles in Figure 4.8. The 
calculated values for ΔH≠ and ΔS≠ are summarised in Table 4.4. 
Table 4.4 Summary of the activation parameters for the consecutive substitution steps of the 
investigated complexes by tu, dmtu and tmtu, (I= 0.1 M LiOTf/HOTf). 
 Nu ΔH≠1/kJ mol-1 ΔS≠1/J mol-1 ΔH≠2/kJ mol-1 ΔS≠2/J mol-1 
Pt(pySPh) tu 31 ± 1 -79 ± 4 23 ± 1 -152 ± 5 
 dmtu 30 ± 1 -91 ± 3 35 ± 1 -74 ± 3 
 tmtu 40 ± 1 -99 ± 2 37 ± 1 -81 ± 4  
Pt(pySPh(t-But)) tu 28 ± 1 -72 ± 4 36 ± 3 -100 ± 9 
 dmtu 45 ± 2 -41 ± 6 47 ± 2 -63 ± 6 
 tmtu 36 ± 1 -84 ± 4 17 ± 2 -177 ± 7 
Pt(pySPhF) tu 38 ± 2 -66 ± 7 38 ± 1 -66 ± 5 
 dmtu 38 ± 1 -66 ± 5 44 ± 2 -49 ± 7 
 tmtu 37 ± 2 -86 ± 7 36 ± 3 -91 ± 10 
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1/T (K-1)  
Figure 4.8 Temperature dependence plots for the reaction of 0.046 mM Pt(pySPh(t-But)) with 
2.75 mM (Nu = tu, dmtu and tmtu). 
4.5.6 Crystal structure of Pt(pySPhF)Cl2 
The crystal structure of Pt(pySPhF)Cl2 was is shown in Figure 4.9. 
 
Figure 4.9: Thermal ellipsoid diagram (50% probability surfaces) of the molecular structure 
of Pt(pySPhF)Cl2. 
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Figure 4.9 shows that pySPhF is coordinated to Pt by N of the pyridyl group and sulphur 
atom of the thioether. The other two sites are occupied by chlorine atoms coordinated in a 
cis fashion to make up a distorted square-planar geometry. From the data in Table 4.5 the 
Cl(2)-Pt(1) bond length (2.3261 Å) which is trans to the thioether is significantly longer than that 
which is trans to the pyridyl nitrogen Cl(1)-Pt(1) (2.3049). The same discrepancies are also 
predicted by DFT calculations. This is due to ease of polarisability of the thioether which forms 
a stronger σ-bond S(1)-Pt(1) to the Pt atom. This weakens the Pt-Cl/OH2 bond trans to it since 
both the S and Cl/OH2 use the same p-orbital on the Pt. the strong trans influence labilises 
(elongates the Pt-Cl bond) the Cl ligand trans to it. Thus, the substitution of the aqua ligands 
occurs at distinct rates and thus the process is consecutive, as already proposed. The phenyl 
ring lies out of plane of the complex (with dihedral angle 78.57 °) and is closer to the Cl atom 
trans to pyridine. This has potential to block the approach of the nucleophile on one side. 
Thus, the Cl/OH2 ligand will be substituted even more slowly when compared to the one trans 
to the thioether. The data of the crystal structure is summarised in Table 4.5. The metrics 
(bond lengths and angles) is summarised in Table 4.6.  
Table 4.5 Comparison of the experimental and theoretical bond lengths (Å) and bond angles 
(°) for Pt(pySPhF)Cl2. 
Bond lengths (Å) 
X-ray DFT 
N(1)-Pt(1) 2.027 (3) d Pt-Npy 2.02 
S(1)-Pt(1) 2.2451 (10) d Pt-S 2.41 
Cl(1)-Pt(1) 2.3049 (13) d Pt-OH2 (1) 2.11 
Cl(2)-Pt(1) 2.3261 (10) d Pt-OH2 (2) 2.12 
Bond angles (°) 
N(1)-Pt(1)-Cl(1) 175.42(8) < Npy-Pt-OH2 (1) 177.9 
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Table 4.6 Crystal data and structure refinement for Pt(pySPhF)Cl2. 
Parameter   
Empirical formula C12H10C12FNPtS 
Formula weight 485.26 
Temperature  100(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P 21/c 
Unit cell dimensions a = 10.136(5) Å α = 90° 
 b = 9.345 (4) Å β = 100.366(5)° 
 c = 14.305(6) Å γ = 90° 
Volume 1332.9(10) Å3 
Z 4 
Density (calculated) 2.418 mg/m3 
Absorption coefficient 11.075 mm-1 
F (000) 904 
Crystal size 0.220 x 0.190 x 0.140 mm3 
Theta range for data collection 2.043 to 28.343°  
Reflections collected 23313 
Independent reflections 3314 [R(int) = 0.0359] 
Completeness to theta = 25.242° 99.9 % 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.318 and 0.183 
Refinement method Full-matrix least-squares of F2 
Data/ restraints/ parameters 3314 / 0 / 163 
Goodness-of-fit on F2 1.157 
Final R indices [I > 2sigma(I)] R1 = 0.0208, wR2 = 0.0480 
R indices (all data) R1 = 0.0216, wR2 = 0.0483 
Largest diff. peak and hole 0.976 and -1.834 e Å-3 
 
 
97 | P a g e  
 
4.6 Discussion 
In this study, three square-planar cis-Pt(II) complexes comprising 2-
(phenylthiomethyl)pyridine chelates with different substituents (Figure 4.1) were 
synthesised, characterized and the substitution reactions of the aqua co-ligands were studied 
using bio-relevant sulphur-containing thiourea nucleophiles. The non-leaving ligand differs in 
the substituents on the phenyl ring of the thioether and this may affect the substitution 
behaviour of the complexes. The unsymmetrical nature of the complexes due to the σ-donor 
thioether and the π-acceptor pyridine moieties, will affect the lability of the aqua ligands 
differently leading to a consecutive substitution process. The phenyl ring on the non-leaving 
ligands bears substituents of different electronic properties on the para-position. 
In comparing the rate of substitution of the first aqua ligand, k1, data in Table 4.3 
shows that the reactivity of cis-Pt(II) complexes follows the trend Pt(pySPh(t-But)) > Pt(pySPhF) > 
Pt(pySPh). If the reactivity of Pt(pySPh(t-But)) with tu is taken as a reference, the ratio of 
reactivity is 12: 1.3: 1, respectively for Pt(pySPh(t-But)): Pt(pySPhF): Pt(pySPh). The first 
substitution occurs at the aqua ligand trans to the thioether for all the complexes. This is in 
accordance with the acquired pKa values in Table 4.1. The difference in the reactivity between 
the complexes can be accounted for in terms of the nature of the para-substituents on the 
periphery of the phenyl ring. The results in Table 4.3 indicate that the positive σ-inductive 
effect of the tert-butyl (-C(CH3)3) substituent at the para-position of the phenyl group 
increases electron density which is in turn donated onto the thioether. This increases the 
strength of the strong trans-directing ability via the ground-state σ-trans-influence.  
Consequently, electron density from the thioether is donated onto the empty 6p orbitals of 
the Pt atom. This leads to the ground state stabilization of the S-Pt bond whilst the Pt-O bond 
trans to itself is labilized and substituted more rapidly by the oncoming thiourea nucleophiles 
compared to Pt(pySPh). An unsubstituted phenyl ring is a net σ-donor of electron density but 
weaker compared to the tert-butyl in Pt(pySPh(t-But)), hence, the slower reactivity of 
Pt(pySPh).62,63  
The negative σ-inductive effect of the para-positioned fluoride substituent in 
Pt(pySPhF) deactivates the ring, making it electron deficient. This process activates the π-
acceptor capacity of the thioether which pulls away electron charge on the Pt metal ion 
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making it more electrophilic. Thus, the approach of the entering thiourea nucleophiles to 
stabilize the transition state is made easier in Pt(pySPhF) compared to Pt(pySPh). Hence, the 
rate of associative substitution of the aqua ligands is greater for Pt(pySPhF) compared to 
Pt(pySPh). The reactivity difference between Pt(pySPh(t-But)) and Pt(pySPhF) is an indication that 
the strong trans-directing ability via the ground-state σ-trans-influence of the thioether is 
greater than its capacity to pull away electron charge via π-back bonding in labilizing the aqua 
ligand trans to this moiety. 
 Density Functional Theory (DFT) calculations were conducted to help support the 
observed kinetic trends in the reactivity of the complexes (Table 4.2).  The observed trend 
can be explained by the fact that the thioether has the capacity to receive electron density 
from the metal centre via π-back bonding. The sulphur atom has synchronous σ-donor/π-
acceptor properties and these are based on the substituents on the para-position of the 
phenyl ring. The coordinated thioether has energetically accessible and vacant 3d-orbitals 
which are capable of accepting electron density from the 5d-orbitals of the metal centre.64 
Since Pt(pySPh(t-But)) has a greater tendency to donate electron charge onto the metal centre, 
the capacity for π-back bonding of sulphur (S←Pt) is likewise greater. This then makes the 
Pt(II) centre more electrophilic and sensitive to the approach of negative charge from the 
thiourea ligands which stabilizes the 18 electron five-coordinate transition state. The π-back 
bonding capacity of the thioether in these set of complexes is confirmed by the distribution 
of electron density in the frontier molecular orbitals (Figure 4.3).  The ground state LUMO is 
localized on the thioether specifically on the S-Pt-O axis and to a lesser extent on the pyridine 
moiety. The same reasoning was used to explain the superior reactivity of a Pt(N-S-N)Cl 
complex [Pt(bis(2-pyridylmethyl)sulfide)OH2](ClO4)2 (Ptdps) compared to its N,N,N analogue 
[Pt(bis(2-pyridylmethyl)amine)OH2](ClO4)2 (Ptdpa) analogue. The central S-atom of the 
former complex accepts electron density from the metal d-orbitals thereby increasing the 
electrophilicity of the Pt and the rate of substituting the leaving group.   
The slower rate of substitution of the second aqua ligand occurs trans to the pyridine 
moiety. The rate constant, k2, for the substitution of the second aqua ligand when tu is 
considered decreases in the ratio: 61: 2.8: 1, for Pt(pySPh(t-But)) : Pt(pySPh) : Pt(pySPhF), 
respectively. The reactivity of the complexes for the second substitution step follows the 
trend: Pt(pySPh(t-But)) > Pt(pySPh) > Pt(pySPhF). This is consistent with the fact that the 
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coordination of the first aqua ligand imparts a steric hindrance to the approach of the 
subsequent entering ligand. Therefore, substitution at the square plane is shielded especially 
from the approach of these nucleophiles towards the Pt metal centre and the formation of a 
new bond is thereby made difficult. The shielding by the coordinated tu is less, hence, it reacts 
faster than the other nucleophiles. However, due to the π-acceptor properties of pyridine it 
is still expected that electron density would be back-donated from the filled d-orbitals of the 
metal centre onto the empty or antibonding orbitals of the pyridine. This would make the 
metal ion more electropositive. Thus, the approach of the entering ligand would help stabilize 
the 18-electron five-coordinate transition state.  
On coordination, the thiourea nucleophiles labilise the pyridine ligand leading to its 
immediate substituting by a third thiourea ligand. This step is fast and independent of the 
concentration of the nucleophiles. This forms the ultimate product Pt(tu)3(κ-SPhR). 195Pt NMR 
spectra (Figure 4.3) confirms the formation of a pendant κ-SN due to the decoordination of 
the pyridyl moiety by a peak at -3884 ppm which corresponds to PtS4.  
 
4.7 Conclusions 
The values of the second-order rate constants, k1 and k2, for the consecutive 
substitution of the aqua ligands in the cis-Pt(II) complexes were sensitive to the nature of 
substituents on the para-position of the thiophenyl. The trans-labilizing effect of sulphur was 
activated or enhanced by the positive σ-inductive donation of density into the phenyl moiety 
such as tert-butyl in the case of Pt(pySPh(t-But)) and the unsubstituted weaker net σ-donor 
phenyl in Pt(pySPh). This leads to an increase in the rate of substitution for Pt(pySPh(t-But)) 
compared to Pt(pySPh). However, the π-acceptor property of the S-atom (thioether) through 
its π* orbitals ensured that the negative σ-inductive effects of substituents such as fluoride 
(in the case of Pt(pySPhF) increased the electrophilicity of the Pt relative to that of Pt(pySPh). 
The low and positive ΔH≠ values and the high and negative ΔS≠ values confirmed an associative 
mode of substitution. This study has demonstrated that the reactivity of square-planar cis-
Pt(II) complexes can be modified through altering the electronic properties of the substituents 
on the bidentate N,S non-leaving ligand.  
100 | P a g e  
 
4.8 References 
1. B. Rosenberg and L. Vancamp, Nature, 1969, 222, 385-386. 
2. T. C. Johnstone, K. Suntharalingam and S. J. Lippard, Chemical Reviews, 2016, 116, 
3436-3486. 
3. J. Reedijk, Chemical Communications, 1996, 801-806. 
4. E. R. Jamieson and S. J. Lippard, Chemical Reviews, 1999, 99, 2467-2498. 
5. C. X. Zhang and S. J. Lippard, Current Opinion in Chemical Biology, 2003, 7, 481-489. 
6. M. Galanski, M. A. Jakupec and B. K. Keppler, Current Medicinal Chemistry, 2005, 12, 
2075-2094. 
7. M. Georgi, B. Adriana and K. Margarita, Current Medicinal Chemistry, 2005, 12, 2177-
2191. 
8. K. R. Harrap, Cancer Treatment Reviews, 1985, 12, 21-33. 
9. L. Kelland, Nat Rev Cancer, 2007, 7, 573-584. 
10. J. Pracharova, T. Saltarella, T. Radosova Muchova, S. Scintilla, V. Novohradsky, O. 
Novakova, F. P. Intini, C. Pacifico, G. Natile, P. Ilik, V. Brabec and J. Kasparkova, 
Journal of Medicinal Chemistry, 2015, 58, 847-859. 
11. T. V. Segapelo, I. A. Guzei, L. C. Spencer, W. E. V. Zyl and J. Darkwa, Inorganica 
Chimica Acta, 2009, 362, 3314-3324. 
12. A. Samanta, G. K. Ghosh, I. Mitra, S. Mukherjee, J. C. Bose, S. Mukhopadhyay, W. 
Linert and S. C. Moi, RSC Adv., 2014, 4, 43516-43524. 
13. B. Desoize and C. Madoulet, Critical Reviews in Oncology/Hematology, 2002, 42, 317-
325. 
14. M. Fanelli, M. Formica, V. Fusi, L. Giorgi, M. Micheloni and P. Paoli, Coordination 
Chemistry Reviews, 2016, 310, 41-79. 
15. M. R. Shehata, M. M. Shoukry, M. A. Mabrouk and R. Van Eldik, Journal of 
Coordination Chemistry, 2016, 69, 522-540. 
16. N. Shahabadi, S. Kashanian and A. Fatahi, Bioinorganic Chemistry and Applications, 
2011, 2011, 687571. 
17. S. Grabner, B. Modec, N. Bukovec, P. Bukovec, M. Čemažar, S. Kranjc, G. Serša and J. 
Sčančar, Journal of Inorganic Biochemistry, 2016, 161, 40-51. 
101 | P a g e  
 
18. G. Berger, L. Fusaro, M. Luhmer, J. Czapla-Masztafiak, E. Lipiec, J. Szlachetko, Y. 
Kayser, D. L. A. Fernandes, J. Sa, F. Dufrasne and S. Bombard, Journal of Biological 
Inorganic Chemistry, 2015, 20, 841-853. 
19. M. N. Noolvi, H. M. Patel and M. Kaur, European Journal of Medicinal Chemistry, 
2012, 54, 447-462. 
20. J. Reedijk, Proceedings of the National Academy of Sciences, 2003, 100, 3611-3616. 
21. J. Reedijk, Platinum Metals Review, 2008, 52, 2-11. 
22. S. Hochreuther, R. Puchta and R. van Eldik, Inorganic Chemistry, 2011, 50, 8984-
8996. 
23. S. Hochreuther, R. Puchta and R. van Eldik, Inorganic Chemistry, 2011, 50, 12747-
12761. 
24. Ž. D. Bugarčić, J. Bogojeski, B. Petrović, S. Hochreuther and R. van Eldik, Dalton 
Transactions, 2012, 41, 12329-12345. 
25. S. Hochreuther, S. T. Nandibewoor, R. Puchta and R. van Eldik, Dalton Transactions, 
2012, 41, 512-522. 
26. B. B. Khusi, A. Mambanda and D. Jaganyi, Transition Metal Chemistry, 2016, 41, 191-
203. 
27. S. Ray, P. Karmakar, A. Chattopadhyay, D. Nandi, R. Sarkar and A. K. Ghosh, 
International Journal of Chemical Kinetics, 2016, 48, 347-357. 
28. U. Fekl and R. van Eldik, European Journal of Inorganic Chemistry, 1998, 1998, 389-
396. 
29. N. Summa, W. Schiessl, R. Puchta, N. van Eikema Hommes and R. van Eldik, Inorganic 
Chemistry, 2006, 45, 2948-2959. 
30. P. K. Ghosh, S. Saha and A. Mahapatra, Chemistry Central Journal, 2007, 1, 23-23. 
31. D. Gibson, Dalton Transactions, 2009, DOI: 10.1039/B918871C, 10681-10689. 
32. Ž. D. Bugarčić, J. Bogojeski and R. van Eldik, Coordination Chemistry Reviews, 2015, 
292, 91-106. 
33. M. R. Malachowski, M. Adams, N. Elia, A. L. Rheingold and R. S. Kelly, Journal of the 
Chemical Society, Dalton Transactions, 1999, DOI: 10.1039/A900223E, 2177-2182. 
34. M. R. Malachowski, M. E. Adams, D. Murray, R. White, N. Elia, A. L. Rheingold, L. N. 
Zakharov and R. S. Kelly, Inorganica Chimica Acta, 2009, 362, 1247-1252. 
102 | P a g e  
 
35. M. J. Rauterkus, S. Fakih, C. Mock, I. Puscasu and B. Krebs, Inorganica Chimica Acta, 
2003, 350, 355-365. 
36. Ž. D. Bugarčić, B. V. Petrović and R. Jelić, Transition Metal Chemistry, 2001, 26, 668-
671. 
37. v. B. Origin 7.5TM SRO, Origin Lab Corporation, Northamption, One, Northamption, 
MA, 01060, USA, 2003. 
38. A. D. Becke, The Journal of Chemical Physics, 1993, 98, 5648-5652. 
39. C. Lee, W. Yang and R. G. Parr, Physical review B, 1988, 37, 785. 
40. P. J. Hay and W. R. Wadt, The Journal of Chemical Physics, 1985, 82, 299-310. 
41. R. A. I. Gaussian 09, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. 
Robb, J. R. Cheeseman,  G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. 
Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. zheng, J. L. 
Sonnenberg, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. 
Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, 
M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. 
Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, 
N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. 
Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyvev, A. J. Austin, R. Cammi, C. 
Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewsi, G. A. Voth, P. 
Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foesman, J. V. 
Ortiz, J. Cioslowski and D. J. Fox, Gaussian, Inc., Wallingford CT, 2009. 
42. S. a. S. B. A. I. Bruker APEX2, 2010, Madison, Wisconsin, USA. 
43. G. Sheldrick, Acta Crystallographica Section A, 2008, 64, 112-122. 
44. D. Jaganyi, F. Tiba, O. Q. Munro, B. Petrović and Ž. D. Bugarčić, Dalton Transactions, 
2006, DOI: 10.1039/B602950G, 2943-2949. 
45. A. Mambanda and D. Jaganyi, Dalton Transactions, 2012, 41, 908-920. 
46. A. Mambanda and D. Jaganyi, Dalton Transactions, 2011, 40, 79-91. 
47. Z. D. Bugarcic, T. Soldatovic, R. Jelic, B. Alguero and A. Grandas, Dalton Transactions, 
2004, 3869-3877. 
48. H. Erturk, A. Hofmann, R. Puchta and R. van Eldik, Dalton Transactions, 2007, DOI: 
10.1039/B700770C, 2295-2301. 
103 | P a g e  
 
49. J. R. L. Priqueler, I. S. Butler and F. D. Rochon, Applied Spectroscopy Reviews, 2006, 
41, 185-226. 
50. K. Lemma, S. K. C. Elmroth and L. I. Elding, Journal of the Chemical Society, Dalton 
Transactions, 2002, 1281-1286. 
51. M. Bellicini, L. Cattalini, G. Marangoni and B. Pitteri, Journal of the Chemical Society, 
Dalton Transactions, 1994, DOI: 10.1039/DT9940001805, 1805-1811. 
52. J. C. Bailar and A. F. Trotman-Dickenson, Comprehensive inorganic chemistry, 
Pergamon Press; distributed by Compendium Publishers [Elmsford, N.Y.], [Oxford, 
1973. 
53. F. Basolo and R. G. Pearson, Mechanisms of inorganic reactions: a study of metal 
complexes in solution, Wiley, 1967, 351-404. 
54. M. L. Tobe and J. Burgess, Inorganic reaction mechanisms, Longman, Harlow, Essex, 
England; New York, 1999, 30-43, 70-112. 
55. B. Pitteri, G. Marangoni and L. Cattalini, Polyhedron, 1995, 14, 2331-2338. 
56. C. A. Mebi, Journal of Chemical Sciences, 2011, 123, 727-731. 
57. I. M. Wekesa and D. Jaganyi, Dalton Transactions, 2014, 43, 2549-2558. 
58. D. P. Rillema, A. J. Cruz, C. Moore, K. Siam, A. Jehan, D. Base, T. Nguyen and W. 
Huang, Inorganic Chemistry, 2013, 52, 596-607. 
59. M. Das and S. E. Livingstone, Journal of the Chemical Society, Dalton Transactions, 
1975, DOI: 10.1039/DT9750000452, 452-455. 
60. R. B. Jordan, Reaction mechanisms of inorganic and organometallic systems, Oxford 
University Press, New York, 1991, 29-40. 
61. S. Asperger, Chemical kinetics and inorganic reaction mechanisms, Kluwer 
Academic/Plenum Publishers, New York, 2003, 34-40, 105-106. 
62. D. Jaganyi, D. Reddy, J. A. Gertenbach, A. Hofmann and R. van Eldik, Dalton 
Transactions, 2004, DOI: 10.1039/B311595J, 299-304. 
63. D. Jaganyi, K.-L. D. Boer, J. Gertenbach and J. Perils, International Journal of Chemical 
Kinetics, 2008, 40, 808-818. 
64. F. A. Cotton and G. Wilkinson, Advanced inorganic chemistry, Wiley, New York, 1988. 
 
 
104 | P a g e  
 
4.9 Supplementary Information 
Table SI 4.1 Selected wavelengths for the first substitution reactions of all three nucleophiles 
at pH 2.  
Complex Nu Wavelength (nm) 
Pt(pySPh) tu 321 
 dmtu 310 
 tmtu 351 
Pt(pySPh(t-But)) tu 280 
 dmtu 280 
 tmtu 335 
Pt(pySPhF) tu 310 
 dmtu 310 
 tmtu 310 
 
Table SI 4.2 Selected wavelengths for the second substitution reactions of all three 
nucleophiles at pH 2.  
Complex Nu Wavelength (nm) 
Pt(pySPh) tu 290 
 dmtu 290 
 tmtu 320 
Pt(pySPh(t-Butyl)) tu 268 
 dmtu 268 
 tmtu 325 
Pt(pySPhF) tu 290 
 dmtu 290 
 tmtu 320 
 
 











Figure SI 4.1 UV-visible spectra for the titration of 0.22 mM Pt(pySPh) with NaOH in the pH 
range 2-8 at T = 298 K. Inset: Absorbance versus pH data at 300 nm. 














Wavelength (nm)  
Figure SI 4.2 UV-visible spectra recorded for the reaction of 0.115 mM Pt(pySPh) with 6.9 
mM tu at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC.      
            
  





































                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
Figure SI 4.3 1H NMR spectral array (aromatic region) for the reaction of [Pt(pySPhF)Cl2] with two equivalents of thiourea (tu) in DMF-d7 at 298 
K. The doublet indicated by H1’ at δ = 9.54 ppm corresponds to the substituted product.  
107 | P a g e  
 
 
Figure SI 4.4 Low resolution ESI mass spectrum of 2-(phenylthiomethyl)pyridine} (pySPh). 
 
 
Figure SI 4.5 1H NMR spectrum of 2-(4-fluoro phenylthiomethyl)pyridine} (pySPhF). 
 



















































































Figure SI 4.9 IR spectrum of [Pt{2-(4-tert-butylthiomethyl)pyridine}Cl2] Pt(pySPh(t-but)). 
 
 
Table SI 4.3 Averaged observed rate constants, kobs1, for the reaction of 0.1147 mM Pt(pySPh) 
with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs1 in s-1 
2.294 1,115 1,606 0.1747 
4.588 1,814 2,418 0.2759 
6.882 2,505 3,202 0.3684 
9.176 3,204 3,947 0.4777 
11.47 3,903 4,852 0.5702 
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Table SI 4.4 Averaged observed rate constants, kobs2, for the reaction of 0.1147 mM Pt(pySPh) 
with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs1 in s-1 
2.294 0,00403 0,00772 0,00531 
4.588 0,00481 0,0082 0,00568 
6.882 0,00594 0,00881 0,00607 
9.176 0,00769 0,00943 0,00644 
11.47 0,00899 0,00981 0,0069 
 
 
Table SI 4.5 Averaged observed rate constants, kobs1, for the reaction of 0.1646 mM 
Pt(pySPh(t-But)) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs1 in s-1 
1.646 7.2 1.776 0.4277 
3.292 14.4 3.869 0.8636 
4.938 21.25 6.385 1.227 
6.584 28.22 8.636 1.738 
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Table SI 4.6 Averaged observed rate constants, kobs2, for the reaction of 0.1646 mM 
Pt(pySPh(t-But)) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs2 in s-1 
3.293 0.4053 0.03305 0,00661 
6.584 0.7176 0.07687 0,01537 
9.876 0.958 0.2033 0,04066 
13.17 1.29 0.3607 0,07214 
16.46 1.535 0.4332 0,08664 
 
 
Table SI 4.7 Averaged observed rate constants, kobs1, for the reaction of 0.04946 mM 
Pt(pySPhF) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs1 in s-1 
0.4946 0.2594 0.2665 0.02513 
0.9892 0.5565 0.5369 0.05632 
1.484 0.8501 0.8377 0.08496 
1.978 1.238 1.111 0.1157 
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Table SI 4.8 Averaged observed rate constants, kobs2, for the reaction of 0.04946 mM 
Pt(pySPhF) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs2 in s-1 
0.9892 0.4626 0.5492 0.04608 
1.978 0.8459 1.044 0.09601 
2.968 1.321 1.403 0.1357 
3.957 1.634 1.701 0.1726 
4.946 2.032 2.079 0.2251 
 
 
Table SI 4.9 Temperature dependence of the second-order rate constants, k1/M-1 s-1, for the 
substitution of the first aqua group in Pt(pySPh) by with different nucleophiles at pH 2 (I = 0.1 
M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -2,10773 0,00347 -2,55019 0,00347 -3,44072 
0,00341 -1,73985 0,00341 -2,1579 0,00341 -3,08275 
0,00336 -1,3843 0,00336 -1,8412 0,00336 -2,87454 
0,0033 -1,14353 0,0033 -1,53686 0,0033 -2,63855 
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Table SI 4.10 Temperature dependence of the second-order rate constants, k1/M-1 s-1, for the 
substitution of the first aqua group in Pt(pySPh(t-But)) by with different nucleophiles at pH 2 (I 
= 0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 3,452 0,00347 0,00551 0,00347 -1,37939 
0,00341 3,67833 0,00341 0,45874 0,00341 -1,06533 
0,00336 3,87228 0,00336 0,77466 0,00336 -0,87487 
0,0033 4,07643 0,0033 1,04257 0,0033 -0,60812 
0,00325 4,19966 0,00325 1,23892 0,00325 -0,38105 
 
 
Table SI 4.11 Temperature dependence of the second-order rate constants, k1/M-1 s-1, for the 
substitution of the first aqua group in Pt(pySPhF) by with different nucleophiles at pH 2 (I = 0.1 
M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 0,03745 0,00347 -0,1442 0,00347 -2,19781 
0,00341 0,37429 0,00341 0,18944 0,00341 -1,86308 
0,00336 0,65352 0,00336 0,40116 0,00336 -1,64965 
0,0033 0,85849 0,0033 0,64788 0,0033 -1,45166 
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Table SI 4.12 Temperature dependence of the second-order rate constants, k2/M-1 s-1, for the 
substitution of the second aqua group in Pt(pySPh) by with different nucleophiles at pH 2 (I = 
0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -0,25642 0,00347 -0,45618 0,00347 -3,44072 
0,00341 0,30694 0,00341 0,0959 0,00341 -3,02749 
0,00336 0,61862 0,00336 0,4656 0,00336 -2,87454 
0,0033 1,26377 0,0033 0,75832 0,0033 -2,63855 




Table SI 4.13 Temperature dependence of the second-order rate constants, k2/M-1 s-1, for the 
substitution of the second aqua group in Pt(pySPh(t-But)) by with different nucleophiles at pH 2 
(I = 0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -3,51136 0,00347 -4,59617 0,00347 -3,57129 
0,00341 -3,15647 0,00341 -4,48904 0,00341 -3,13877 
0,00336 -2,92145 0,00336 -4,31196 0,00336 -2,78179 
0,0033 -2,66823 0,0033 -4,25058 0,0033 -2,47998 
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Table SI 4.14 Temperature dependence of the second-order rate constants, k2/M-1 s-1, for the 
substitution of the second aqua group in Pt(pySPhF) by with different nucleophiles at pH 2 (I = 
0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -0,1442 0,00347 -0,24178 0,00347 -2,44072 
0,00341 0,18944 0,00341 0,09918 0,00341 -2,02749 
0,00336 0,40116 0,00336 0,46139 0,00336 -1,87454 
0,0033 0,64788 0,0033 0,66689 0,0033 -1,63855 







Figure SI 4.15 Eyring plots for (a) first and (b) second substitution steps for the reactions of 
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Chapter 5 
Role of extended π-conjugation on the rate of substitution of aqua ligands in 
cis-Pt(II) complexes with 2-((4-substituted)phenylthiomethyl)quinoline non-
leaving ligands. 
5.0 Abstract 
The sequential substitution of aqua ligands from [Pt{2-(phenylthiomethyl)quinoline} 
(H2O)2]2+ Pt(QnSPh), [Pt{2-(4-tert-butylphenylthiomethyl)quinoline}(H2O)2]2+ Pt(QnSPh(t-But)), 
[Pt{2-(4-fluorophenylthiomethyl)quinoline}(H2O)2]2+ Pt(QnSPhF) and [Pt{2-(4-tert-
butylphenylthiomethyl)pyridine(H2O)2]2+ Pt(pySPh(t-But)) by three neutral S-containing 
nucleophiles (Nu) with different steric sizes, thiourea (tu), N,N’-dimethylthiourea (dmtu) and 
N,N,N’N’-tetramethylthiourea (tmtu), was studied under pseudo-first-order conditions as a 
function of concentration and temperature using stopped-flow and UV-visible 
spectrophotometric techniques.    
The observed pseudo-first-order rate constants for the substitutions can be described 
by the rate law: kobs(1/2) = k2(1/2)[Nu]. The first aqua ligand was substituted opposite to the 
strong σ-trans-directing thioether followed by the aqua ligand opposite to the quinoline or 
pyridine moieties. The rate of substituting the aqua ligand from the complexes was influenced 
by the σ-donating tert-butyl of Pt(QnSPh(t-But)) and σ-withdrawing fluoro of Pt(QnSPhF) on the 
para-position of the phenyl ring. In both complexes, the substituents on the phenyl ring of 
the thioether accelerated the rate of substitution when compared to the unsubstituted 
analogue Pt(QnSPh). When the reactivity for Pt(pySPh(t-But)) is compared to Pt(QnSPh(t-But)), the 
latter is found to be less reactive by a factor of 13 due to the poor π-acceptor properties of 
the quinoline ring. Second-order rate constants, k2(1st), for the substitution of the first aqua 
ligand ranged between 9.1 - 21.2 M-1 s-1 for Pt(QnSPh), 86.4 - 325.4 M-1 s-1 for Pt(QnSPh(t-But)), 
58.9 -287.4 M-1 s-1 for Pt(QnSPhF) and 126.7 - 4325.4 M-1 s-1 Pt(pySPh(t-But)). The ranges of the 
second-order rate constants, k2(2nd), are always lower than the k2(1st)’s and are 0.35 - 8.9 M-1 
s-1 for Pt(QnSPh), 2.3 - 19.6 M-1 s-1 for Pt(QnSPh(t-But)) and 0.29 - 4.8 M-1 s-1 for Pt(QnSPhF) and 
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6.6 - 24.4 M-1 s-1 Pt(pySPh(t-But)). The second-order rate constants were sensitive to the steric 
bulk of the entering nucleophiles. The high and negative activation entropy and low and 
positive activation enthalpy values (Table 5.4) support an associative mechanism of 
activation, characteristic of substitution reactions occurring in square-planar complexes.   
5.1 Introduction 
Transition metals of low-spin d8 square-planar Pt(II) complexes have been a subject of 
medicinal interest for years.1-4 It is now known that their reactions with DNA nucleic bases is 
the main mechanistic pathway for anticancer activity against cancerous cells.5,6 Modification 
of both steric and electronic attributes of the non-leaving ligand is key to adjusting the 
reactivity of Pt(II) complexes required to optimise their antitumour potency.7,8 This argument 
is demonstrated by the high reactivity factors of between 103 - 105 of the analogous Pd(II) 
complexes over the Pt(II) analogues, yet the majority are inactive anticancer agents.9 The high 
reactivity of Pd(II) complexes renders them inactive anticancer agents due to rapid 
deactivation by non-targeted substrates in the plasmic fluids.10 Additionally, this also leads to 
high toxicity and development of resistance.11,12 However, the reactivity of Pd(II) compounds 
can be slowed down to levels commonly reported for Pt(II) complexes by introducing sterically 
bulky non-leaving ligands which retards facile approach of plasmic nucleophiles.13,14 
The reactivity of Pt(II) complexes that possess two sites for substitution can be 
affected by both steric and electronic factors in the structure of the non-leaving ligand. Pt(II) 
complexes which have N,N-13,15-25 or N,S-26-28 bidentate non-leaving ligands usually display a 
two-step consecutive substitution of the labile leaving groups, at rates that are dependent on 
the electronic (σ-donor/π-acceptor) and steric demands of the resident ligand as well as the 
co-ordinated nucleophile after the first substitution step. Even in complexes where the 
coordinated bidentate ligand is symmetrical, a consecutive substitution usually occur.29 In one 
such set of complexes, substitution of the first leaving group was followed by ring-opening of 
the S,S bidentate (where S,S = 1,2-bis(phenylsulfanyl)ethane) when neutral pyridine was used 
as a substituting ligand.30  
When the non-leaving ligand has fused aromatic rings, the rate of substitution is 
increased due to the strong π-acceptor property of the ligand. Theoretically, extending the π-
surface of a strong π-acceptor ring such as pyridine to a quinoline moiety is expected to 
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accelerate the rate of substitution due to an increased propensity of the latter moiety to 
receive electron density into its low-energy, extended molecular orbitals through back 
bonding. However, recent reports31-33 have demonstrated an antithesis of this observation 
for which a dominant σ-cis-effect of an isoquinoline and quinoline moieties for tridentate 
N,N,N terpy-analogues retard the rate of substitution of the labile leaving group relative to 
Pt(terpy). This has been consistently observed due to accumulation of electron density on the 
Pt(II) metal centre of the iso/quinolyl complexes.31-33 This leads to the destabilization of the 
transition state.34,35 A similar trend in reactivity was observed by Khusi et al.36 for N,N 
bidentate coordinated Pt(II) complexes for which replacing the pyridy moiety of the bidentate 
with a quinolyl moiety retarded the rate of stepwise substitution of the aqua leaving groups 
positioned trans to the moiety. This study serves to extend the knowledge on the role of 
extended π-conjugation of a non-leaving ligand on the rate of aqua ligand substitution in cis-
Pt(II) complexes bearing 2-((4-substituted)phenylthiomethyl)quinoline N,S bidentate ligands 
(see Figure 5.1). The entering thiourea nucleophiles were chosen due to their neutral 
character, good aqueous solubility and nucleophilicity.37  
 












Synthesis of the ligands was carried out under inert nitrogen conditions using standard 
Schlenk techniques. Ligand and complex precursors were obtained from Aldrich and used 
without further purification. Silver trifluoromethanesulfonate (CF3SO3Ag, 99 %, Aldrich) was 
stored under nitrogen as per specifications and used as received. The nucleophiles viz., 
thiourea (tu, 99 %), N,N-dimethylthiourea (dmtu, 99 %), N,N,N’,N’-tetramethylthiourea and 
(tmtu, 99 %) were also purchased from Aldrich and used without further purification. 
Ultrapure water (MODULAB purification system) was used for all aqueous reactions. All other 
chemicals and solvents were of reagent grade and used as received. 
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5.2.2 Synthesis of the N,S ligands 
Bidentate N,S ligands, namely 2-(phenylthiomethyl)quinoline QnSPh, 2-(4-tert-
butylphenylthiomethyl)quinoline QnSPh(t-But)) and 2-(4-fluorophenylthiomethyl)quinoline 
QnSPhF were prepared via a nucleophilic S-alkylation reaction of either thiophenol, 4-tert-
butylthiophenol, or 4-fluorothiophenol with 2-(chloromethyl)quinoline hydrochloride 
(Scheme 5.1).38,39 The pyridyl ligand 2-(4-tert-butylphenylthiomethyl)pyridine pySPh(t-But)  was 
synthesised as described in Chapter 4, Section 4.2.2 and was included herein for comparison 
purpose. All ligands were obtained in moderate to satisfactory yields (58-64 %) and as yellow 
or brown oils of adequate purity for further use for platinum coordination. The purity of the 
ligands was confirmed by 1H and 13C NMR, TOF-MS-ESI+ and CHN elemental analysis 
techniques. The IR spectra of the ligands gave the following peak frequencies cm-1: 3100-3000 
(broad, medium, Csp3-H stretch); 1583 (sharp and strong, Csp2=N stretch, quinolyl rings) 
.HCl
R = H         ; QnSPh 
R = t-But    ; QnSPh(t-But)




Scheme 5.1 Synthesis of the 2-(phenylthiomethyl)quinoline ligands. 
2-(phenylthiomethyl)quinoline (QnSPh) 
The yield of 1.073 g (63 %, brown) for QnSPh was obtained. Proton-1 NMR (400 MHz: CDCl3):  
δH (ppm) referenced to TMS; 4.47 (s, 2H, -CH2-), 7.16-7.20 (t, 1H, Ph), 7.24-7.27 (t, 2H, Ph), 
7.40-7.42 (d, 2H, Ph), 7.52-7.56 (d, 1H, Qn), 7.52-7.56 (t, 1H, Qn), 7.71-7.75 (t, 1H, Qn), 7.80-
7.82 (d, 1H, Qn), 8.07 (d, 1H, Qn), 8.13 (d, 1H, Qn). Carbon-13 NMR (100 MHz: CDCl3): δC 
(ppm); 41.1; 120.9; 126.4; 127.1; 127.5; 128.9; 129.1; 129.7; 136.9; 158.1. Infrared (KBr, 4000-
650 cm-1) ̅: 3056 (C=C-H asymmetric stretch), 1596 (C=N, quinolyl). Time-of-flight MS-ESI+ 
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m/z: 252.0961, 100 (M)+. Anal. Calc. for C16H13NS:  C: 76.46, H: 5.21, N: 5.57, S: 12.76 %. Found: 
C: 76.31, H: 5.25, N: 5.21, S: 12.51 %. 
2-(4-tert-butylthiophenol)quinoline (QnSPh(t-But)) 
The yield of 1.241 g (58 %, yellow) for QnSPh(t-But) was obtained. Proton-1 NMR (400 MHz: 
CDCl3):  δH (ppm) referenced to TMS; 1.30 (s, 9H, -C(CH3)3), 4.45 (s, 2H, -CH2-), 7.27 (d, 2H, Ph) 
7.35 (d, 2H, Ph) 7.51 (t,1H, Qn), 7.56 (d, 1H, Qn), 7.70-7.74 (t, 1H, Qn), 7.79-7.81 (d, 1H, Qn), 
8.08 (d, 1H, Qn), 8.10-8.12 (d, 1H, Qn). Carbon-13 NMR (100 MHz: CDCl3): δC (ppm); 41.8; 
115.8; 116.1; 122.1; 123.1; 130.3854; 133.1091; 136.6; 149.3; 157.6. Infrared (KBr, 4000-650 
cm-1) ̅: 3059 (C=C-H Asymmetric stretch), 1598 (C=N, quinolyl). Anal. Calc. for C20H21NS:  C: 
78.13, H: 6.88, N: 4.56, S: 10.43 %. Found: C: 78.01, H: 6.12, N: 4.53, S: 10.84 %. 
2-(4-fluorothiophenol)quinoline (QnSPhF) 
The yield of 1.139 g (64 %, orange) for QnSPhF was obtained. Proton-1 NMR (400 MHz: CDCl3):  
δH (ppm) referenced to TMS; 4.40 (s, 2H, -CH2-), 6.92-6.96 (d, 2H, Ph), 7.34-7.38 (d,2H, Ph), 
7.47-7.49 (d, 1H, Qn), 7.52-7.56 (t, 1H, Qn), 7.70-7.74 (t, 1H, Qn), 7.79-7.81 (d, 1H, Qn), 8.05 
(d, 1H, Qn), 8.11 (d, 1H, Qn). Carbon-13 NMR (100 MHz: CDCl3): δC (ppm); 42.3; 115.9; 116.1; 
11.0; 126.5; 127.5; 129.8; 131.3; 133.1; 158.0. Infrared (KBr, 4000-650 cm-1) ̅: 3057 (C=C-H 
asymmetric stretch), 1592 (C=N, quinolyl). Time-of-flight MS-ESI+ m/z: 268, 100 (M-1). Anal. 
Calc. for C16H12FNS:  C: 71.35, H: 4.49, N: 5.20, S: 11.91 %. Found: C: 71.29, H: 4.31, N: 5.15, S: 
11.43 %. 
2-(4-tert-butylthiophenol)pyridine (pySPh(t-But)) (see also Chapter 4 Section 4.2.2) 
The yield of 1.457 g (57 %, light-brown) for pySPh(t-But) was obtained. Proton-1 NMR (400 MHz: 
CDCl3): δH (ppm) referenced to TMS; 1.30 (s, 9H, -C(CH3)3), 4.27 (s, 2H, -CH2-), 7.17-7.18 (t,1H, 
py), 7.28 (d, 4H, Ph), 7.36 (d, 1H, py), 7.62-7.65 (t, 1H, py), 8.55 (d, 1H, py). Infrared (KBr, 4000-
650 cm-1) ̅: 3059 (C=C-H asymmetric stretch), 1598 (C=N, pyridyl). Time-of-flight MS-ESI+ m/z: 
258.1181, 100 (M+1). Anal. Calc. for C16H19NS:  C: 74.66, H: 7.44, N: 5.44, S: 12.46 %. Found: 
C: 74.47, H: 7.50, N: 5.58, S: 12.28 %. 
5.2.3 Synthesis of Pt(II) complexes 
Three mononuclear cis-Pt(II) complexes viz., [Pt{2-(phenylthiomethyl)quinoline}Cl2], 
Pt(QnSPh)Cl2, [Pt{2-(4-tert-butylthiophenol)quinoline}Cl2], Pt(QnSPh(t-But))Cl2, and [Pt{2-(4-
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fluorothiophenol)quinoline}Cl2], Pt(QnSPhF)Cl2, were synthesised from their respective ligands 
according to a method outlined in Chapter 4, Section 4.2.3. The purity of the complexes was 
confirmed by NMR (1H, 13C, and 195Pt), CHN elemental analyser, TOF MS-ESI+ and IR 
spectroscopy. 
The yield of 0.3576 g (77 %) for Pt(QnSPh)Cl2 was obtained. Proton-1 NMR (400 MHz: DMF-
d7): δH (ppm) referenced to TMS; 4.30 (d, 2H, -CH2-, AB-spin system), 7.16 (t, 1H, Ph), 7.27 (t, 
2H, Ph), 7.37 (d, 2H, Ph), 7.33 (t, 1H, Qn), 7.52-7.54 (d, 1H, Qn), 7.60-7.64 (t, 1H, Qn), 8.56 (d, 
1H, Qn). Platinum-195 NMR (400 MHz: DMF-d7): δPt (ppm); -2717. Infrared (KBr, 4000-650 cm-
1) ̅: 3055 (C=C-H asymmetric stretch), 1583 (C=N, quinolyl). Anal. Calc. for C16H13Cl2NPtS:  C: 
37.15, H: 2.53, N: 2.71, S: 6.20 %. Found: C: 36.98, H: 2.42, N: 2.57, S: 6.02 %. 
The yield of 0.2048 g (60 %, yellow) for Pt(QnSPh(t-But))Cl2 was obtained. Proton-1 NMR (400 
MHz: CDCl3): δH (ppm) referenced to TMS; 1.30 (s, 9H, -C(CH3)3), 4.27 (d, 2H, -CH2-, AB-spin 
system), 7.17-7.18 (t, 1H, Qn), 7.28 (d, 4H, Ph), 7.36 (d, 1H, Qn), 7.62-7.65 (t, 1H, Qn), 8.55 (d, 
1H, Qn). Platinum-195 Pt NMR (400 MHz: DMF-d7): δPt (ppm); -2711. Infrared (KBr, 4000-650 
cm-1) ̅: 3059 (C=C-H asymmetric stretch), 1598 (C=N, quinolyl). Anal. Calc. for C20H21Cl2NPtS:  
C: 41.89, H: 3.69, N: 2.44, S: 5.59 %. Found: C: 41.35, H: 3.30, N: 2.69, S: 6.57 %. 
The yield of 0.1986 g (44 %, yellow) for Pt(QnSPhF)Cl2 was obtained. Proton-1 NMR (400 MHz: 
CDCl3): δH (ppm) referenced to TMS; 4.19 (d, 2H, -CH2-, AB-spin system), 6.91-7.00 (d, 2H, Ph), 
7.12-7.15 (t, 1H, Qn), 7.23 (d, 1H, Qn), 7.32 (d, 2H, Ph), 7.57-7.60 (t, 1H, Qn), 8.51-8.52 (d, 1H, 
Qn). Platinum-195 NMR (400 MHz: DMF-d7): δPt (ppm); -2718. Infrared (KBr, 4000-650 cm-1) 
̅: 3066 (C=C-H asymmetric stretch), 1588 (C=N, quinolyl). Anal. Calc. for C16H12Cl2FNPtS: C: 
35.90, H: 2.26, N: 2.62, S: 5.98 %. Found: C: 35.14, H: 2.05, N: 2.52, S: 6.06 %. 
The yield of 0.3257 g (57 %, light-brown) for Pt(pySPh(t-But))Cl2 was obtained. Proton-1 NMR 
(400 MHz: CDCl3): δH (ppm) referenced to TMS; 1.30 (s, 9H, -C(CH3)3), 4.27 (d, 2H, -CH2-, AB-
spin system), 7.17-7.18 (t,1H, py), 7.28 (d, 4H, Ph), 7.36 (d, 1H, py), 7.62-7.65 (t, 1H, py), 8.55 
(d, 1H, py). Platinum-195 NMR (400 MHz: DMF-d7): δPt (ppm); -2786. Infrared (KBr, 4000-650 
cm-1) ̅: 3059 (C=C-H asymmetric stretch), 1598 (C=N, pyridyl). Anal. Calc. for C16H19Cl2NPtS:  
C: 36.72, H: 3.66, N: 2.68, S: 6.13 %. Found: C: 36.85, H: 3.53, N: 2.53, S: 7.06 %. 
 
124 | P a g e  
 
5.3 Preparation of the diaqua Pt(II) complexes 
Solutions of the diaqua Pt(II) complexes of Pt(QnSPh)Cl2, Pt(QnSPh(t-But))Cl2, and 
Pt(QnSPhF)Cl2 were prepared following a method described in literature40 and elaborated in 
Chapter 4 section 4.2.4. Solutions of the thiourea nucleophiles viz., tu, dmtu and tmtu were 
prepared by dissolving a known amount of the nucleophile in 0.1 M LiOTf/HOTf solution. The 
adjustment of I = 0.10 M with CF3SO3Li was undertaken to ensure a constant ionic strength 
throughout the kinetic measurements. 
5.4 Instrumentation and physical measurements 
NMR spectrometers (Bruker Avance DRX 400 or DRX 500) and a FLASH 2000 CHN 
analyser were used for the characterization and chemical analysis of the synthesized ligands 
and complexes. Low-resolution electron-spray ionization (ESI+) mass spectra of the ligands 
and complexes were analysed on a time-of-flight (TOF) micromass spectrometer. A Perkin 
Elmer Spectrum One FTIR spectrometer using KBr discs was used to obtain Infrared (IR) 
spectra of the ligands and complexes. Rapid kinetic measurements were followed using an 
Applied Photophysics SX 18MV stopped-flow spectrophotometer coupled to an online data 
acquisition system. The temperature of the instrument was controlled to within ± 0.1 oC for 
all measurements. A Cary 100 BIO UV-visible spectrophotometer equipped with a Varian 
Peltier temperature controller with an accuracy of ± 0.05 oC was used for the determination 
of the pKa values of the diaqua complexes. The pH measurements were determined on a 
Jenway 4330 pH meter equipped with a 4.5 µm glass electrode. The micro-electrode was 
calibrated at 25 oC using standard buffer solutions (Merck) at pH 4.0, 7.0, and 10.0. pKa 
titration curves and time-resolved kinetic traces were graphically analysed using Origin 
7.5®software package.41  
5.4.1 pKa determination for the diaqua complexes 
Spectrophotometric acid-base titrations were undertaken for the determination of 
pKa values of the diaqua complexes. Changes in absorbance of the diaqua complex after 
addition of aliquots of NaOH were plotted as a function of pH within the range 2-9. In the low 
pH range (2-3), ΔpH for the titrated solution was small and thus required crushed NaOH 
pellets. For the subsequent increase in pH, dilute NaOH solutions of varying concentrations 
were used for the titrations. After each addition of a portion of NaOH, approximately 1 mL 
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samples were taken from the titration vessel for pH measurement. The samples were 
discarded to avoid probable contamination from leaching chloride ions from the pH 
electrode. The spectral data were analysed with Origin7.5® software suite for which the pKa 
values were obtained from a plot of the sigmoidal curve fitting of absorbance vs pH. 
5.4.2 Kinetics measurements 
The rate of substitution of the coordinated aqua ligands from the Pt(II) complexes 
were undertaken under pseudo-first-order conditions for which the concentration of 
nucleophiles was at least 10-fold in excess of the Pt(II) complex. At all times, the solutions 
were kept at pH 2 to ensure the presence of only the diaqua form of the complexes in solution. 
The rate of slow reactions was followed on the UV-visible spectrophotometer following a 
manual mixing of the complex and the nucleophile in a tandem Suprasil cuvette. For rapid 
reactions, an automated stopped-flow analyser equipped with a pressure-driven cross-
plunger for an instant mixing of the complex and nucleophile solutions was used. Prior to 
kinetics measurements on the stopped-flow, trial kinetic reactions of the Pt(II) metal 
complexes with the nucleophiles were briefly undertaken spectrophotometrically. This was 
done to determine suitable wavelengths at which kinetic traces could be followed. All the 
reported rate constants from the stopped-flow analyser are averages of six to eight 
independent kinetic runs. The temperature dependence of the rate of substitution was 
studied within the range of 15-35 oC.  
5.4.3 Computer simulation studies 
The geometry-optimized molecular structures of the complexes Pt(QnSPh), 
Pt(QnSPh(t-But)) and Pt(QnSPhF) were computed at the DFT level of theory following the 
(B3LYP(CPCM)/LANL2DZp//B3LYP/-LAN2DZp) method42-44 powered by the Gaussian 09 
software suite.45 The geometry optimized structures were conducted in the gaseous phase 
and the calculated structural parameters are presented in Table 5.2 and Figure 5.4, 
respectively. A charge of +2 was maintained for the cationic diaqua complexes.  
5.5 Results 
Three square-planar Pt(II) complexes comprising 2-(phenylthiomethyl)quinoline 
bidentate (N,S) chelates (Figure 5.1) were synthesised, characterized and their rates of 
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reaction with nucleophiles were investigated. The substituents on the phenyl ring of the N,S 
carrier ligand backbone confers different electronic and steric effects on the structure of the 
complexes, which in turn influence the rate of substitution from the complexes.  
5.5.1 Acidity of the diaqua Pt(II) complexes 
The Figure 5.2 shows an example of the spectral changes observed during the pKa 
titration of Pt(QnSPh) with NaOH. The pKa values were calculated from separate single 
sigmoidal curve fittings of changes in absorbance data using the Boltmann distribution 
parameters as shown from the inset in Figure 5.2 for the complex Pt(QnSPh). Origin 7.5 
software suite was used to acquire the pKa values for the consecutive deprotonation of the 
aqua co-ligands. The values are summarised in Table 5.1. The acid-base neutralisation 
reaction is a consecutive two-step reaction process and is summarised in Scheme 5.2 where 
the [Pt(N,S) (H2O)(OH)] species is an intermediate. The pyridyl complex Pt(pySPh(t-But)) was 
included to compare the pKa values. 


















Scheme 5.2 Deprotonation of the diaqua Pt(II) complexes  
 Table 5.1 Summary of pKa values obtained for the consecutive deprotonation of aqua ligands 
coordinated to the Pt(II) complexes 
 Pt(QnSPh) Pt(QnSPh(t-But)) Pt(QnSPhF) Pt(pySPh(t-But)) 
pKa1 3.95 ± 0.04 4.12 ± 0.01 4.00 ± 0.02 a3.87 
pKa2  5.85 ± 0.02 6.10 ± 0.05 5.67 ± 0.03 a5.60 
     apKa values reproduced from Chapter 4, Table 4.1. 
127 | P a g e  
 
The results in Table 5.1 clearly show the sensitivity of the pKa values on the electronic 
effects of the substituents on the phenyl para-position. The pKa1 values for the deprotonation 
of the first coordinated aqua ligand increase in the order: Pt(pySPh(t-But)) < Pt(QnSPhF) < 
Pt(QnSPh) < Pt(QnSPh(t-But)), respectively. The positive σ-inductive effect of the tert-butyl group 
causes accumulation of electron density on the Pt(II) metal centre for the complex 
Pt(QnSPh(t-But)). This makes the Pt(II) ion less electrophilic and the formation of the aqua-
hydroxo species from the diaqua kinetically unfavourable due to a weaker Pt-OH2 bond which 
makes deprotonation of the aqua ligand more difficult. Consequently, a higher pKa1 value is 
observed for Pt(QnSPh(t-But)) when compared to Pt(QnSPh) which only has a weak σ-donor 
phenyl ring.  
Due to the negative σ-inductive effect of the fluoro substituent, it withdraws electron 
density from the phenyl group, making the metal centre more electrophilic in Pt(QnSPhF). 
Hence, it can stabilize the hydroxo species formed during the neutralization process. This 
trend in the pKa results from this study is the same as that reported by Khusi et al.36 for the 
bidentate  N,N quinoline-bearing Pt(II) complexes. The complex bearing electron-withdrawing 
groups, (-CF3), on the 3,5-positions of the pyrazole ring had a higher NBO charge on the Pt(II) 
ion. Thus, a lower pKa of 4.07 was reported when compared to a pKa of 4.88 for the analogous 






















Figure 5.2 UV-visible spectra for the titration of 0.2 mM Pt(QnSPh) with NaOH in the pH range 
2-7 at T = 298 K. Inset: Absorbance versus pH data at 284 nm. 
The lower pKa values for the complex Pt(pySPh(t-But)) when compared to its quinolyl 
analogue can be explained by the π-acceptor properties of the pyridine. Relative to the 
quinolyl group of Pt(QnSPh(t-But)), the pyridyl group of Pt(pySPh(t-But)) stabilizes the hydroxo 
species due to its superior withdrawal of electron density from the Pt(II) metal centre.26 As a 
result, deprotonation of the first aqua ligand occurs at lower pKa1 values for Pt(pySPh(t-But)) 
when compared to the quinolyl derivative.  
5.5.2 DFT-calculated optimised structures 
The three Pt(II) complexes all have a common quinolyl moiety in the bidentate N,S non-
leaving ligand and only differ in the substituents in the phenyl ring of the thioether group. 
Density Functional Theory (DFT) calculations were performed to compare the structural 
parameters due to differences on the substituents on the thioether group. The coordination 
of the N,S-bidentate ligands to Pt is similar to that of Pt(II) complexes previously 
reported.32,33,36 Geometry-optimized structures and the HOMO and LUMO frontier molecular 
orbitals are depicted in Table 5.2, while the molecular geometry optimized parameters are 
summarized in Figure 5.3. Bond angles indicate a slightly distorted square-planar around the 
Pt(II) metal centre.  
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For all the complexes, a significant isodensity of the HOMOs lies on the quinoline 
moiety. The HOMOs are also located on the Pt(II) metal centre but at a much lower density.     
The mapping of the electronic charge distribution of the HOMOs of the quinolyl complexes 
implies a less electrophilic Pt(II) ion when compared to their pyridyl analogues reported in 
Chapter 5 Section 5.3.2. Therefore, it would be expected that the quinolyl complexes have a 
lower rate of substitution when compared to the pyridyl complex. The LUMOs are 
concentrated on the thioether and to a lesser extent on the quinoline moiety. Electron density 
on the thioether indicates the π-acceptor capacity of this moiety and its propensity to pull 
away electronic charge from the metal centre, making it more electropositive. There is no 
significant difference in the energy gaps, ΔE (HOMO-LUMO) of the frontier orbitals, although 
the strong electron-donating tert-butyl moiety for Pt(QnSPh(t-But)) increases the gap slightly 
when compared to the weak σ-donor phenyl for Pt(QnSPh) and electron-withdrawing fluoro 
for Pt(QnSPhF) substituents. The NBO charges increase in the following order: Pt(QnSPh(t-But)) 
(0.641) < Pt(QnSPh) (0.645) < Pt(QnSPhF) (0.648) < Pt(pySPh(t-But)) (0.676) and reflects the π-
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R = t-Butyl







Table 5.2 DFT calculated parameters for the cis-Pt(II). 
Property Pt(QnSPh) Pt(QnSPh(t-But)) Pt(QnSPhF) Pt(pySPh(t-But))b 
MO Energy (eV)     
LUMO -3.27 -3.23 -3.30 -3.09 
HOMO -7.20 -7.19 -7.22 -7.09 
∆EL-H 3.93 3.96 3.92 4.00 
NBO charges     
Pt 0.645 0.641 0.648 0.676 
Bond lengths (Å)     
d Pt-aNqn/py 2.04 2.04 2.04 2.02 
d Pt-S 2.40 2.39 2.40 2.41 
d Pt-OH2 (1) 2.13 2.13 2.13 2.12 
d Pt-OH2 (2) 2.11 2.10 2.10 2.11 
Bond angle (o)     
S-Pt-OH2 (1) 174.8 172.9 175.1 176.6 
Nqn/py-Pt-OH2 (2) 178.5 178.1 178.5 177.9 
A 98.7 97.9 98.9 96.4 
B 82.5 83.0 82.5 83.9 
C 99.3 98.7 99.3 92.8 
D 79.5 80.7 79.3 86.9 
aNqn/py = coordinated N-donor atom in the quinoline or pyridine ring. 
bDFT-simulated calculations reproduced from Chapter 4, Table 4.2. 
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Figure 5.3 DFT geometry-optimized structures of the Pt(II) complexes. 
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5.5.3 Kinetic Measurements 
Substitution of the aqua co-ligands from the Pt(II) complexes by thiourea nucleophiles 
proceeds by a two-step sequential process represented by k2(1st) and k2(2nd) as depicted in 
Scheme 5.3. The mechanism of substitution is based on 195Pt NMR data for the pyridyl 
derivatives already described in Chapter 4, Section 4.3.2. The first substitution forms B which 
reacts with a second nucleophile to form C whose N-end of the N,S non-leaving ligand is 
simultaneously labilised by the trans coordinated thiourea nucleophile, facilitating the rapid 
coordination a third thiourea nucleophile to produce D, for which four S atoms are 











Nu = tu; dmtu;tmtu









Scheme 5.3 Schematic representation of the two-step substitution of the aqua ligands and 
the simultaneous decoordination of the N-end of the N,S ligand by entering thiourea 
nucleophiles (Nu = tu, dmtu and tmtu). 
Substitution of the aqua ligand trans to the thioether by thiourea nucleophiles, represented 
as the first step (A → B) was monitored on the stopped-flow reaction analyser. Figure 5.4 
shows recorded UV-visible spectral changes for the reaction of Pt(QnSPh) and dmtu used to 
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choose the appropriate wavelength for monitoring the reaction on the stopped-flow 
instrument.  













Wavelength (nm)  
Figure 5.4 Preliminary UV-visible spectra prior to kinetic measurements on the stopped-flow 
recorded for the reaction of 0.05 mM Pt(QnSPh) with 3 mM dmtu at pH 2. 
The plots of kobs(1st) vs [Nu] gave linear regressions lines as shown in Figure 5.5 for the reaction 


















Figure 5.5 Plots of kobs1 vs [Nu] for the (a) first and (b) second substitutions steps of the 
reaction of 0.1 mM Pt(QnSPh)) at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
The rate law for the substitution process can be expressed by Equation 5.1.49,50  
kobs(1/2) = k2(1st/2nd)[Nu] + k-1(1st/2nd) ≈ k2(1st/2nd)[Nu]   (5.1) 
where [Nu] = tu, dmtu and tmtu.  
The second-order rate constants k2(1st) was determined from the slopes of the plots of 
kobs(1st) vs [Nu]. The intercepts of k2(1st) represent either a solvolysis pathway for which a 
solvent molecule substitutes the aqua ligand prior to being subsequently substituted by the 
entering nucleophiles or the reverse substitution of the thiourea nucleophiles by water 
molecules. The first-order rate constants, k-1(1st), were neglected due to their small 
magnitudes when compared to those of k2(1st) which represent the direct substitution of the 
aqua ligand by the thiourea nucleophiles. The dependence of the k2(1st) rate constants on 
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Table 5.3 Summary of the rate constants for the consecutive substitution steps. 
 Nu k2(1st)/M-1 s-1 k2(2nd)/10-1 M-1 s-1 
 tu 21.2 ± 0.1 89.4 ± 2.8 
Pt(QnSPh) dmtu 13.3 ± 0.1 56.8 ± 2.6 
 tmtu 9.1 ± 0.4 3.5 ± 0.1 
 tu 335.4 ± 2.3 196.0 ± 1.0 
Pt(QnSPh(t-But)) dmtu 253.6 ± 1.6 115.1 ± 1.7 
 tmtu 86.4 ± 0.4 23.5 ± 0.8 
 tu 287.4 ± 3.9 48.1 ± 1.1 
Pt(QnSPhF) dmtu 154.5 ± 4.2 26.4 ± 0.7 
 tmtu 58.9 ± 1.3 2.9 ± 0.6 
 tu 4325.4 ± 15.7 242.6 ± 11.6 
Pt(pySPh(t-But))a dmtu 635.5 ± 11.1 172.0 ± 0.5 
 tmtu 126.7 ± 2.0 65.9 ± 6.5 
aKinetic data reproduced from Chapter 4, Table 4.3. 
A typical time-resolved kinetic trace for the substitution of the first aqua ligand for the 
reaction of Pt(QnSPh) and 40-fold tu is depicted in Figure 5.6.  











Wavelength (nm)  
Figure 5.6 A typical time-resolved kinetic trace at 293 nm for the first substitution step for the 
reaction of 0.115 mM Pt(QnSPh) and 2.29 mM tu followed on the stopped-flow analyser.  
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The second substitution step (B → C) is ascribed to the substitution of the second aqua 
ligand trans to the quinoline or pyridine moieties. This step is represented by the rate 
constant k2(2nd) which is determined from the plot of kobs2 vs [Nu]. The slower rate of 
substitution of the second aqua ligand is due to crowding of the square-plane by the 
coordinated thiourea nucleophiles. The σ-inductive donation of the coordinated thiourea 
nucleophile further increases the electron density onto the metal centre making it less 
electrophilic. Combined, these factors result in the slower rate of substitution of the second 
aqua ligand.  
As described for the pyridyl analogues, the substitution of the second aqua ligand to 
form C triggers a rapid and simultaneous trans labilisation of the N-end of the N,S non-leaving 
ligand by a third thiourea nucleophile resulting in a PtS4 species, D. This mechanism is similar 
to that already reported in Chapter 4, Section 4.3.2 for the Pt(II) complexes with pyridyl 
moieties. The temperature dependence of the second-order rate constants was regressed 
according to the Eyring Equation 5.2.51  
ln[k2(1st/2nd)/T] = -(ΔH≠1/2/R).1/T + [23.8 + (ΔS≠1/2/R)]                                 (5.2) 
where T and R represent the Kelvin temperature and ideal gas constant (8.315 J K-1 mol-1), 









Figure 5.7 Eyring plots for (a) first and (b) second substitution steps for the reactions of 0.1 
mM Pt(QnSPh) and thiourea nucleophiles, pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
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The activation enthalpy (ΔH≠1/2) and activation entropy (ΔS≠1/2) were calculated from the slope 
and y-intercepts of the plots, respectively. The data is summarized in Table 5.4. 
Table 5.4 Summary of the activation parameters for the consecutive substitution steps. 
 Nu ΔH≠(1st)/kJ mol-1 ΔS≠(1st)/J mol-1 K-1 ΔH≠(2nd)/kJ mol-1 ΔS≠(2nd)/J mol-1 K-1 
 tu 44 ± 2 -63 ± 7 39 ± 1 -87 ± 3 
Pt(QnSPh) dmtu 38 ± 1 -66 ± 5 56 ± 2 -79 ± 5 
 tmtu 41 ± 3 -86 ± 9 38 ± 4 -81 ± 11 
 tu 69 ± 3 -93 ± 8 56 ± 1 -89 ± 3 
Pt(QnSPh(t-But)) dmtu 57 ± 2 -106 ± 6 49 ± 1   -96 ± 3 
 tmtu   43 ± 2 -86 ± 7 38 ± 3   -81 ± 8 
 tu 53 ± 3 -28 ± 9 43 ± 2 -78 ± 6 
Pt(QnSPhF) dmtu 53 ± 2 -28 ± 6 69 ± 3 -73 ± 8 
 tmtu 40 ± 3 -79 ± 8 34 ± 2 -93 ± 6 
 tu 28 ± 1 -72 ± 4 36 ± 3 -100 ± 9 
Pt(pySPh(t-But)) dmtu 45 ± 2 -41 ± 6 47 ± 2 -63 ± 6 
 tmtu 36 ± 1 -84 ± 4 37 ± 2 -177 ± 7 
 
5.6 Discussion  
The results in Table 5.3 indicate that the rate of substitution of the aqua leaving groups 
is sensitive to the nature of the substituents on the phenyl group of the coordinated 
thioether. The aqua ligand which is trans to the thioether group is substituted first. This is due 
to the strong σ-trans-directing ability of this moiety which labilizes the Pt-OH2(1) bond trans 
to its position. The substitution of the first aqua ligand by thiourea as the entering nucleophile 
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decreases in the following order: Pt(pySPh(t-But)) < Pt(QnSPh(t-But)) < Pt(QnSPhF < Pt(QnSPh) and 
by factors of 204: 15: 14: and 1, respectively.  
The strong positive σ-inductive donation of the tert-butyl substituent of Pt(QnSPh(t-But)) 
enhances the trans-directing ability of the thioether. This leads to an increased rate of 
substitution via the ground-state trans-influence when compared to the weaker σ-donor 
phenyl group for Pt(QnSPh. Due to the biphilic nature of the thioether, its π-acceptor capacity 
is boosted by the negative σ-inductive withdrawal of the flouro substituent for Pt(QnSPhF and 
leads to an increase in the rate of substitution when compared to Pt(QnSPh. As a result, 
electron density is back-donated from the filled 5d-orbitals of the Pt(II) ion of Pt(QnSPhF onto 
the empty 3d-orbitals of its thioether, resulting in a more electropositive metal centre. 
Consequently, the formation of the bond with the entering thiourea nucleophiles stabilizes 
the transition states of the reactions of Pt(QnSPhF relative to that of Pt(QnSPh.  
Replacing the pyridine group with quinoline results in a decrease in the rate of 
substitution of the aqua leaving groups. A comparison of the rate constants for Pt(pySPh(t-But)) 
and Pt(QnSPh(t-But)) demonstrate this fact. The decreased reactivity for Pt(QnSPh(t-But)) when 
compared to Pt(pySPh(t-But)) is due to the poor π-back-donation of the quinolyl group which 
increases electron density on the Pt(II) metal centre. Similar trends have been reported by 
Khusi et al36, Ongoma and Jaganyi31, Kinunda and Jaganyi32 and Wekesa and Jaganyi.33 
The second substitution of the aqua leaving group occurs trans to the quinoline 
moiety. Coordination of the first thiourea nucleophile imparts a steric hindrance upon the 
axial approach of the subsequent ligands. The steric hindrance of the coordinated thiourea 
on square-plane accounts for the slower substitution of the second aqua ligand. The reactivity 
factors for the substitution of the second aqua when thiourea is used as the entering 
nucleophile are 6: 5: 2: 1 for and order of reactivity of the complexes is Pt(pySPh(t-But))] < 
Pt(QnSPh(t-But)) < Pt(QnSPhF < Pt(QnSPh). 
The substituting thiourea nucleophiles have a biphilic character in that they can act as 
thiols (σ-donors) as well as thioethers (σ-donors/π-acceptors).52 Consequently, the thiourea 
ligand trans to the coordinated quinoline or pyridine can potentially labilise the Pt-N bond to 
these moieties via its strong σ-donor character.34 The labilization of the Pt-N bonds leads to 
the facile substitution of these moieties from the coordination sphere by a third thiourea 
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nucleophile as outlined in Scheme 5.3 as well as in Chapter 4, Section 4.3.2. However, the N,S 
bidentate of the ligand remains coordinated to the Pt(II) metal centre through the S atom of 
the thioether. The labilization effect of the thioether by trans-coordinated thiourea is levelled 
off by its strong σ-donor capacity.      
 
5.7 Conclusions 
Substitution of aqua ligands in three complexes bearing 2-(phenylthiomethyl)quinoline 
chelates were studied spectrophotometrically under pseudo-first-order conditions. The 
substitution of the first aqua ligand is dependent upon the nature of the substituents and 
decreases in the order: Pt(pySPh(t-But)) > Pt(QnSPh(t-But)) > Pt(QnSPhF > Pt(QnSPh). Both electron-
donating {Pt(QnSPh(t-But))} and {Pt(pySPh(t-But))} and electron-withdrawing groups {Pt(QnSPhF} 
increase the rate of substitution when compared to Pt(QnSPh). Replacing the π-acceptor 
pyridine with a poor π-acceptor and better groups such as the quinolyl moiety retards the 
rate of substitution. The reactivity of the nucleophiles towards all the complexes decreases in 
the order: tu > dmtu > tmtu, which reflects the influence of their steric bulkiness. Low 
enthalpies of activation, negative entropies of activation and dependence of rate on the 
concentration of the nucleophiles all support an associative mode of substitution of the labile 
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5.7 Supplementary Information 
Table SI 5.1 Selected wavelengths for the first substitution reactions of all three nucleophiles 
at pH 2.  
Complex Nu Wavelength (nm) 
Pt(QnSPh) tu 293 
 dmtu 293 
 tmtu 353 
Pt(QnSPh(t-But)) tu 305 
 dmtu 305 
 tmtu 329 
Pt(QnSPhF) tu 283   
 dmtu 283 
 tmtu 340 
 
 
Table SI 5.2 Selected wavelengths for the second substitution reactions of all three 
nucleophiles at pH 2.  
Complex Nu Wavelength (nm) 
Pt(QnSPh) tu 276 
 dmtu 276 
 tmtu 324 
Pt(QnSPh(t-Butyl)) tu 285 
 dmtu 285 
 tmtu 295 
Pt(QnSPhF) tu 270 
 dmtu 270 
 tmtu 315 
 







































































Figure SI 5.5 IR spectrum of [Pt{2-(4-tert-butylphenylthiomethyl)quinoline}Cl2] Pt(QnSPh(t-But)). 
 
 
Figure SI 5.6 Low resolution ESI mass spectrum of 2-(4-tert-butylphenylthiomethyl)quinoline 
QnSPh(t-But)). 
148 | P a g e  
 
Table SI 5.3 Averaged observed rate constants, kobs1, for the reaction of 0.05405 mM 
Pt(QnSPh) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs1 in s-1 
0,00108 0,09735 0,06952 0,01732 
0,00216 0,1196 0,07946 0,03057 
0,00324 0,1426 0,08987 0,0432 
0,00432 0,1657 0,09915 0,05968 




Table SI 5.4 Averaged observed rate constants, kobs2, for the reaction of 0.05405 mM 
Pt(QnSPh) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs1 in s-1 
0,00108 0,00561 0,00502 8,93717E-5 
0,00216 0,00642 0,00542 1,3011E-4 
0,00324 0,00746 0,00615 1,65183E-4 
0,00432 0,00853 0,00672 1,99758E-4 
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Table SI 5.5 Averaged observed rate constants, kobs1, for the reaction of 0.0783 mM 
Pt(QnSPh(t-But)) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs1 in s-1 
1.566 0,061 0,021 0,0888 
3.132 0,78 0,38 0,2735 
4.698 1,295 0,75 0,4193 
6.264 1,8212 1,1502 0,5318 




Table SI 5.6 Averaged observed rate constants, kobs2, for the reaction of 0.0783 mM 
Pt(QnSPh(t-But)) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs2 in s-1 
1.566 0,04106 0,03586 0,00421 
3.132 0,0735 0,05826 0,00904 
4.698 0,1016 0,08085 0,01266 
6.264 0,128 0,1022 0,01814 
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Table SI 5.7 Averaged observed rate constants, kobs1, for the reaction of 0.04483 mM 
Pt(QnSPhF) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs1 in s-1 
8,966E-4 0,225 0,2457 0,1268 
0,00179 0,5033 0,4047 0,1741 
0,00269 0,7529 0,5453 0,2357 
0,00359 1,016 0,6761 0,2852 




Table SI 5.8 Averaged observed rate constants, kobs2, for the reaction of 0.04483 mM 
Pt(QnSPhF) with different nucleophiles at pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
Nucleophile tu dmtu tmtu 
[Nu] in mM kobs2 in s-1 
4,483E-4 0,00546 0,00572 5,46427E-4 
8,966E-4 0,00681 0,00791 6,80592E-4 
0,00134 0,00769 0,01005 7,69024E-4 
0,00179 0,00921 0,01235 9,20846E-4 
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Table SI 5.9 Temperature dependence of the second-order rate constants, k1/M-1 s-1, for the 
substitution of the first aqua group in Pt(QnSPh) by with different nucleophiles at pH 2 (I = 0.1 
M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -0,1442 0,00347 -2,24241 0,00347 -3,12544 
0,00341 0,18944 0,00341 -1,98224 0,00341 -2,69938 
0,00336 0,40116 0,00336 -1,59347 0,00336 -2,39599 
0,0033 0,64788 0,0033 -1,302 0,0033 -2,19206 





Table SI 5.10 Temperature dependence of the second-order rate constants, k1/M-1 s-1, for the 
substitution of the first aqua group in Pt(QnSPh(t-But)) by with different nucleophiles at pH 2 (I 
= 0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 2,09996 0,00347 -0,32261 0,00347 -3,68197 
0,00341 2,80831 0,00341 0,26667 0,00341 -3,36791 
0,00336 3,23629 0,00336 0,70998 0,00336 -3,17746 
0,0033 3,60264 0,0033 0,9943 0,0033 -2,9107 
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Table SI 5.11 Temperature dependence of the second-order rate constants, k1/M-1 s-1, for the 
substitution of the first aqua group in Pt(QnSPhF) by with different nucleophiles at pH 2 (I = 
0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -0,35392 0,00347 -1,82184 0,00347 -2,545 
0,00341 0,12255 0,00341 -1,40305 0,00341 -2,11578 
0,00336 0,5321 0,00336 -0,99272 0,00336 -1,83149 
0,0033 0,80128 0,0033 -0,70567 0,0033 -1,62541 




Table SI 5.12 Temperature dependence of the second-order rate constants, k2/M-1 s-1, for the 
substitution of the second aqua group in Pt(QnSPh) by with different nucleophiles at pH 2 (I = 
0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -2,20773 0,00347 -2,65019 0,00347 -3,44072 
0,00341 -1,73985 0,00341 -2,1579 0,00341 -3,02749 
0,00336 -1,3843 0,00336 -1,8412 0,00336 -2,87454 
0,0033 -1,14353 0,0033 -1,53686 0,0033 -2,63855 
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Table SI 5.13 Temperature dependence of the second-order rate constants, k2/M-1 s-1, for the 
substitution of the second aqua group in Pt(QnSPh(t-But)) by with different nucleophiles at pH 
2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -4,7374 0,00347 -5,02454 0,00347 -4,95834 
0,00341 -3,82398 0,00341 -4,85676 0,00341 -3,9557 
0,00336 -3,38353 0,00336 -4,56424 0,00336 -3,18646 
0,0033 -3,00933 0,0033 -4,51769 0,0033 -2,80756 




Table SI 5.14 Temperature dependence of the second-order rate constants, k2/M-1 s-1, for the 
substitution of the second aqua group in Pt(QnSPhF) by with different nucleophiles at pH 2 (I 
= 0.1 M LiOTf/HOTf) and 25 oC. 
tu dmtu tmtu 
1/T/ K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 1/T/K-1 ln(k2/T) 
0,00347 -1,10773 0,00347 -1,55019 0,00347 -2,44072 
0,00341 -0,73985 0,00341 -1,1579 0,00341 -2,08275 
0,00336 -0,3843 0,00336 -0,8412 0,00336 -1,87454 
0,0033 -0,14353 0,0033 -0,53686 0,0033 -1,63855 


















Figure SI 5.7 Eyring plots for (a) first and (b) second substitution steps for the reactions of 0.1 
mM Pt(QnSPhF) and thiourea nucleophiles, pH 2 (I = 0.1 M LiOTf/HOTf) and 25 oC. 
 
 
(a) (b) 
